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I. Abstract 
Activation of otherwise unreactive substrates is a common strategy in chemistry and 
in nature. Adenylate-forming enzymes use adenosine monophosphate to activate 
the hydroxyl of their carboxylic substrate, creating a better leaving group. In a 
second step this reactive group is replaced in a nucleophilic elimination reaction to 
form esters, amides or thioesters. Recent studies have revealed that NRPS-
independent siderophore (NIS) synthetases are also adenylate-forming enzymes, but 
are not included in the current superfamily description. NIS enzymes are involved in 
biosynthesis of high-affinity iron chelators which are used for iron acquisition by 
many pathogenic microorganisms. This is an important area of study, not only for 
potential therapeutic intervention, but also to illuminate new enzyme chemistries. 
Here the structural and biochemical studies of AcsD from Pectobacterium 
chrysanthemi are reported. AcsD is a NIS synthetase involved in achromobactin 
biosynthesis. The co-complex structures of ATP and citrate provide a mechanism for 
the stereospecific formation of an enzyme-bound citryl-adenylate. This intermediate 
reacts with L-serine to form a likely achromobactin precursor. A detailed 
characterization of AcsD nucleophile profile showed that it can not only catalyze 
ester formation, but also amide and possibly thioester formation, creating new 
stereospecific citric acid derivatives. The structure of a N-citryl-ethylenediamine 
product co-complex identifies the residues that are important for both recognition of 
L-serine and for catalyzing ester formation.  
The structural studies on the processive enzyme AlcC, which is involved in the final 
step of alcaligin biosynthesis of Bordetella pertussis, show that it has a similar 
topology to AcsD. It also shows that ATP is coordinated in a manner similar to that 
seen in AcsD. Biochemical studies of a substrate analogue establish that AlcC is not 
only capable of synthesizing substrate dimers and trimers, but also able to assemble 
the respective dimer and trimer macrocycles. A series of docked binding models 
have been developed to illustrate the likely substrate coordination and the steps 
along dimerization and macrocyclization formation.  
Structural and mechanistic comparison of NIS enzymes with other adenylate-forming 
enzymes highlights the diversity of the fold, active site architecture, and metal 
coordination that has evolved. Hence, a new classification scheme for adenylate 
forming enzymes is proposed. 
  
— III — 
II. Table of Contents 
I. Abstract .................................................................................................................... ii 
II. Table of Contents ..................................................................................................... iii 
III. List of publications .................................................................................................. vii 
IV. Declarations ........................................................................................................... viii 
V. Copyright ................................................................................................................. ix 
VI. Acknowledgments .................................................................................................... x 
VII. Dedications .............................................................................................................. xi 
VIII. List of abbreviations ............................................................................................... xii 
IX. List of Figures ........................................................................................................ xvii 
X. List of Tables ........................................................................................................... xx 
Chapter 1 - Introduction ....................................................................................1 
1.1 Siderophore-mediated iron uptake in bacteria ......................................................... 2 
1.2 Adenylate-forming enzymes ..................................................................................... 4 
1.2.1 Adenylate-forming enzymes .......................................................................................... 6 
1.2.1.1 Adenylation domain of NRPS ........................................................................................ 8 
1.2.1.2 Acyl- or aryl CoA synthetases ....................................................................................... 9 
1.2.1.3 Luciferase and other oxidoreductases .......................................................................... 9 
1.2.2 Aminoacyl-tRNA synthetases ....................................................................................... 10 
1.2.3 NRPS-independent siderophore synthetases ............................................................... 11 
1.3 NRPS pathway ........................................................................................................ 12 
1.4 NIS pathway ........................................................................................................... 14 
1.5 Achromobactin biosynthesis pathway .................................................................... 18 
1.6 Alcaligin biosynthesis pathway ............................................................................... 22 
Chapter 2 - AcsD .............................................................................................. 26 
2.1 Introduction ............................................................................................................ 27 
2.1.1 Summary ...................................................................................................................... 27 
2.1.2 AcsD apo-structure ....................................................................................................... 28 
2.2 Materials and methods ........................................................................................... 31 
2.2.1 Overproduction and purification of wt AcsD ................................................................ 31 
2.2.2 Co-complex crystallization of AcsD ............................................................................... 33 
2.2.2.1 Attempt to obtain a citrate co-complex with ATP-γ-S ................................................ 33 
2.2.2.2 ATP co-complex .......................................................................................................... 34 
2.2.2.3 AMP - sulfate co-complex ........................................................................................... 34 
2.2.2.4 Citrate, adenosine and sulfate co-complex ................................................................ 34 
2.2.2.5 Citryl-ethylenediamine co-complex ............................................................................ 35 
2.2.3 Structural biology: data collection and refinement ...................................................... 35 
2.2.3.1 Citrate co-complex structure ...................................................................................... 36 
2.2.3.2 ATP co-complex structure ........................................................................................... 37 
2.2.3.3 AMP – sulfate co-complex structure ........................................................................... 37 
2.2.3.4 Adenosine – citrate – sulfate co-complex structure ................................................... 38 
2.2.3.5 Citryl-ethylenediamine co-complex ............................................................................ 38 
  
— IV — 
2.2.4 Single mutation of AcsD residues ................................................................................. 42 
2.2.4.1 Primer design and site directed mutagenesis ............................................................. 42 
2.2.4.2 Expression and purification of mutated AcsD ............................................................. 45 
2.2.5 AMP production assay ................................................................................................. 45 
2.2.6 Kinetic studies .............................................................................................................. 47 
2.2.7 Activity test for nucleophilic substrates ....................................................................... 48 
2.2.8 Mass spectroscopic analysis citric acid derivatives ....................................................... 48 
2.3 Results .................................................................................................................... 50 
2.3.1 Protein purification ...................................................................................................... 50 
2.3.1.1 Immobilized-metal affinity chromatography ............................................................. 50 
2.3.1.2 Desalting and tag removal ......................................................................................... 50 
2.3.1.3 Gel filtration ............................................................................................................... 52 
2.3.2 AcsD activity assay and kinetics ................................................................................... 53 
2.3.2.1 Data evaluation .......................................................................................................... 54 
2.3.2.2 Stability and verification of AMP activity assay ......................................................... 54 
2.3.2.3 Testing of proposed nucleophiles ............................................................................... 57 
2.3.2.4 AcsD reaction generates AMP and PPi ....................................................................... 58 
2.3.2.5 Kinetic data ................................................................................................................. 59 
2.3.3 Screening and optimization of co-crystals .................................................................... 61 
2.3.4 NIS conserved residues in active site ............................................................................ 62 
2.3.5 Co-complex structures ................................................................................................. 64 
2.3.5.1 ATP coordination ........................................................................................................ 65 
2.3.5.2 Citric acid coordination ............................................................................................... 68 
2.3.6 AcsD shares part of the cAPK fold of kinases ................................................................ 69 
2.3.7 Mutational studies ....................................................................................................... 71 
2.3.8 Mass spectroscopy of AcsD reaction product ............................................................... 75 
2.3.8.1 Timeline of AcsD reaction ........................................................................................... 75 
2.3.8.2 Tandem mass spectrometry of citryl-L-serine ............................................................ 76 
2.3.9 Catalysis of ester, amide and thioester bond formation ............................................... 79 
2.3.9.1 Systematic screening for possible nucleophiles .......................................................... 79 
2.3.9.2 Structural studies ........................................................................................................ 87 
2.3.9.3 Mutational studies ..................................................................................................... 89 
2.4 Discussion ............................................................................................................... 90 
2.4.1 Structural aspects ......................................................................................................... 90 
2.4.2 AcsD is capable of assembling enantioselective citrate amides and esters ................... 91 
2.4.3 Molecular mechanism .................................................................................................. 94 
2.4.3.1 AcsD forms an enzyme bound citrate adenylate intermediate .................................. 94 
2.4.3.2 AcsD liberates O-citryl-L-serine and AMP ................................................................... 95 
2.4.3.3 The fate of pyrophosphate ......................................................................................... 97 
2.4.4 Mechanistic link to kinases .......................................................................................... 97 
2.5 Conclusion .............................................................................................................. 99 
2.6 Future work .......................................................................................................... 101 
Chapter 3 - AlcC ............................................................................................. 103 
3.1 Introduction .......................................................................................................... 104 
3.1.1 Summary .................................................................................................................... 104 
3.1.2 AlcC apo structure ...................................................................................................... 105 
  
— V — 
3.1.3 AlcC substrates ........................................................................................................... 106 
3.2 Materials and methods ......................................................................................... 108 
3.2.1 Overproduction and purification of AlcC .................................................................... 108 
3.2.2 Crystallization, data collection and refinement of AlcC .............................................. 109 
3.2.2.1 AlcC apo structure .................................................................................................... 109 
3.2.2.2 Adenosine-SO4
2-
 co-complex structure ..................................................................... 109 
3.2.2.3 ATP co-complex structure ......................................................................................... 110 
3.2.3 AMP production assay ............................................................................................... 112 
3.2.4 Mass spectrometry .................................................................................................... 113 
3.3 Results .................................................................................................................. 114 
3.3.1 Protein purification .................................................................................................... 114 
3.3.1.1 Immobilized-metal affinity chromatography ........................................................... 114 
3.3.1.2 Desalting, tag removal and gel filtration ................................................................. 115 
3.3.2 Crystallization of AlcC ................................................................................................. 117 
3.3.2.1 Co-crystallization of various substrates .................................................................... 117 
3.3.2.2 Soaking of AlcC crystals ............................................................................................ 118 
3.3.3 Co-complex structures ............................................................................................... 119 
3.3.4 AlcC structure comparison with AcsD ......................................................................... 121 
3.3.5 Comparison of AlcC and AcsD ATP coordination......................................................... 122 
3.3.6 Activity assay for AlcC ................................................................................................ 126 
3.3.7 Mass spectroscopic analysis ....................................................................................... 127 
3.3.7.1 AlcC forms a Sub204 dimer ....................................................................................... 127 
3.3.7.2 AlcC forms a Sub204 dimer macrocycle .................................................................... 128 
3.3.7.3 MS/MS analysis of Sub204 dimer and Sub2042 macrocycle ..................................... 129 
3.3.7.4 AlcC forms a Sub204 trimer and trimer macrocycle ................................................. 133 
3.4 Discussion ............................................................................................................. 137 
3.4.1 AlcC dimerization interface ........................................................................................ 137 
3.4.2 Conserved ATP binding motifs in NIS family C ............................................................ 140 
3.4.3 AlcC is a processive enzyme and forms macrocycles .................................................. 142 
3.5 Conclusion ............................................................................................................ 148 
3.6 Future work .......................................................................................................... 150 
Chapter 4 - Adenylation ................................................................................. 152 
4.1 Introduction .......................................................................................................... 153 
4.1.1 Summary .................................................................................................................... 153 
4.2 Results and discussion .......................................................................................... 155 
4.2.1 Same reaction but very different domain architectures ............................................. 155 
4.2.2 ATP binding ................................................................................................................ 157 
4.2.3 Role of metals ............................................................................................................ 159 
4.2.4 Catalytic residues ....................................................................................................... 160 
4.2.5 The release of pyrophosphate .................................................................................... 162 
4.3 Conclusion ............................................................................................................ 163 
4.4 Future work .......................................................................................................... 166 
  
— VI — 
5. Bibliography ................................................................................................... 168 
6. Appendix ....................................................................................................... 176 
A. AcsD substrate coordination ................................................................................. 176 
B. Circular dichroism spectra of AcsD mutants ......................................................... 180 
C. Sequence identity of AlcC and other NIS family members .................................... 181 
D. Sequence alignment of NIS-family C ..................................................................... 182 
E. Analysis of dimer formation and macrocyclization ............................................... 184 
F. Work on AcsA ....................................................................................................... 185 
F.1. Introduction ............................................................................................................... 185 
F.2. Results and discussion ................................................................................................ 185 
F.2.1. Protein expression and purification .......................................................................... 185 
F.2.2. Screening for AcsA crystallization conditions ........................................................... 186 
F.2.3. Identification of  protein crystals .............................................................................. 187 
F.3. Conclusion and future work ....................................................................................... 190 
G. Work on DesD ....................................................................................................... 191 
G.1. Introduction ............................................................................................................... 191 
G.2. Results and discussion ................................................................................................ 191 
G.2.1. Expression and purification of DesD ......................................................................... 191 
G.2.2. DesD has no TEV-recognition site but thrombin cleaving site .................................. 193 
G.2.3. DesD initial screening for crystallization condition................................................... 193 
G.2.4. Methylation of DesD ................................................................................................. 194 
G.2.5. DesD-GFP-His8 fusion construct ................................................................................ 194 
G.2.6. DesD-GFP-His8 protein expression ............................................................................ 196 
G.2.7. Screening with cleaved and non cleaved DesD-GFP-His8 .......................................... 197 
G.3. Conclusion and future work ....................................................................................... 199 
H. Publications .......................................................................................................... 200 
 
  
— VII — 
III. List of publications 
 
Most of the results shown and discussed in this thesis are published or will be 
published soon. 
 
 
Publications 
Schmelz, S., N. Kadi, et al. (2009). "AcsD catalyzes enantioselective citrate 
desymmetrization in siderophore biosynthesis." Nature Chemical Biology 5(3): 174-
182. 
 
Schmelz, S. and J. H. Naismith "Adenylate-forming enzymes." Current Opinion in 
Structural Biology In Press, Corrected Proof. 
 
Schmelz, S. et al. (2010). "Structural basis for acyl acceptor specificity in the 
achromobactin biosynthetic enzyme AcsD." (writing in progress). 
 
 
 
 
Other publication/presentation 
 
Talk at the 14th CCP4 Northern Protein Structure Workshop, Carlisle 2007 
 
Title:  
AcsD Co-complex structure of an NRPS-independent siderophore synthetase 
Award: student prize for best oral presentation 
 
 
Poster presentation at the American crystallographic association (ACA) meeting, 
Toronto 2009 
 
Poster title: 
Characterization of a new adenylating enzyme class involved in bacterial siderophore 
biosynthesis 
 
  
— VIII — 
IV. Declarations 
 
I, Stefan Schmelz, hereby certify that this thesis, which is approximately 35’000 
words in length, has been written by me, that it is the record of work carried out by 
me and that it has not been submitted in any previous application for a higher 
degree.  
 
I was admitted as a research student in January 2007 and as a candidate for the 
degree of Doctor of Philosophy (PhD) in January 2008; the higher study for which this 
is a record was carried out in the University of St Andrews between 2007 and 2009.  
 
 
Date:________________________ Signed: _______________________ 
 Stefan Schmelz 
 
 
 
 
I hereby certify that the candidate has fulfilled the conditions of the Resolution and 
Regulations appropriate for the degree of Doctor of Philosophy at the University of 
St. Andrews and that the candidate is qualified to submit this thesis in application for 
that degree. 
 
Date:________________________ Signed: _______________________ 
 James H. Naismith 
  
— IX — 
V. Copyright 
 
In submitting this thesis to the University of St Andrews we understand that we are giving 
permission for it to be made available for use in accordance with the regulations of the 
University Library for the time being in force, subject to any copyright vested in the work not 
being affected thereby.  We also understand that the title and the abstract will be published, 
and that a copy of the work may be made and supplied to any bona fide library or research 
worker, that my thesis will be electronically accessible for personal or research use unless 
exempt by award of an embargo as requested below, and that the library has the right to 
migrate my thesis into new electronic forms as required to ensure continued access to the 
thesis. We have obtained any third-party copyright permissions that may be required in 
order to allow such access and migration.  
 
The following is an agreed request by candidate and supervisor regarding the electronic 
publication of this thesis: 
 
Embargo on printed copy and electronic copy for the same fixed period of one year on the 
following ground: 
  
Publication would preclude future publication. 
 
 
 
Date:________________________ Signed: _______________________ 
 Stefan Schmelz 
 
 
Date:________________________ Signed: _______________________ 
 James H. Naismith 
 
 
  
— X — 
VI. Acknowledgments 
 
I am extremely thankful to my supervisor, Professor James H. Naismith, for giving me 
the opportunity to carry out this work and also for his encouragement, guidance and 
support from the initial to the final stages of each project and throughout the writing 
up period. His enthusiasm for crystallography and molecular mechanisms clearly 
helped a crystallographic “rookie” to get fascinated by a scientific field often 
described as boring. 
I would also like to show my gratitude to Professor Gregory L. Challis and his post 
doc, Dr Nadia Kadi, from the University of Warwick, who collaborated in these 
projects, and welcomed me for one week in their laboratory. I much appreciate their 
time in synthesizing substrates as well as the many helpful scientific discussions. My 
special thanks go to Dr Catherine H Botting, who did a great job in acquiring MS and 
MS/MS data for the timeline and fragmentation experiments, and her assistance and 
expertise during data analysis. 
I am indebted to my many colleagues for providing a nice work environment and a 
lot of support during my PhD. I am especially grateful to Gregor Hagelüken, 
Srikanathasan Velupillai (better known as Kannan), Lester Carter, Hexian Huang, 
Kerstin Steiner, Lucile Moynie, Simon Bushell, Kenneth Johnson, Stephen McMahon, 
Changjiang Dong and the rest of Lab 224. All of them helped and supported me in 
numerous ways to make this thesis possible. I am especially grateful to Lester Carter 
and Geethanjali Selvaretnam (better known as Geetha) for proof reading. 
I extend my gratitude to my parents, sisters, little nephew Noah and the rest of my 
family who supported me through the last three years abroad in Scotland. Special 
thanks to Verena Herbst, for her endless support, understanding and her love.   
 
Thanks all, 
Stefan Schmelz 
  
— XI — 
VII. Dedications 
 
 
To my family... 
  
— XII — 
VIII. List of abbreviations 
 % percent 
° degree 
∞ infinite 
 
A 
α-KG α- ketoglutaric acid 
Å angstrom 
A600 Absorbance at 600 nm 
aaRS(s) aminoacyl-tRNA synthetase(s) 
Acs achromobactin biosynthesis protein 
AcsA Achromobactin biosynthesis protein A 
AcsD Achromobactin biosynthesis protein D 
AcsE Achromobactin biosynthesis protein E 
ADN adenosine 
ADP adenosine diphosphate 
AlcC alcaligin biosynthesis protein C 
AMP adenosine monophosphate 
Amp ampicillin 
ATP adenosine triphosphate 
 
B 
B. bronchiseptica  Bordetella bronchiseptica  
B. pertussis Bordetella pertussis 
 
C 
C Celsius 
cAPK cyclic AMP-dependent protein kinase 
CCP4 Collaborative Computational Project No. 4 
CD Circular Dichroism (Spectroscopy) 
CID collisionally induced dissociation 
CoA Coenzyme A 
CV column volume 
 
D 
 
Da Dalton 
DABA L-2,4-diaminobutyric acid 
DesD desferrioxamine biosynthesis protein D 
  
— XIII — 
DMSO dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
DNAseI deoxyribonuclease I 
dNTP deoxyribonucleotide triphosphate 
DPIA  Division of Plant Industry Archive 
DpnI Diplococcus pneumonia G41 restriction endonuclease I (NEB) 
DTT 1,4-dithiothreitol 
 
E 
 
E.coli Escherichia coli 
e.g. for example 
EA ethanolamine 
EDA ethylenediamine 
EDTA ethylenediaminetetraacetic acid 
Em emission 
ESI-MS  electrospray ionization – mass spectroscopy 
ESRF European Synchrotron Radiation Facility 
Ex excitation 
 
F 
FDACS Florida Department of Agriculture and Consumer Services 
FU fluorescence unit(s) 
 
G 
g gram 
GE General electric 
GF gel filtration 
 
H  
h hour 
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
His6 penta histidine 
HP  high-performance 
 
I 
IMAC immobilized metal affinity chromatography 
IPTG isopropyl-β-D-thiogalactopyranoside  
  
— XIV — 
 
J 
JCSG Joint Center for Structural Genomics  
K 
 
kDa kilo Dalton 
keV kilo electron volt 
KG ketoglutaric acid 
kg kilogram 
KM Michaelis-Menten constant 
 
L 
L liter 
LB Luria-Bertani 
LCT  liquid chromatography time-of-flight 
LDH lactate dehydrogenase 
Ltd limited company 
 
M 
M mol 
m meter 
MES 2-(N-morpholino) ethanesulfonic acid 
M/z mass charge ratio 
mg milligram 
Mg magnesium 
min minutes 
MK myokinase 
mL milliliter 
mM millimole 
mm  millimeter 
MS mass spectrometry 
MS/MS tandem mass spectrometry 
MT methyltransferase 
µg microgram 
µL microliter 
µM micromole 
µm micrometer 
  
— XV — 
N 
NADH/NAD+ nicotinamide adenine dinucleotide (reduced/oxidized) 
NADPH/NADP+ nicotinamide adenine dinucleotide phosphate (reduced/oxidized) 
NCBI  National Center for Biotechnology Information 
NCS non-crystallographic symmetry 
NIS NRPS-independent siderophore 
nm nanometer 
NRPS non-ribosomal peptide synthetases  
NTP ribonucleoside triphosphate 
O 
O/N over night 
 
P 
PAGE polyacrylamide gel electrophoresis  
PCP  peptidyl carrier protein 
PCR polymerase chain reaction 
PDB Protein Data Bank (database also refers to file type) 
PEG polyethylene glycol  
PEP phosphoenolpyruvate 
PFU DNA polymerase of Pyrococcus furiosus 
PISA  Protein Interfaces, Surfaces and Assemblies (web service) 
PK pyruvate kinase 
PLP pyridoxal-5’- phosphate 
Pol DNA polymerase 
PPi pyrophosphate 
 
R 
rmsd root mean square deviation 
rpm revolutions per minute 
RT room temperature 
 
S 
[S] substrate concentration 
Sub204 N-hydroxy-N-succinylputrescine 
Sub220 N-(4-Amino-3-hydroxy-butyl)-N-hydroxy-succinamic acid 
S/N supernatant 
SDS sodium dodecyl sulfate  
sec seconds 
SeMet selenomethionine 
  
— XVI — 
SER surface entropy reduction 
SPoRT Structural Proteomics of Rational Targets Initiative 
SSPF Scottish Structural Proteomics Facility 
 
T 
TE thioesterase 
TEV tobacco etch virus  
TLS  Translation/Libration/Screw rotation 
TOF time of flight 
TRIS tris(hydroxymethyl)aminomethane 
TRIS-HCl tris(hydroxymethyl)aminomethane Hydrochloride 
tRNA transfer ribonucleic acid 
 
U 
U unit(s) 
UV ultra violet (radiation) 
 
V 
v  enzyme reaction rate 
(v/v) volume per volume 
vmax enzyme’s maximum reaction rate 
 
W 
(w/v) weight per volume 
wt wild type 
 
 
  
— XVII — 
IX.  List of Figures  
Figure 1.1: Siderophore mediated iron acquisition in prokaryotes. ......................................................... 3 
Figure 1.2: Adenylation is a biochemical important process .................................................................... 5 
Figure 1.3: Adenylate-forming enzymes. .................................................................................................. 7 
Figure 1.4: Diversity of molecules synthesized by NRPS pathways ........................................................ 12 
Figure 1.5: Non-ribosomal peptide biosynthesis .................................................................................... 13 
Figure 1.6: Siderophores synthesized by NIS enzymes ........................................................................... 15 
Figure 1.7: NIS superfamily: type A, B and C enzymes. .......................................................................... 16 
Figure 1.8: Proposed mechanisms NIS enzymes .................................................................................... 17 
Figure 1.9: Examples of diseases and malfunctions in plants caused by Pectobacteria ........................ 19 
Figure 1.10: Achromobactin biosynthesis. ............................................................................................. 20 
Figure 1.11: Domain annotation for achromobactin synthetase proteins A, C and D ........................... 21 
Figure 1.12: Reported cases of pertussis ................................................................................................ 22 
Figure 1.13: Alcaligin biosynthesis .......................................................................................................... 24 
Figure 2.1: AcsD apo-structure ............................................................................................................... 28 
Figure 2.2: Analytic gel filtration of AcsD ............................................................................................... 30 
Figure 2.3: AcsD expression construct. ................................................................................................... 31 
Figure 2.4: Electron density of co-complex structures. .......................................................................... 40 
Figure 2.5: Stereo view of FoFc electron density maps of AcsD co-complex structures. ........................ 41 
Figure 2.6: Schematics for AMP activity assay ....................................................................................... 47 
Figure 2.7: First step in His6-AcsD purification and TEV cleavage........................................................... 51 
Figure 2.8: Last purification step of AcsD ............................................................................................... 52 
Figure 2.9: AcsD activity assay setup. ..................................................................................................... 53 
Figure 2.10: Control reactions for AMP activity assay. ........................................................................... 55 
Figure 2.11: Activity assay with likely natural substrates ....................................................................... 57 
Figure 2.12: AMP production by AcsD. ................................................................................................... 58 
Figure 2.13: Enzyme kinetics for citrate ................................................................................................. 59 
Figure 2.14: Initial crystal condition of AcsD co-complex ....................................................................... 61 
Figure 2.15: Crystal gallery of AcsD crystals ........................................................................................... 62 
Figure 2.16: Conserved active site residues ........................................................................................... 63 
Figure 2.17: Complex structures of AcsD from Pectobacterium chrysanthemi ...................................... 64 
Figure 2.18: AcsD substrate coordination .............................................................................................. 66 
Figure 2.19: Surface representation of the water filled cavity ............................................................... 67 
Figure 2.20: Similarity between AcsD and the cAPK fold ....................................................................... 69 
Figure 2.21: Essential features of the cAPK fold required for catalysis .................................................. 70 
Figure 2.22: AMP activity assay for wt AcsD and active site mutants. ................................................... 72 
  
— XVIII — 
Figure 2.23: Mutation in ATP binding cavity .......................................................................................... 73 
Figure 2.24: Mass spectroscopy of AcsD reaction with L-serine ............................................................ 75 
Figure 2.25: MS/MS analysis of AcsD and control reactions .................................................................. 77 
Figure 2.26: Possible O-citryl-L-serine (ester) and N-citryl-L-serine (amide) MS/MS fragments ............ 78 
Figure 2.27: Nucleophilic specificity of AcsD .......................................................................................... 80 
Figure 2.28: MS spectra of AcsD catalyzed citric acid ester and amides ................................................ 83 
Figure 2.29: MS/MS spectra of AcsD citric acid ester and amide products ............................................ 84 
Figure 2.30: Theoretical fragmentation pattern of citryl-hydroxylamine .............................................. 85 
Figure 2.31: MS analysis of AcsD reaction with L-cysteine ..................................................................... 86 
Figure 2.32: AcsD citryl-ethylenediamine (EDA) co-complex ................................................................. 87 
Figure 2.33: AcsD citryl-ethylenediamine coordination ......................................................................... 88 
Figure 2.34: Mutational studies of nucleophile binding site .................................................................. 89 
Figure 2.35: Model of coordinated O-citryl-L-serine .............................................................................. 93 
Figure 2.36: First step of AcsD mechanism. ............................................................................................ 95 
Figure 2.37: Second step in AcsD reaction ............................................................................................. 96 
Figure 2.38: Comparison of AcsD and kinase ATP .................................................................................. 98 
Figure 2.39: Likely citrate analogues for future AcsD mutants ............................................................ 102 
Figure 3.1: AlcC apo-structure .............................................................................................................. 105 
Figure 3.2: AlcC substrate consumption ............................................................................................... 107 
Figure 3.3: Electron density of AlcC co-complex structures. ................................................................ 112 
Figure 3.4: His6-AlcC purification and TEV cleavage ............................................................................. 114 
Figure 3.5: Desalting and gel filtration elution profiles for AlcC ........................................................... 115 
Figure 3.6: SDS-PAGE of AlcC gel elution profile .................................................................................. 116 
Figure 3.7: Co-complex crystals of AlcC ................................................................................................ 117 
Figure 3.8: Chemical structure of desferrioxamine B mesylate............................................................ 118 
Figure 3.9: Coordination of AlcC ligands............................................................................................... 119 
Figure 3.10: AlcC active site is more ordered upon ATP coordination ................................................. 120 
Figure 3.11: AlcC and AcsD have a similar topology ............................................................................. 121 
Figure 3.12: Comparison of ATP coordination in AlcC and AcsD. ......................................................... 122 
Figure 3.13: Coordination of ATP adenosine moiety in AlcC and AcsD. ............................................... 123 
Figure 3.14: AMP production by AlcC. .................................................................................................. 126 
Figure 3.15: AlcC mass spectrometry analysis of Sub204 dimer formation ......................................... 127 
Figure 3.16: AlcC mass spectrometry analysis of Sub204 macrocycle formation ................................ 128 
Figure 3.17: MS/MS fragmentation pattern of Sub204 dimer product ................................................ 129 
Figure 3.18: MS/MS fragmentation pattern of Sub204 dimer sodium adduct .................................... 130 
Figure 3.19: MS/MS fragmentation pattern of Sub204 dimer macrocycle .......................................... 132 
Figure 3.20: AlcC is capable of producing Sub204 trimers ................................................................... 133 
Figure 3.21: MS/MS analysis of Sub204 trimer peak. ........................................................................... 134 
  
— XIX — 
Figure 3.22:  MS/MS analysis of Sub204 trimer sodium adduct peak .................................................. 135 
Figure 3.23: MS/MS analysis of Sub204 trimer macrocycle peak ........................................................ 136 
Figure 3.24: AcsD and AlcC dimer interface comparison ..................................................................... 137 
Figure 3.25: AlcC dimer interface ......................................................................................................... 138 
Figure 3.26: Conserved motifs of the AlcC dimer interface .................................................................. 139 
Figure 3.27: Conserved ATP binding motifs of NIS synthetase family C ............................................... 140 
Figure 3.28: Docked models of Sub220 and final products in AlcC active site ..................................... 144 
Figure 3.29: Docked models of alcaligin and the Sub204 trimer in AlcC active site ............................. 145 
Figure 3.30: Similarities between AlcC and DesD ................................................................................. 146 
Figure 4.1: Old and new classification system of adenylate forming enzymes .................................... 153 
Figure 4.2: Comparison of the transition state of a dissociative and associative reaction .................. 155 
Figure 4.3: Domain movement in class I and II adenylating enzymes .................................................. 158 
Figure 4.4: Coordination of α phosphate in different classes of adenylate-forming enzymes ............ 160 
Figure 4.5: Active site alignment of different classes of adenylate-forming enzymes ......................... 161 
Figure 4.6: Chemical conservation of the serine protease triad .......................................................... 164 
Figure 4.7: Circular dichroism spectra for AcsD mutants ..................................................................... 180 
Figure 4.8: Analysis of dimer formation and macrocyclization ............................................................ 184 
 
Following figures were drawn with PyMOL and labeled with CorelDraw: 
Fig. 1.3, 2.1, 2.4, 2.5, 2.16b-c, 2.17, 2.18, 2.19, 2.20, 2.21, 2.23a, 2.32, 2.33, 2.35, 
2.36a-b, 2.37a-b, 3.1, 3.3, 3.9, 3.10, 3.11a-b, 3.11d, 3.12, 3.13, 3.24, 3.25, 3.26c, 3.28, 
3.29, 4.3, 4.4, 4.5, 4.6  
  
 
Following figures were drawn with ChemBioDraw and labeled with CorelDraw: 
1.2b, 1.4, 1.6, 1.8, 1.10, 1.13, 2.6, 2.26, 2.27b-c, 2.30, 2.36d, 2.37c, 2.38, 2.39, 3.2, 
3.8, 3.15, 3.16, 3.17, 3.18, 3.19, 3.20, 3.21, 3.22, 3.23, 3.30, 4.2 
 
 
Following graphs were generated in Origin (OrignLabs) and labeled in CorelDraw: 
Fig. 2.2, 2.9, 2.10, 2.11, 2.12, 2.13, 2.22, 2.23b, 2.27a, 2.34, 3.14,  
 
 
Following figures were drawn or labeled with Corel Draw: 
Fig. 1.1, 1.2a, 1.5, 2.3, 2.6, 3.4, 3.6, 3.26a, 3.27,  
 
 
Following figures were drawn with Microsoft Powerpoint: 
Fig. 2.36c, 4.1,  
 
 
 
  
— XX — 
X. List of Tables 
Table 2.1: Data and refinement statistics of AcsD complex structures .................................................. 39 
Table 2.2: List of site-directed mutations in AcsD .................................................................................. 43 
Table 2.3: PCR reaction mix for site directed mutations in AcsD ........................................................... 44 
Table 2.4: PCR reaction time table for site directed mutations ............................................................. 44 
Table 2.5: Site directed mutations for primers 13, 14, 21 ...................................................................... 44 
Table 2.6: Derived apparent kinetic parameters for citric acid .............................................................. 60 
Table 2.7: MS/MS fragmentation pattern of O- and N-citryl-L-serine .................................................... 79 
Table 3.1: AlcC data collection and refinement statistics. .................................................................... 111 
Table 3.2: ATP coordination in AlcC and AcsD ...................................................................................... 124 
Table 4.1: Interactions between AcsD and ATP .................................................................................... 176 
Table 4.2: Interactions between AcsD and citrate (overlap with ATP) ................................................. 177 
Table 4.3: Interactions between AcsD and citrate ............................................................................... 178 
Table 4.4: Interactions between AcsD and N-citryl-EDA ...................................................................... 179 
Table 4.5: Sequence identity and similarities of NIS synthetases in relation to AlcC ........................... 181 
 
  
— 1 — 
Chapter 1 -  Introduction 
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1.1 Siderophore-mediated iron uptake in bacteria 
Iron plays an essential role in the cell metabolism of all living organisms. It is, for 
instance, incorporated into the heme complexes of cytochrome proteins which 
mediate redox reactions, and the oxygen carrier proteins such as hemoglobin, 
myoglobin and leghemoglobin (Kiese 1966; Chance 1967; Beri and Chandra 1993). 
Iron is also essential in the iron-sulfur clusters of nitrogenases (nitrogen fixation) and 
hydrogenases (anaerobic hydrogen metabolism) (Rees 2002). Other non-heme 
containing iron proteins are ribonucleotide reductases and methane 
monooxygenases, which reduce ribose to deoxyribose in DNA biosynthesis (Atkin et 
al. 1973) or oxidize methane to methanol in methanotrophic bacteria (Higgins et al. 
1981), respectively.  
Although iron is one of the most abundant elements on earth, all living organisms 
have limited access to it (Köster 2001; Rouault 2003) due to the insoluble nature of 
iron(III) (the ferric form; Fe3+) at physiological conditions. Fe3+ is the predominant 
form of Fe ions in an oxygen atmosphere. Iron acquisition from the environment is 
problematic for saprophytic organisms. Pathogens of higher eukaryotes compete for 
iron in the host that is tightly bound to transferrin, a transport and storage glyco 
protein (Rouault 2003). Many microorganisms achieve this by the biosynthesis and 
excretion of low molecular weight iron chelating compounds, the so called 
siderophores (Drechsel and Jung 1998; Challis 2005).  
Siderophores gather iron(III) from the environment or their host. The resulting iron-
chelate complexes are re-assimilated by an iron uptake system (Figure 1.1). In Gram 
positive bacteria siderophore-iron(III) complexes are recognized by membrane-
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associated lipoprotein receptors and transported into the cytoplasm by ATP-
dependent ABC transporters (Köster 2001). There iron is reduced to iron(II) and the 
liberated siderophore molecules are recycled (re-used or degraded). In Gram 
negative microorganism the receptors for siderophore-iron(III) complex are located 
in the outer membrane. The complex is recognized and then transported by a TonB 
proton pump into the periplasm, where a soluble transport and receptor protein 
binds the complex and directs it to an ABC transporter analogous to the one found in 
Gram positive bacteria (Figure 1.1) (Köster 2005).  
Synthesis of siderophores in bacteria is primarily accomplished by two main 
pathways: the well studied non-ribosomal peptide synthetases (NRPS) pathway and 
the less well described NRPS-independent siderophore (NIS) pathway. Enzymes of 
both pathways are members of the adenylate-forming enzyme family. 
 
Figure 1.1: Siderophore mediated iron acquisition in prokaryotes.  
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1.2 Adenylate-forming enzymes 
Adenylation is an elegant biochemical process that is used to carboxylate substrates 
for a second nucleophilic attack. The enzymes catalyze a two step reaction (Figure 
1.2a). In the first step, condensation of a carboxylate substrate and ATP is performed 
to generate a carboxylated adenylate. In the second step the highly reactive 
adenylate intermediate reacts with a second substrate forming the final 
carboxylated product. The mechanism proceeds through a five coordinated 
phosphorus transition state stabilized by the enzyme (Figure 1.2b).  
Adenylating enzymes are involved in various metabolic pathways such as ribosomal 
and non-ribosomal peptide synthesis, fatty acid oxidation and enzyme regulation. 
Based on a sequence analysis, a superfamily with four sub-families of adenylate-
forming enzymes was proposed (Fulda et al. 1994). Aminoacyl-tRNA synthetases, 
which perform a similar adenylation reaction (Perona and Hou 2007), but are a 
structurally distinct family, have not been integrated into the scheme. Recent studies 
suggest that NRPS-independent siderophore (NIS) synthetases also activate their 
substrate by adenylation (Kadi et al. 2008; Kadi and Challis 2009), but show no 
sequence identity to other adenylate forming enzymes. This suggests a new 
classification scheme may be needed (Schmelz and Naismith 2009). 
  
— 5 — 
 
a 
 
 b 
 
Figure 1.2: Adenylation is a biochemical important process (a) Schematic representation of the two step process 
of adenylation. In the first reaction step adenylate-forming enzymes activate their substrate with ATP (A) by 
generating a reactive substrate-adenylate intermediate and pyrophosphate (PPi), which is instantly released. In 
the second part of the reaction a nucleophile (N) reacts with the activated intermediate and liberates the final 
product and adenosine monophosphate. (b) Chemical representation of the two step adenylation reaction 
catalyzed by adenylate-forming enzymes to activate an alcohol, amide or sulfhydryl moiety of the nucleophile 
forming a pentavalent transition state. 
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1.2.1 Adenylate-forming enzymes 
Adenylate-forming enzymes were subdivided into four separate, but closely related 
sub-families (Fulda et al. 1994), comprising the adenylation domains of NRPS (May et 
al. 2002; Challis and Naismith 2004), acyl- or aryl CoA synthetases (Jogl and Tong 
2004), the class of luciferase oxidoreductases (Conti et al. 1997) and eukaryotic long 
chain acyl-CoA ligases. In many publications, adenylate-forming enzymes are just 
divided into three families, combining acyl-/aryl CoA synthetases and eukaryotic long 
chain acyl-CoA ligases. 
 Although the superfamily of adenylate forming enzymes has been known for several 
decades, it was only thirteen years ago that the first structure of a member (firefly 
luciferase from P. pyralis) was solved (Conti et al. 1996). So far eleven other 
structures have been reported comprising the characteristic two-domain 
architecture, described as “hammer-and-anvil” topology with a large N-terminal 
(anvil) and a much smaller C-terminal (hammer) domain (Baldwin 1996; Conti et al. 
1996; Kochan et al. 2009) (Figure 1.3a).  
The N-terminal fold is subdivided into three sub-domains with an α/β topology, 
topped by a αβαβα sandwich and a β-barrel (Conti et al. 1996). The C-terminal 
domain on top is made up of five β-strands and three α-helices. The interface of the 
N- and C-terminal domain forms the catalytic site. A hinge region provides the C-
terminal domain with flexibility, and allows switching from the adenylate-forming to 
the thioester-forming conformation. The rotation of the C-terminal domain shifts a 
conserved catalytic lysine residue in and out of the active site, and also controls its 
solvent accessibility (Kochan et al. 2009; Osman et al. 2009). In contrast to other 
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adenylate-forming enzymes, such as aminoacyl-tRNA synthetases, this domain 
movement during catalysis is unique.  
 
 
a b     
    
  
     
Figure 1.3: Adenylate-forming enzymes. N- and C-terminus are marked with blue and red spheres, respectively. 
The N-terminal and C-terminal domain are colored in green and yellow, respectively. (a) non-ribosomal 
independent Gramicidin synthetase N-terminal adenylation domain in complex with AMP (red spheres) and 
phenylalanine (blue spheres, PDB code: 1amu). (b) Crystal structure of a predicted acyl-CoA synthetase from 
E. coli, with an unusual three domain architecture (3dmy). (c) LeuRS form T. thermophilus (1obc) a class I 
aminoacyl tRNA synthetase in complex with a sulfamoyl analogue of leucyl-adenylate (red spheres) and leucine 
(blue spheres). (d) monomer of human GlyRS (2pme) a subclass class II aminoacyl-tRNA synthetase. 
d 
c 
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In the superfamily of adenylate-forming enzymes ATP is coordinated in a U-shaped 
formation through a highly conserved glycine-rich loop containing the consensus 
sequence YTSG(S/T)TGxPKG (Marahiel et al. 1997). This loop shows similarities with 
the ATP-binding region in some aminoacyl-tRNA synthetases.   
1.2.1.1 Adenylation domain of NRPS  
Non-ribosomal peptide synthetases (NRPS) synthesize small peptides with biological 
activities ranging from antibiotics to immune suppressors (Challis and Naismith 
2004). NRPS are modular enzymes comprising three core domains, an adenylation 
(A) domain, a peptidyl carrier protein (PCP) domain and a condensation (C) domain. 
NRPS catalyze the formation of peptide bonds by activation of their amino acid 
substrates using an adenylation step which generates a highly reactive amino- or 
iminoacyl adenylate intermediate (see section 1.2, Figure 1.5). This adenylate 
intermediate reacts with a phosphopantetheinyl prosthetic group of the PCP domain 
forming a reactive thioester. The C domain subsequently catalyzes an amide bond 
formation with the following aminoacyl thioester attached to an upstream PCP 
domain. The A domain of NRPS belongs to the adenylate-forming enzyme super-
family and is responsible for the selection of a specific substrate and its activation. So 
far three structures have been reported: the N-terminal phenylalanine-activating A 
domain of gramicidin synthetase I, GrsA (Figure 1.3a) (Conti et al. 1997), 2,3-
dihydroxybenzoate-activating E domain DhbE (May et al. 2002) and D-alanyl carrier 
protein ligase DltA (Yonus et al. 2008).   
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1.2.1.2 Acyl- or aryl CoA synthetases  
Acyl-/aryl CoA-synthetases, also known as thiokinases, are the second sub-family of 
adenylate-forming enzymes. They catalyze formation of acyl-/aryl-CoA from short or 
medium chain fatty acids and coenzyme A in a two step adenylation reaction. First 
the fatty acid substrates are adenylated and then transferred onto coenzyme A. The 
activation of carboxylic acids with coenzyme A is an important metabolic key 
reaction and is involved in fatty acid synthesis, fatty acid β-oxidation and metabolic 
citric acid cycle. To date, four structures in this sub-family have been published: 
Acetyl-CoA of S. enteric (Gulick et al. 2003) and S. cerevisiae (Jogl and Tong 2004), 
human acyl-coenzyme A (Kochan et al. 2009) and long chain fatty acid-CoA ligase 
from T. thermophilus (Hisanaga et al. 2004).  
While these four structures have the characteristic two domain architecture, another 
recently solved structure of FdrA, a “predicted Acyl-CoA synthetase” from E. coli 
(3dmy), comprises three domains: a large N-terminal domain, a bigger middle 
domain substituting the usual C-terminal domain of adenylate-forming enzymes, and 
a small C-terminal domain, wrapping parts of the N-terminal domain (Figure 1.3b). 
However, the enzyme’s function is unclear.  
1.2.1.3 Luciferase and other oxidoreductases 
Oxidoreductases are exemplified by firefly luciferase, which drives bioluminescence, 
in this case enzymatic generated light for mating. The light is emitted by luciferin, a 
heterocyclic compound, which is oxidized by molecular oxygen. First luciferin is 
adenylated by luciferase forming luciferyl-adenylate. Thereafter molecular oxygen 
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oxidizes the activated luciferin. This reaction emits light and generates oxyluciferin 
and adenosine monophosphate. A second structure from L. cruciata was solved 
recently by the group of Nakatsu et al (Nakatsu et al. 2006). Both structures show 
the characteristic N-terminal and C-terminal domains and share basic sequence 
similarities with NRPS adenylation domains and Acyl-CoA synthetases, but not with 
aminoacyl-tRNAses (Nakatsu et al. 2006). The oxidoreductase 4-chlorobenzoyl-CoA 
ligase (Wu et al. 2009) and the benzoate CoA ligases from Burkholderia species 
(Bains and Boulanger 2007) have been determined recently. While 4-chlorobenzoyl-
CoA ligase catalyzes the initial dehalogenation step of 4-chlorobenzoate, benzoate 
CoA ligase performs the coenzyme A dependent thioesterification of benzoate.   
1.2.2 Aminoacyl-tRNA synthetases 
Aminoacyl-tRNA synthetases (aaRSs) are involved in recognition, activation and 
covalently binding of amino acids to their associated tRNA. This transfer occurs in a 
similar two-step mechanism as described for adenylate-forming enzymes. After 
initial activation of the amino acid with ATP the amino acid adenylate is transferred 
to the 3’ or 2’ hydroxyl group of tRNA forming a covalent ester bond. The group of 
aaRSs was subdivided into two evolutionarily distinct classes with several subclasses, 
for full details see reviews of (O'Donoghue and Luthey-Schulten 2003) and (Woese et 
al. 2000). Aminoacyl-tRNA synthetases are well-characterized. The first structural 
work was published in the mid 70’s (Irwin et al. 1976), and the first co-complex with 
tRNA was reported four years later (Giege et al. 1980; Giege et al. 1982; Lorber et al. 
1983). These studies showed that the two main families are not structurally related 
and have evolved convergently (Figure 1.3c,d) (Cusack et al. 1990; Eriani et al. 1990). 
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While ATP in family I is bound in a Rossmann fold along with two conserved 
sequence signatures HIGH and KMSKS, ATP in family II enzymes is coordinated by a 
seven strand anti-parallel β-sheet with three conserved motifs (Cusack 1995; Crepin 
et al. 2006). 
1.2.3 NRPS-independent siderophore synthetases  
NRPS-independent siderophore (NIS) synthetases are a new enzyme class discovered 
less than 20 years ago. 88 different enzymes were identified and subdivided into 
three phylogenetic groups called type A, B and C. The enzymes are involved in 
different steps in biosynthesis of siderophores (Challis 2005). Siderophore 
biosynthesis pathways are often activated by pathogenic bacteria during host 
invasion and hence are potential drug targets. In contrast to NRPS enzymes, which 
are also involved in siderophore synthesis, NIS enzymes are not well studied. All 
enzymes, AcsD, AcsA, AlcC and DesD, reported in this thesis are NIS enzymes. AcsD 
and AcsA are involved in achromobactin biosynthesis of P. chrysanthemi, a plant 
pathogen. AlcC and DesD on the other hand catalyze the final steps in alcaligin and 
desferrioxamine biosynthesis, respectively.  
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1.3 NRPS pathway 
Usually peptide bond formation, for instance in protein biosynthesis, is catalyzed by 
ribosomes. However, non-ribosomal peptide synthetases (NRPS) were found to 
catalyze peptide bond formation in a diverse group of smaller molecules (Figure 1.4).  
 
Figure 1.4: Diversity of molecules synthesized by NRPS pathways (modified from Challis and Naismith 2004). 
 
The diversity reaches from peptide-based antibiotics such as vancomycin (van 
Wageningen et al. 1998) to immune suppressors like cyclosporine (e.g. used in 
treatment after organ transplants) or bleomycin, which is an anti tumor drug (Weber 
et al. 1994; Du et al. 2000). Furthermore, NRPS are intensively studied and well 
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characterized and are also involved in siderophore biosynthesis, such as in 
enterobactin biosynthesis from E. coli (Crosa and Walsh 2002). Most NRPS 
assembled molecules are cyclic and contain non-proteinogenic amino acids. NRPS 
are large protein complexes of iterative enzyme domains (Figure 1.5). The number of 
modules and domains in the enzyme is dependent on the final number of 
incorporated and utilized substrate molecules. NRPS have been reported in several 
siderophore assembling systems (Gehring et al. 1998; Yu et al. 1998; Miller et al. 
2002). NRPS comprise three types of modules: the initiation, elongation and 
termination modules (Figure 1.5a).  
 a 
 
 b 
 
Figure 1.5: Non-ribosomal peptide biosynthesis. (a) Modules and domains involved in NRPS biosynthesis 
(modified from Challis and Naismith 2004). A minimal elongation module comprises three core domains: 
condensation (C), adenylation (A) and thiolation (T) domain. While the initiation module lacks a condensation 
domain the termination module has an additional thioesterase (TE) domain. Some NRPS comprise additional 
epimerization (E), methyltransferase (MT) or special condensation domains (Cy), able to catalyze intramolecular 
heterocyclizations. (b) Schematic representation of the NRPS reaction and the transfer of intermediates between 
different domains (modified from Marahiel et al. 2009). 
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A minimal elongation module consists of three core domains: condensation (C), 
adenylation (A) and a peptidyl carrier (PCP) domain, respectively. The PCP domain is 
also known as thiolation or T domain (Lautru and Challis 2004). The initiation module 
usually lacks a condensation domain, while the termination module has an additional 
thioesterase (TE) domain to liberate the finalized peptide. At the start of each 
reaction domain A selectively binds and activates an amino or carboxylic acid via 
adenylation (Figure 1.5b). Thereafter the generated aminoacyl adenylate is passed 
on and covalently bound to a thiol group in the PCP domain forming an active 
thioester. This substrate activation occurs in every module and consumes ATP. The 
final bond formation (whether peptide or ester) happens between two subsequent 
PCP domain aminoacyl thioesters. Certain NRPS comprise additional epimerization 
(E) domains (racemization of Cα- carbons in amino acids), methyltransferase (MT) 
domains (methylation of amines) or special condensation (Cy) domains, which 
catalyze condensation and intramolecular heterocyclization of serine, cysteine and 
threonine residues. This modular complexity and flexibility explains the diversity of 
NRPS synthesized molecules.  
1.4 NIS pathway 
Several non-peptide based bacterial siderophores are synthesized by a second 
pathway (Figure 1.6). This so called NRPS-independent siderophores (NIS) 
biosynthesis pathway appears to be present in over 40 species of bacteria (Challis 
2005). In 1986, initial biochemical genetic studies showed that aerobactin (Figure 
1.6), an E. coli siderophore, is biosynthesized via an unknown NRPS-independent 
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pathway (de Lorenzo et al. 1986; de Lorenzo and Neilands 1986). In aerobactin the 
functional iron-chelating groups are linked by two amide bonds to either side of a 
dicarboxylic acid. These reactions are catalyzed by IucA and IucC, two NIS enzymes, 
and remained an exception over nearly 10 years. Since then more NIS siderophores 
were discovered (Figure 1.7). Their pathways involve up to three functionally related 
enzymes to the aerobactin pathway (Challis 2005). Several NIS-synthesized iron 
chelators were proven to be essential for pathogenesis and development of 
pathogens within their hosts. Aerobactin for instance is synthesized by many virulent 
strains of E. coli (Warner et al. 1981) while anthrachelin was confirmed to be crucial 
for growth of Bacillus anthracis in macrophages (Cendrowski et al. 2004). 
 
Figure 1.6: Siderophores synthesized by NIS enzymes: achromobactin, petrobactin, aerobactin, vibrioferrin, 
rhizobactin 1021, alcaligin and desferrioxamine E (modified from Challis 2005; Wilson et al. 2006). 
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Based on sequence similarity to enzymes of the aerobactin biosynthesis (IucA and 
IucC) Challis et al. proposed a new superfamily of NRPS-independent siderophore 
synthetases. Phylogenetic analysis showed that its 88 members are clustered into 
three distinct groups: Type A, B and C, respectively (Figure 1.7). Each group was 
found to have distinct substrate specificity (Challis 2005; Challis 2007). Type A 
enzymes catalyze amide or ester bond formation of amine or alcohol substrates with 
one of the two prochiral carboxyl groups of citric acid (Figure 1.8a). Type B on the 
 
Figure 1.7: NIS superfamily: type A, B and C enzymes. Highlighted and labeled are the proteins: AcsD/AcsA, AlcC 
and DesD which are involved in achromobactin biosynthesis in Pectobacterium chrysanthemi, alcaligin 
biosynthesis in Bordetella pertussis and in desferrioxamine biosynthesis in Streptomyces coelicolor, respectively 
(modified from Challis 2005; Challis 2007). 
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other hand performs amide bond formation of amino groups and the C5-carboxyl 
group of α-ketoglutaric acid (α-KG) (Figure 1.8b). Type C catalyzes amide or ester 
bond formation of amino or alcohol groups of various substrates with monoamine or 
monoester derivatives of citric or succinic acid (Figure 1.8c). 
 
Figure 1.8: Proposed mechanisms NIS enzymes (modified from Challis 2005; Challis 2007). (a) Reaction of type A 
enzymes. (b) Reaction of type B enzymes. (c) Reaction of type C enzymes. 
 
Unlike NRPS, which were intensively studied and are well understood, NIS enzymes 
have only recently drawn attention (Kadi and Challis 2009).  In 2007, when I started 
the work on NIS enzymes no protein structure of a superfamily member was 
reported. NIS enzymes are interesting targets due to their chemistry and potential 
use in biotransformation. Therefore we decided to obtain structural data for each 
superfamily member and examine their chemical mechanisms. 
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1.5 Achromobactin biosynthesis pathway  
Achromobactin, a tris-α-hydroxycarboxylate siderophore (Figure 1.6), is 
biosynthesized via a NIS pathway and excreted by the plant pathogen 
Pectobacterium (formerly Erwinia) chrysanthemi (Münzinger et al. 2000; Franza et al. 
2005). It plays an important role as a virulence factor during plant infection (Franza 
et al. 2005). P. chrysanthemi leads to worldwide economic losses by inducing soft-
rotting, wilting, dwarfing and other plant dysfunctions (Figure 1.9) in a wide range of 
crops including potatoes, bananas, date palms, maize and greenhouse crops 
(Perombelon and Kelman 1980; Abdalla 2001; Palacio-Bielsa et al. 2006; Slawiak et 
al. 2009). This is primarily caused by secretion of cell wall degenerating enzymes, 
such as pectin and pectate lyases, methylesterases and polygalacturonases 
(Hugouvieux-Cotte-Pattat et al. 1996). Expression of these enzymes is important for 
pathogenesis of P. chrysanthemi and is co-regulated by several environmental 
conditions such as iron limitation. Depending on iron availability, P. chrysanthemi is 
able to express two siderophore-mediated iron uptake systems (Franza et al. 2002). 
Under adequate conditions, the siderophore chrysobactin is synthesized and used 
for iron acquisition, but in response to iron depletion expression of achromobactin is 
initiated instead (Franza et al. 2005). Among the acs genes that direct achromobactin 
biosynthesis, three NIS gens, acsD, acsA and acsC, were located. AcsD, AcsA and AcsC 
are type A, B and C NIS synthetases, respectively and comprise a characteristic 
IucA/IucC domain, found in aerobactin biosynthesis enzymes (Figure 1.11). Gene 
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inactivation studies confirmed that Acs proteins are required for siderophore 
biosynthesis in P. chrysanthemi (Franza et al. 2005).  
  
  
  
Figure 1.9: Examples of diseases and malfunctions in plants caused by Pectobacteria (a) Soft rot disease in aloe 
(Mandal and Maiti 2005)  (b) Black leg disease in potato, plants yellow, rolled upper leaves, potato tuber: watery, 
soft rot of disintegrating flesh (c and d) (b-d source: www.unece.org); (e) Bacterial soft rot in  Euphorbia spp. (D. 
Davison DPIA/FDACS Bugwood.org) (f) Dwarfing caused by P. chrysanthemi (D. Davison DPIA/FDACS 
Bugwood.org). 
 
A model of achromobactin biosynthesis (Figure 1.10) suggests that L-2,4-
diaminobutyric acid (DABA) or ethanolamine (derived from decarboxylation of serine 
by AcsE) is bound via an amide or an ester bond to one of the prochiral carboxyl 
groups of citric acid (Challis 2005). This condensation reaction is performed by AcsD, 
a type A enzyme. Depending on the utilized substrate, the type C siderophore AcsC 
www.unece.org 
www.unece.org www.unece.org 
a 
c 
e 
b 
d 
f 
  
— 20 — 
catalyzes the linkage of the remaining substrate onto the other prochiral carboxyl 
group of citric acid. Finally, the resulting citric acid derivative is twice acylated with 
α-ketoglutaric acid on either site by AcsA to yield achromobactin (Challis 2005; 
Challis 2007) (Figure 1.10). While AcsD and AcsC are expected to catalyze only one 
condensation reaction, AcsA is proposed to be a processive enzyme performing two 
condensation reactions. Hence achromobactin biosynthesis is an excellent model 
system for studying the substrate specificity, catalytic mechanism and structural 
biology of NIS synthetases, due to its involvement in all three NIS types. 
 
a 
 
b 
 
Figure 1.10: Achromobactin biosynthesis. (a) Gene cluster directing achromobactin biosynthesis in P. chrysanthemi. 
(b) Proposed model of achromobactin biosynthesis (Challis 2005; Challis 2007). AcsE, a pyridoxal phosphate (PLP) 
dependent enzyme, presumably decarboxylates L-serine generating ethanolamine (EA). AcsD than might utilizes EA 
or 1,4-diaminobutyric acid (DABA) forming an ester or amide bond with citric acid. Depending on AcsD, subsequent 
AcsC consumes the remaining substrate binding it to the second prochiral carboxyl of citric acid. AcsA, the last 
enzyme, acylates the two amino groups on either site with α-ketoglutarate in the resulting citric acid derivative to 
form the final product achromobactin. Embedded substrates are highlighted in distinct colors for clarity. 
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Figure 1.11: Domain annotation for achromobactin synthetase proteins A, C and D (NCBI Conserved Domain 
Search; http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi). 
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1.6 Alcaligin biosynthesis pathway  
Alcaligin, a macrocyclic dihydroxamate siderophore (Nishio et al. 1988), is produced 
and excreted by Bordetella bronchiseptica and Bordetella pertussis. While B. 
bronchiseptica is the causative agent for bronchitis in smaller mammals such as cats, 
dogs and rabbits, B. pertussis is an obligate human pathogen causing whooping 
cough. Known as a common infant and young children’s disease, it is a persistent 
respiratory illness and can lead to pneumonia, seizures and encephalopathy and 
eventually death (Galanis et al. 2006).  
 
Figure 1.12: Reported cases of pertussis (1947–2007) and hospitalizations (1993–2007) in Germany (Hellenbrand 
et al. 2009). Abbreviations: FEG: Former East Germany, FWG: Former West Germany, GDR: German Democratic 
Republic. 
 
To fight whooping cough an active immunization was introduced in many countries 
over 50 years ago. Though vaccination was successful for the first 30 years, pertussis 
cases started rising worldwide in the past 20 years. Many studies were carried out 
searching for explanations and strategies to solve this problem. A recent study in 
Source: BioMed Central (Hellenbrand et al. 2009) 
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Germany demonstrates that after implementation of vaccination in the early 1960s, 
pertussis cases initially dropped from over 200 to less than 1 out of 100’000 
inhabitants by 1992. Ever since, increasing number of pertussis cases are reported 
(Figure 1.12). One of the many reasons for this is the refusal of parents to vaccinate 
their children and themselves. This behavior definitely increases the risk of B. 
pertussis related infections as an American study demonstrates (Glanz et al. 2009).  
However, it was also notified that older children, adolescents and adults in countries 
with high vaccination coverage are now more affected than previously, which is 
surprising. It was also found that an asymptomatic history (no distinctive cough) in 
older patients often leads to misdiagnosis causing delayed or incorrect treatment 
(Tan et al. 2005; Galanis et al. 2006; Hellenbrand et al. 2009; Melo et al. 2009), 
whereas an early detection is critical and decisive (Melo et al. 2009). 
Pertussis, a disease thought to be “defeated” or under control, has made a come-
back. Hence, searching for advanced antibiotics or B. pertussis drug targets still 
remains an important field of study. Such a target might be the biosynthesis of 
siderophores and their uptake systems. Alcaligin and enterobactin siderophore 
biosynthesis for instance, are triggered by iron limitation and shown to be vital for B. 
pertussis pathogenicity during host invasion and its manifestation (Brickman et al. 
2008; Brickman and Armstrong 2009). Although alcaligin was discovered more than 
20 years ago (Nishio et al. 1988), its biosynthesis is still unclear. The involvement of 
two gene clusters, alcABC and alcR, has been verified (Beaumont et al. 1998; Kang 
and Armstrong 1998) and a likely biosynthesis pathway was proposed (Figure 1.13) 
(Challis 2005; Brickman et al. 2007).  
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The gene product of alcC is AlcC, a type C NIS enzyme (Figure 1.13a) and comprises, 
like other NIS synthetases, a characteristic IucA/IucC domain (Figure 1.13b). AlcC is a 
processive enzyme and performs the final two steps in alcaligin biosynthesis (Figure 
1.13b). First it catalyzes the dimerization of two molecules of N-(4-amino-3-hydroxy-
butyl)-N-hydroxy-succinamic acid, a likely product of AlcE. Then it generates a 
macrocycle of the dimer to yield alcaligin (Figure 1.13b) (Challis 2005). Each reaction 
a 
 
 
 
b 
 
 
c 
 
Figure 1.13: Alcaligin biosynthesis. (a) Proposed gene cluster directing alcaligin biosynthesis in B. pertussis and B. 
bronchiseptica. (b) Domain annotation for alcaligin synthetase protein C using NCBI’s conserved domain search tools 
(see also Figure 1.11). (c) Proposed model of alcaligin biosynthesis (Challis 2005; Brickman et al. 2007). AlcC, the only 
NIS enzyme in alcaligin biosynthesis, is a type C enzyme (processive enzyme) catalyzing the last two steps, 
dimerization and macrocyclization, to finalize the macrocyclic dihydroxamate siderophore.  
 
  
— 25 — 
is catalyzed in a similar two step adenylation reaction, as discussed in section 1.2, by 
consuming ATP (Challis et al, not published). In contrast to achromobactin 
biosynthesis, AlcC is the only NIS enzyme involved in alcaligin formation. Studying 
siderophore-mediated iron uptake systems might discover new ways to harm or at 
least slow down bacterial growth in mammals. This was impressively demonstrated 
by Register et al. In their study, neonatal pigs were treated with a B. bronchiseptica 
alcaligin synthesis mutant. Although the pigs were infected, they developed milder 
clinical symptoms than a control group (Register et al. 2001). 
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Chapter 2 -  AcsD 
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2.1 Introduction 
2.1.1 Summary 
In this chapter, the structural and biochemical studies of AcsD from Pectobacterium 
(formerly Erwinia) chrysanthemi are reported. This enzyme is part of a biosynthetic 
pathway that produces the siderophore achromobactin. Siderophore production is a 
known target for new antibacterial agents. AcsD is proposed to esterify the 
symmetric molecule citric acid in a stereochemical controlled two step reaction. Co-
complex structures of ATP, citrate and N-citryl-ethylenediamine product complex 
provide a mechanistic rationale for stereospecific formation of an enzyme-bound 
(3R)-citryl-adenylate, which disintegrates by a nucleophilic attack with L-serine 
forming O-citryl-L-serine, a likely achromobactin precursor. Site directed mutations 
and biochemical studies assign roles to the catalytic residues. 
A detailed characterization of the substrate profile for the second reaction step 
demonstrated that AcsD is capable of assembling enantioselective citrate amides, 
esters and possibly thioesters. The product co-complex identifies important residues 
for recognition of L-serine. One of the isolated mutants shows a reversal of specificity 
with respect to non-natural substrates. This suggests that AcsD (and other members 
of the superfamily) may have biotransformation potential. Structural and 
biochemical data suggests that AcsD is a novel adenylate-forming enzyme with a new 
fold and chemical catalysis strategy.  
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2.1.2 AcsD apo-structure 
The apo-structure of AcsD was solved and refined in the Structural Proteomics of 
Rational Targets Initiative (SPoRT) in St Andrews when I began this project. Therefore 
the overall structure of AcsD will be introduced briefly. AcsD comprises 620 amino 
acids with a total weight of about 70 kDa. The analysis of the structural data with 
PISA (Krissinel and Henrick 2007) identified a homo dimer with a small interface 
across 20 residues (making 4 hydrogen bonds) which buries 821 Å2 per monomer 
(Figure 2.1a). Analytic gel filtration was used to confirm the dimeric state of AcsD 
(Figure 2.2).  
 a 
 
 b 
     
Figure 2.1: AcsD apo-structure (a) Dimer of AcsD, facing the interface. The C-terminal domain is colored in blue, 
middle domain in red and N-terminal domain in green. (b) AcsD monomer in stereo view, facing the possible 
binding pocket. Coloring as above. Secondary structure elements are labeled from the N-terminus. The NIS 
synthetase conserved loop L7 covers the possible binding pocket. 
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AcsD monomers are composed of three domains which together are best visualized 
as a cupped hand. The N-terminal domain (residues 7 – 147, the fingers of the hand) 
forms a three helix bundle flanked by a four stranded anti-parallel β-sheet. A 28 
residue loop (L1) interrupted by a four residue helix lies outside to the strand (Figure 
2.1b). This domain forms the dimer interface. Four hydrogen bonds located in this 
domain are involved in dimerization. Surprisingly, none of these hydrogen bonding 
residues are conserved among the superfamily. The middle domain (wrist of hand) is 
located opposite the N-terminal domain and is linked to it by a disordered large loop 
(residues 164-197, shown in blue). The 31 residue loop is stabilized by a network of 
intramolecular interactions and E193, which is conserved throughout the 
superfamily and makes 3 salt bridges with K177 and R179. Later two residues are 
also well conserved throughout NIS enzymes. The middle domain includes 182 
residues folded in a twisted 8 stranded anti-parallel β-sheet interspersed with 5 α-
helices and an extended loop structure. Seven residues, H242, S279, R281, T282, 
K293, T301 and R305, conserved throughout the NIS superfamily are within this 
domain and three, namely S279, R281 and T282, are situated on L5. A high level of 
sequence conservation is also illustrated in L7, which with L4 seals the cavity created 
by the arrangement of the three domains, throughout type A enzymes of the NIS 
superfamily which is not preserved in type B or C. 
The C-terminal domain (residues 381 – 587) is predominantly α-helical and leads 
back to the N-terminal, what creates a cavity, the active site, in the middle of the 
structure (Figure 2.1b). A large 4 helix bundle is flanked by a three stranded anti-
parallel β-sheet on the inside and by a small two stranded anti-parallel β-sheet on 
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the outside. As in the other domains, the secondary structure elements are 
interspersed with large loops, two of which, L9 and L10, are on the inner face of the 
domain and are home to three superfamily conserved residues, H444, N447 and 
D464 and N509 which is conserved in type A enzymes only. 
     
Figure 2.2: Analytic gel filtration of AcsD. Elution profile of AcsD shows a prominent peak at 80 mL. The observed 
retention volume indicates that AcsD is a dimer (D). Void volume is labeled with V. 
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2.2 Materials and methods 
2.2.1 Overproduction and purification of wt AcsD 
The gene encoding AcsD was amplified from cosmid pL9G1 and cloned into 
pET151/D-TOPO by Prof. Challis’ group, University of Warwick. AcsD construct codes 
for the protein fused with an N-terminal His6-TEV tag (Figure 2.3).  
 
The His6-tag and tobacco etch virus (TEV) cleaving site are used for protein 
purification. The AcsD plasmid was transformed in Escherichia coli BL21 (DE3). The 
transformed cells were grown from 1:200 dilutions of overnight cultures in 1 L flasks 
containing LB medium (Luria-Broth) with a final ampicillin concentration of 100 µg/L 
in an orbital shaker at 200 rpm at 37 °C. When the cells reached an A600 = 0.6, 
0.4 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added and the temperature 
was lowered to 15 °C. High temperatures led to insoluble over-expressed protein. 
After a further 18 hour incubation period, cells were harvested by centrifugation 
6000 rpm, 4 °C for 15 min (Beckman JLA 8.1000), and resuspended and homogenized 
in 100-200 mL binding buffer (20 mM sodium phosphate, 40 mM imidazole, 500 mM 
NaCl, 10 % (v/v) glycerol), 1 mg/mL lysozyme, 40 µg/mL DNAse I and two tablets of 
EDTA-free protease inhibitor cocktail (Roche Diagnostics). Cell lysis was performed 
either in a cell disrupter (Constant Systems Ltd) or by sonication (6-8 cycles of 30 s 
 
Figure 2.3: AcsD expression construct. Cleavable His6-tagged protein construct of AcsD including a spacer (colored 
in black) 
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and 1 min break). Cell debris and unlysed cells were separated by centrifugation at 
20,000 rpm (rotor SS-34) for 30 min at 4 °C.  
The first purification step of His6-AcsD was performed by immobilized metal affinity 
chromatography (IMAC) with Ni-beads. Therefore 3 mL of column material (6 mL of 
slurry) was added to supernatant (S/N) and incubated for 15 min and gently stirred, 
to allow binding of His6-tagged protein to the nickel-beads. Unbound protein was 
removed by washing with 50-100 column volumes (CV) of binding buffer (20 mM 
sodium phosphate, 40 mM imidazole, 500 mM NaCl, 10 % (v/v) glycerol). His6-AcsD 
was eluted in three steps with 2-3 CV elution buffer (20 mM sodium phosphate, 
500 mM imidazole, 500 mM NaCl, 10 % (v/v) glycerol). Eluted protein solutions were 
desalted using a HiPrep 26/10 desalting column (Amersham Bioscience) with 20 mM 
Tris pH 7.5, 500 mM NaCl, 10 % (v/v) glycerol. The His6-tag was cleaved with a 1:50 
dilution of 1 mg/mL TEV-protease (O/N at RT) and removed by a 5 mL HisTrap HP 
column (Amersham Bioscience). In a final purification step, impurities were 
separated from AcsD protein via gel filtration (GF), using a Superdex 200 or Sephacryl 
200 column (GE Healthcare) with GF buffer (50 mM Tris pH 7.5, 500 mM NaCl, 10 % 
(v/v) glycerol). After tag removal AcsD comprises six additional residues at the N-
terminus (GIDPFT) with a final weight of 71 140 Da. The purified protein was 
concentrated to 6 or 9 mg/mL using protein concentrating devices (50 kDa Vivaspin), 
frozen in liquid nitrogen and stored at – 80 °C. The protein yield of AcsD wt per liter 
cell culture was 1.8 mg pure protein. Purification purity and integrity was monitored 
by SDS gel electrophoresis using 4-12 % SDS-polyacrylamide gels from Invitrogen. 
The identity and integrity of protein was confirmed by mass spectrometry.  
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2.2.2 Co-complex crystallization of AcsD 
The initial crystal condition for apo AcsD was 0.1 M TRIS–HCl pH 8.5 and 1.0 M 
sodium tartrate (McMahon et al. 2008). Attempts to co-crystallize in this condition 
failed. New crystallization conditions for AcsD co-complex crystals were identified by 
rescreening with a variety of commercially available crystallization solutions (The 
Classics, JCSG+, Pegs, Wizard I+II crystallization screens from QIAGEN) using three 
different final protein concentrations as described for the apo crystallization 
(McMahon et al. 2008). Successful conditions and optimization are discussed in 
subsequent sections for each co-complex individually. A crystal gallery is shown in 
Figure 2.15.  
2.2.2.1 Attempt to obtain a citrate co-complex with ATP-γ-S 
For citrate complex formation a new crystal condition (20 % (w/v) polyethylene 
glycol (PEG) 8000 0.1 M TRIS-HCl pH 8.5) was obtained and systematically optimized 
in conventional hanging drop grid screens. Prior to crystal droplet setup, AcsD was 
incubated with 2 mM ATP-γ-S (Sigma A1388) at room temperature for 10 min and 
centrifuged at 4 °C for 5 min to remove potential aggregates. This step was 
performed to bind ATP-γ-S and citric acid (from the optimized crystallization 
condition) in the active site of AcsD. Complex crystals grew in hanging drops from 
equal mixtures (3 µL each) of 0.1 M TRIS-HCl pH 7.8, 26 % (w/v) PEG 8000, 300 mM 
sodium citrate tribasic, 2 mM ATP-γ-S (Sigma) and 6 mg/mL AcsD to full size (~0.2 x 
0.4 mm) in one week at 20 °C.  
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2.2.2.2 ATP co-complex 
The complex with ATP was obtained using 0.1 M TRIS-HCl pH 7.8, 26 % (w/v) 
PEG 8000 and 300 mM L-serine (Sigma S4500). Protein (6 mg/mL) was pre-incubated 
with 5 mM of ATP (dissolved in water with adjusted pH 7.8) at room temperature for 
10 min. Forming protein/ATP precipitate was removed by centrifugation in a table 
top centrifuge (14’000 rpm for 5 min at 4 °C). 1 µL of supernatant and equal amount 
of precipitant was used in hanging drop crystal trails. Co-complex crystals grew 
slower to full size (~0.2 x 0.4 mm) within 2-3 weeks at 20 °C. 
2.2.2.3 AMP - sulfate co-complex 
The complex with AMP was obtained using equal volumes of protein (9 mg/mL) and 
0.1 M sodium cacodylate pH 6.5, 29 % (w/v) PEG 8000 and 200 mM (NH4)2SO4 and 10 
mM AMP. Crystals grew within days and reached full size (~0.08 x 0.11 mm) within 
two weeks at 20 °C.  
2.2.2.4 Citrate, adenosine and sulfate co-complex 
The citric acid, adenosine and sulfate co-complex crystals were obtained in hanging 
drops from equal mixtures (3 µL each) of AcsD (9 mg/mL) and precipitant (0.1 M 
sodium cacodylate pH 6.5, 29 % (w/v) PEG 8000 and 200 mM (NH4)2SO4 10 mM 
sodium citrate, 5 mM adenosine). Crystals grew fast within several days and reached 
their full size (> 0.1 x 0.15 mm) within two weeks at 20 °C. 
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2.2.2.5 Citryl-ethylenediamine co-complex 
For co-crystallization with N-citryl-ethylenediamine 9 mg/mL wt AcsD (stored in 
protein buffer: 50 mM Tris-HCl pH 7.5, 500 mM NaCl, 10 % (v/v) glycerol) was 
incubated for one hour with 15 mM ethylenediamine, 10 mM MgCl2, 15 mM ATP and 
15 mM citrate. The supernatant was used to grow N-citryl-ethylenediamine co-
complex crystals in hanging drops from equal mixtures (2+2 µL) with 0.1 M HEPES 
pH 7.2, 17 % (w/v) PEG 8000, 7.5 % (v/v) glycerol at 20 °C. Crystals started growing 
after a few days and grew within two weeks to large crystals with a size of 
approximately 0.2 x 0.6 mm. 
2.2.3 Structural biology: data collection and refinement 
Data collection was carried out on different beam lines at the European Synchrotron 
Radiation Facility (ESRF, Grenoble). The 2.25 Å native structure (3FFE) was used to 
phase all co-complex structures of AcsD. Structures were refined using REFMAC5 
(Murshudov et al. 1997) with or without TLS (Winn et al. 2001), NCS restraints and 
WinCoot (Emsley and Cowtan 2004) for manual manipulation.   
Electron density maps (FoFc and 2FoFc) for each ligand are shown in Figure 2.4. All 
ligand structures were fully refined without ligand atoms. Water atoms were added 
and refined before ligand atoms were placed in the active site and refined. Data 
collection and refinement statistics are presented in Table 2.1. It was not possible to 
locate residues 1-6, 99, 572-577 and 588-626 in the experimental maps. The ATP and 
citrate (overlaps with ATP) data sets were solved in the same space group as the 
apo-structure (P212121). All other structures were solved in P1. Refinement was 
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validated using the structure validation service MolProbity (Davis et al. 2007) to 
ensure that clash scores, rotamer outliers, Ramachandran outliers and Cβ-deviations 
are within acceptable range for the resolution. The following PDB codes were 
deposited in Protein Data Bank (PDB): 2W02 (ATP), 2W04 (citrate artifact), 2W03 
(citrate, adenosine, SO4
2-).  
2.2.3.1 Citrate co-complex structure 
Data of the citrate complex crystal were collected on ID23-1. Crystals were cryo-
protected by soaking the crystal in 20 % (v/v) PEG 400 and cryo-cooled at -173 °C. 
Two data sets to 2.2 Å were collected at a beam wavelength of 0.9803 Å (energy of 
12.648 keV). The first data set was collected with an exposure time of 1.0 second at 
5 % beam transmission over 120° starting at 0.0° phi  with an oscillation range of 0.5° 
and 0.0° overlap. The second data set was collected from phi 60° to 120°. In both 
cases the detector distance was set to 321 mm. Both data sets were indexed and 
integrated separately using “mosflm” and combined and scaled with "Scala" from 
the CCP4 package (Collaborative Computational Project, number 4. 1994) to 2.8 Å. 
The AcsD apo-structure was used as a model for molecular replacement with “auto 
MolRep” (CCP4). The structure was refined in several cycles with seven NCS 
restraints and one TLS  group per monomer which was identified by the TLS motion 
determination server (Painter and Merritt 2006). Only electron density for a citrate 
and not for ATP-γ-S was found in the active site. 
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2.2.3.2 ATP co-complex structure 
Data of the ATP complex crystal were collected on ID14-2. Crystals were cryo-
protected with 20 % (v/v) PEG 400 and cryo-cooled at -173 °C. Two data sets at 2 Å 
(high resolution pass) and 3 Å (low resolution pass) were collected at a beam 
wavelength of 0.933 Å (energy of 13.289 keV). The high resolution data set was 
collected with an exposure time of 5.0 s at 100 % beam transmission over 180° 
starting at 280.0° phi with an oscillation range of 0.5° and no overlap. The low 
resolution data collection was carried out in the same manner as the high resolution 
data set, but with 3 s exposure time. Both data sets were indexed and integrated 
using XDS (Kabsch 1993), and combined and scaled with “XSCALE” to 2.2 Å. The 
structure was refined with four NCS restraints and three TLS groups per monomer 
(Painter and Merritt 2006). 
2.2.3.3 AMP – sulfate co-complex structure 
Data of the AMP – sulfate co-complex crystal were collected on ID14-2. Crystals were 
cryo-protected with 20 % (v/v) PEG 400. Two data sets were collected at a beam 
wavelength of 0.933 Å (energy of 13.289 keV) with the detector edge at 2 Å (distance 
182.1 mm) starting at a phi angle of 0° to 100° and 95° to 220°, respectively. An 
exposure time of 5.0 s at 100 % beam transmission, 100x100 µm beam size and an 
oscillation range of 0.5° (no overlap) were used. Data were indexed and integrated 
using XDS, and combined and scaled with “XSCALE” to 2.5 Å (Kabsch 1993). 
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2.2.3.4 Adenosine – citrate – sulfate co-complex structure 
Data of the adenosine – citrate - sulfate co-complex was collected at 2.6 Å (d = 
319.7 mm) at ID23-2. Crystals were cryo-protected with 20 % (v/v) PEG 400 and cryo-
cooled at -173 °C. An exposure time of 0.8 s at 10 % beam transmission was used to 
collect 105° starting at 20.0° phi with an oscillation range of 0.5° and no overlap. 
Beam wavelength was λ = 0.8726 Å (14.209 keV) with a beam size of 200x200 µm. 
Data set was indexed and integrated using XDS and scaled with “XSCALE” to 2.95 Å. 
The structure was refined with four NCS restraints and three TLS groups per 
monomer (Painter and Merritt 2006).  
2.2.3.5 Citryl-ethylenediamine co-complex 
Two data sets for the ethylenediamine co-complex were collected on ID29 to 1.9 Å. 
Crystals were cryo-protected with 0.1 M HEPES pH 7.2, 19 % (w/v) PEG 8000, 20 % 
(v/v) glycerol and cryo-cooled at -173 °C. Both data sets were collected at a beam 
wavelength of 0.979 Å (energy of 12.664 keV) with an exposure time of 0.2 s at 8 % 
beam transmission over 130° starting at -20° phi and 200° starting at 100°, 
respectively. In both cases an oscillation range of 0.5° with 0.0° overlap was chosen. 
The detector distance was set to 271.3 mm. Data were indexed and integrated 
separately using HKL2000 and scaled together using “SCALEPACK” (part of HKL2000 
(Otwinowski and Minor 1997)) to 2 Å.  
 
 
 
 
  
— 39 — 
Table 2.1: Data and refinement statistics of AcsD complex structures (including apo structure solved in SPorT) 
 
 
  
Apo 
 
Citrate 
(overlaps 
with ATP) 
 
ATP 
 
AMP-SO4
2- 
 
Adenosine– 
citrate –SO4 
2- 
 
Citryl-EDA- 
ATP 
Data collection       
Space group P212121 P212121 P212121 P1 P1 P1 
Cell dimensions 
(Å), (°) 
 
a= 80.3, 
b= 95.7, 
c= 161.1 
a= 80.4, 
b= 95.6, 
c= 160.3 
a= 79.9, 
b= 94.5, 
c= 57.8 
a=57.7, 
b=70.0, 
c=96.0 
α=95.0, 
β =102.0, 
γ=94.7 
a=57.6, 
b=69.1, 
c=94.2 
α=95.4, 
β =101.5, 
γ=95.1 
a = 57.7 
b = 71.5 
c = 95.6 
α = 97.3 
β = 102.0 
γ =91.0 
Resolution (Å)* 
(high resolution) 
50.0-2.25 
(2.38-2.25) 
81.6 -2.8 
(2.95-2.8) 
81.1-2.2 
(2.95-2.2) 
39.7-2.5 
(2.6-2.5) 
45.9 - 2.95 
(3.11-2.95) 
50.0-2.00 
(2.07-2.0) 
Rmerge 9.8 (40.2) 15.7 (40.7) 11.4 (38.1) 7.5 (29.6) 14.3 (44.5) 6.4 (35.0) 
I/σ(I) 11.5 (3.2) 10.6 (3.0) 15.7 (5.9) 5.6 (1.7) 6.2 (1.9) 12.8 (2.7) 
Completeness ( %) 94.4 (91.5) 99.4 (99.9) 99.9 (99.9) 96.58 (94.6) 98.2 (98.5) 93.8 (74.7) 
Aver. redundancy 3.0 (3.0) 4.2 (4.3) 10.1 (7.3) 2.6 2.0 (2.0) 3.1 (2.7) 
Vm(Å
3/Da) 2.2 2.2 2.1 2.7 2.6 2.7 
Solvent ( %) 43 43 42 54 53 55 
Software XDS/XSCALE mosflm/Scala XDS/XSCALE XDS/XSCALE XDS/XSCALE HKL2000 
Refinement       
Unique reflections 56200 30736 61355 46179 29165 89038 
Rwork /  Rfree 18.6 / 24.1 20.2 / 28.0 21.6 / 27.7 20.5/26.1 20.2 / 26.7 19.0 / 23.1 
No. atoms 
     Protein  
     Water  
     Citrate  
     ATP 
     AMP 
     Adenosine  
     L-serine  
     Mg 
     SO4 
    glycerol 
    citryl-EDA 
 
9250 
505 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
9215 
130 
13 
0 
0 
0 
0 
0 
0 
0 
0 
 
9252 
277 
0 
62 
0 
0 
7 
2 
0 
0 
0 
 
9192 
169 
0 
0 
46 
0 
0 
0 
10 
0 
0 
 
9361 
73 
13 
0 
0 
38 
0 
0 
10 
0 
0 
 
9484 
571 
0 
62 
0 
0 
0 
2 
0 
30 
16 
B-factors (Å2) 
     Protein 
     Water 
     Citrate 
     ATP 
     AMP 
     Mg 
     L-serine 
     Adenosine 
     SO4 
     glycerol 
     citryl-EDA 
 
17 
25 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
12 
12 
4 
11 
0 
0 
0 
0 
0 
0 
0 
 
12 
12 
9 
12 
0 
23 
13 
0 
0 
0 
0 
 
48 
44 
0 
0 
49 
0 
0 
0 
47 
0 
0 
 
20 
9 
27 
0 
0 
0 
0 
39 
23 
0 
0 
 
38 
42 
0 
35 
0 
36 
0 
0 
0 
32 
47 
Rmsd 
bonds(Å)/angles (°) 
 
0.008/1.099 
 
0.013/1.461 
 
0.01/1.330 
 
0.015/1.563 
 
0.016/1.747 
 
0.010/1.260 
B-factor dev. 
Bond/angle (Å2) 
Main chain 
Side chain 
 
 
0.657/0.750 
1.313/2.033 
 
 
0.451/0.783 
1.096/1.823 
 
 
0.495/0.823 
1.278/1.939 
 
 
0.755/1.422 
2.101/3.479 
 
 
0.568/1.031 
1.539/2.561 
 
 
0.750/1.256 
1.733/2.705 
MolProbity score 
(percentile) 
PDB code 
98 
 
3FFE 
95 
 
2W02 
95 
 
2W04 
95 
 
 
83 
 
2W03 
95 
 
 
* Values in parentheses refer to the highest resolution shell 
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Figure 2.4: Electron density of co-complex structures. (a) 2FoFc map of citrate (overlaps with ATP) contoured at 
1.0 σ. (b) FoFc map of citrate (overlaps with ATP) contoured at 2.5 σ. (c) 2FoFc map of ATP contoured at 1 σ. (d) 
FoFc map of ATP contoured at 2.5 σ. (e) 2FoFc map of AMP contoured at 1.0 σ. (f) FoFc map of AMP contoured at 
2.5 σ. (g) 2FoFc map of adenosine, sulfate and citrate contoured at 1.0 σ. (h) 2FoFc map of adenosine, sulfate 
and citrate contoured at 2.5 σ. (i) 2FoFc electron density map of N-citryl-ethylenediamine at 1 σ. (j) FoFc electron 
density map of  N-citryl-ethylenediamine  at 2.5 σ. 
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a 
 
b 
 
c 
 
d 
 
e 
 
Figure 2.5: Stereo view of FoFc electron density maps of AcsD co-complex structures. (a) Citrate (overlaps with 
ATP) (b) ATP. (c) AMP. (d) Adenosine, sulfate and citrate. (e) N-citryl-ethylenediamine. All maps are contoured  
at 2.5 σ. 
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2.2.4 Single mutation of AcsD residues 
2.2.4.1 Primer design and site directed mutagenesis 
Site directed mutations were generated following the QuikChange (Stratagene) 
protocol with primers shown in Table 2.2. Mutations were inserted by 20 up to 
40 bases long primers carrying a central designated mutation. Polymerase chain 
reaction (PCR) was used to amplify the wt template using these synthesized primers 
to insert the right mutation. In a final step the methylated wt template was removed 
by digestion with DpnI, a DNAse specific for methylated DNA. All primers were 
synthesized by Eurogentec and stored at – 20 °C. While PFU was used as standard 
DNA polymerase, in certain cases the use of Phusion Hot Start High-Fidelity DNA 
polymerase (Finnzymes) was successful, as indicated in Table 2.2. Protocols for 
reaction mix and PCR programs are shown in Table 2.3 and Table 2.4, respectively. 
Due to problems with PCR amplification, primers for mutants 13, 14 and 21 were 
constructed with a modified QuikChange protocol (Liu and Naismith 2008). Here the 
primers are constructed with 5’-overhangs to ensure exponential amplification. PCR 
for these mutants was carried out with PFU DNA polymerase and a modified reaction 
schedule (Table 2.5). After successful amplification, the wt DNA template was 
digested with 10 units of DpnI in a water bath (37 °C, 1 h). All PCR products were 
purified using Montage Single Sample PCR Cleanup column (Millipore) as described 
in the kit manual. After transformation with calcium chloride competent E. coli DH5α 
cells (45 sec at 42 °C), samples were incubated in an orbital shaker (90 min, 37 °C, 
200 rpm) and plated on LB agar plates containing ampicillin. Overnight cultures of 
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plated clones (10 mL LB, 37 °C) were prepared and plasmid DNA extracted using the 
Wizard® Plus SV Minipreps DNA Purification System (Promega). Each mutation was 
verified by the sequencing service of the University of Dundee 
(http://www.dnaseq.co.uk/). Prior protein expression mutated plasmids were 
transformed into BL21 (DE3) E. coli cells. 
Table 2.2: List of site-directed mutations in AcsD; PCR was carried out with DNA polymerases (pol) PFU (P) or 
Phusion Hot start High-Fidelity DNA Polymerase (H) (Finnzymes) as indicated. All successful steps in mutating, 
purifying and testing of each mutant are marked with () or otherwise as failed. 
position no mutation codon new codon primer DNA sequence mutated pol purified assayed
H170 1 A CAC GCC fw GATTGTGGTTCGGCGCCCCCAGCCACCCCGCGC
rv GCGCGGGGTGGCTGGGGGCGCCGAACCACAATC
E193 2 A GAA GCG fw GCAGTGGGCGCCTGCGTTTCAGGCCCGCG
rv CGCGGGCCTGAAACGCAGGCGCCCACTGC
3 Q GAA CAG fw GCAGTGGGCGCCTCAGTTTCAGGCCCGCG
rv CGCGGGCCTGAAACTGAGGCGCCCACTGC
4 D GAA GAC fw CAGTGGGCGCCTGACTTTCAGGCCCGC
rv GCGGGCCTGAAAGTCAGGCGCCCACTG
H242 5 N CAC AAC fw GCCATCATCTGTATGAACCCGGTGCAGGCGCAAC
rv GTTGCGCCTGCACCGGGTTCATACAGATGATGGC
6 A CAC GCG fw CGCCATCATCTGTATGGCGCCGGTGCAGGCGCAAC
rv GTTGCGCCTGCACCGGCGCCATACAGATGATGGCG
S279 7 A TCT GCG fw GCCAGCCCGACAGCCGCGATTCGTACCTGGTTC
rv GAACCAGGTACGAATCGCGGCTGTCGGGCTGGC
F291 8 Y TTC TAT fw GACGATCACGACTACTTCATCAAAGGTTCGCTC
rv GAGCGAACCTTTGATGAAGTAGTCGTGAGCGTC
T301 9 A ACC GCC fw GAATGTGCGCATCGCCAACTGTGTGCGC
rv GCGCACACAGTTGGCGATGCGCACATTC
R305 10 A CGC GCC fw CATCACCAACTGTGTGGCCAAAAACGCCTGGTATG
rv CATACCAGGCGTTTTTGGGCACACAGTTGGTGATG
11 K CGC AAG fw GCGCATCACCAACTGTGTGAAGAAAAACGCCTGGTATGAAC
rv GTTCATACCAGGCGTTTTTCTTCACACAGTTGGTGATGCGC
E442 12 A GAG GCG vw CACGGCGTGGTGATGGCGCCGCACCTGCAAAAC
rv GTTTTGCAGGTGCGGCGCCATCACCACGCCGTG
13 Q GAG CAG vw GCGTGGTGATGCAGCCGCACCTGCAAAACAGCGTG
rv GGCTGCATCACCACGCCGTGATTGAAGAACAGCGAC
14 D GAG GAT vw GCGTGGTGATGGATCCGCACCTGCAAAACAGCGTG
rv GGATCCATCACCACGCCGTGATTGAAGAACAGCGAC
H444 15 A CAC GCG fw GTGGTGATGGAGCCGGCGCTGCAAAACAGCGTGC
rv GCACGCTGTTTTGCAGCGCCGGCTCCATCACCAC
16 N CAC AAC fw GTGGTGATGGAGCCGAACCTGCAAAACAGCGTGC
rv GCACGCTGTTTTGCAGGTTCGGCTCCATCACCAC
D464 17 A GAT GCG fw CAGGTGCTGCTGCGCGCGTTCGAAGGCGTAAAACTG
rv CAGTTTTACGCCTTCGAACGCGCGCAGCAGCACCTG
18 N GAT AAC vw CAGGTGCTGCTGCGCAACTTCGAAGGCGTAAAACTG
rv CAGTTTTACGCCTTCGAAGTTGCGCAGCAGCACCTG
R501 19 A CGC GCC fw CGAACAGGGCTGGAATGCCATCATGTACTGCCTG
rv CAGGCAGTACATGATGGCATTCCAGCCCTGTTCG
20 K CGC AAA fw CCGCGAACAGGGCTGGAATAAAATCATGTACTGCCTGTTC
rv GAACAGGCAGTACATGATTTTATTCCAGCCCTGTTCGCGG
K563 21 A AAA GCG fw CGGTAGCGTGCGCGACCAACCTTAAGGTCCGGCTGG
rv AGGTCGCGCACGCTACCGGATGGCCGGCGATCAGC
R576 22 A CGT GCG vw GCGGCCGAGGCCGATGCGCAGGCCAGCTATGTTC
rv GAACATAGCTGGCCTGCGCATCGGCCTCGGCCGC
23 K CGT AAA vw GGCGGCCGAGGCCGATAAACAGGCCAGCTATGTTCG
rv CGAACATAGCTGGCCTGTTTATCGGCCTCGGCCGCC  P  
 P
failed
 P
failed
 P
failed
 P
 H
 P
 P
 P
 H


 P
 P
 P
failed
 P
 P
 P
 P
 
 
 
 
 
 
 
 
 
 
 
 
 
failed
 
 
P  
P  
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Table 2.4: PCR reaction time table for site directed mutations with Phusion Hot start Fidelity DNA polymerase (a)
and PFU DNA polymerase (b) 
 
step cycle temp. time step cycle temp. time
1 1x 95 °C 5 min 1 1x 95 °C 2 min
2 16x 95 °C 30 sec 2 16x 95 °C 1 min
50 °C 30 sec 57 °C 45 sec
72 °C 8 min 72 °C 15 min
3 1x 72 °C 7 min 3 1x 72 °C 7 min
4 °C ∞ 4 °C ∞
a b
 
 
Table 2.5: Site directed mutations for primers 13, 14, 21 using PFU DNA polymerase. (a) PCR reaction mix. 
(b) Program used for PCR amplification. 
 
a
solution vol step cycle temp. time
5x PFU reaction buffer 10 µL 1 1x 95 °C 5 min
primer forward (10 µM) 1.15 µL 2 11x 95 °C 1 min
primer reverse (10 µM) 1.15 µL 58 °C 1 min
wt
 DNA (21 ng/µL) 0.5 µL 72 °C 16 min
dNTPs (10mM) 1 µL 3 2x 95 °C 1 min
water 34.5 µL 50 °C 1 min
PFU (2.5 U/µL) 1 µL 72 °C 16 min
reaction  volume 50 µL 4 1x 72 °C 7 min
4 °C ∞
b
 
Table 2.3: PCR reaction mix for site directed mutations in AcsD. (a) Reaction mix with Phusion Hot start Fidelity 
DNA polymerase. (b)  Reaction mix with PFU DNA polymerase. 
 
a b
solution vol solution vol
5x Phusion reaction buffer 10 µL 10x reaction buffer 5 µL
primer forward (10 µM) 1.5 µL primer forward (10 µM) 1 µL
primer reverse (10 µM) 1.5 µL primer reverse (10 µM) 1 µL
wt
 DNA (40 ng/µL) 1 µL wt  DNA (25 ng/µL) 2 µL
dNTPs (10mM) 1 µL dNTPs (10mM) 1 µL
DMSO (100 (v/v )% 1 µL
water 34.5 µL water 40 µL
DNA Polymerase (3 U/µL) 1 µL DNA Polymerase (2.5 U/µL) 1 µL
reaction  volume 50 µL reaction  volume 50 µL  
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2.2.4.2 Expression and purification of mutated AcsD 
Cultures of E. coli BL21 (DE3) (Novagen) containing AcsD point mutations were 
launched in 100 mL LB /Amp overnight at 37 °C. These were diluted 1:200 into 3x1 L 
flasks containing LB medium with a final ampicillin concentration of 100 µg/L and 
incubated in an orbital shaker at 250 rpm. When cultures reached an A600 = 0.8, 
0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added and the temperature 
lowered to 15 °C for a further 18 hour incubation period. Cell harvest and the first 
purification step were carried out as described in section 2.2.1. The His6-tag of most 
mutants was not removed (enzyme activity showed no differences between tagged 
and non-tagged protein version). An additional desalting or dialysis step (desalting 
buffer: 50 mM TRIS-HCl pH 7.5, 500 mM NaCl, and 10 %  (v/v) glycerol) was applied 
to remove imidazole, which was introduced in the IMAC purification step. Mutated 
AcsD and His6-AcsD was concentrated to 2 – 9 mg/mL using protein concentrating 
devices (50 kDa Vivaspin); flash frozen in liquid nitrogen and stored at - 80 °C. 
Protein yields varied and were in the range of 1 – 2 mg pure protein per liter cell 
culture.  
2.2.5 AMP production assay 
The activity of wt and mutated AcsD were tested in a modified coupled enzyme 
assay developed on basis of Wu and Hill (Wu and Hill 1993). As described in section 
1.5, AcsD liberates adenosine monophosphate by catalyzing the carboxylation of 
ethanolamine or L-2,4-diaminobutyric acid (DABA) with one of the prochiral carboxyl 
groups of citric acid (Challis 2007). Preliminary tests showed that AcsD uses ATP as 
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energy source and also performs a condensation reaction between citric acid and 
other nucleophiles like L-serine (Challis et al, unpublished data). The AMP production 
assay is based on coupling the liberation of AMP to the lactate dehydrogenase (LDH) 
oxidation of nicotinamide adenine dinucleotide (NADH). Figure 2.6 shows the 
enzymes and substrates used in the assay. The formed AMP (by the condensation 
reaction of citric acid and ethanolamine or DABA catalyzed by AcsD) is converted via 
myokinase (MK) into two ADP molecules using one ATP. In the following step two 
ATP molecules are regenerated by pyruvate kinase (PK), which catalyses 
dephosphorylation of phosphoenol pyruvate (PEP) to pyruvate. In the final reaction 
LDH oxidizes NADH by reducing pyruvate to lactate. The decrease in NADH levels can 
be monitored whether by absorbance spectroscopy at 340 nm or by fluorescence 
spectroscopy at 376 nm excitation and 462 nm emission wavelength.  
The reaction contained 50 mM TRIS-HCl buffer (pH 8.0), 3 mM ATP, 15 mM MgCl2, 
1.5 mM phosphoenol pyruvate, 0.25 mM NADH, 2 µM wt or mutant His6-AcsD, 12.6 
units of lactate dehydrogenase, 8.4 units of pyruvate kinase, 4 units of myokinase, 
75 mM L-serine and 2 mM citric acid at a total volume of 140 μL. The assay was 
carried out in triplicate using a Cary Eclipse spectrometer (Varian) and Perkin-Elmer 
1 mL cuvettes. The mixture was incubated at 20 °C for 5 min and the reaction started 
by adding of 2 µM wt or mutated AcsD. Incubation times varied from 20 minutes 
(AcsD) up to 12 h (mutants). The decrease in NADH fluorescence (excitation 376 nm 
and emission 462 nm) in real time was monitored. For the ADP production assay, the 
same procedure was used, but myokinase was omitted from reactions. All data were 
processed using Excel 2003 and Origin 7 (OriginLab).  
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2.2.6 Kinetic studies 
To obtain kinetic data, the AMP production assay was carried out as described in the 
previous section. The reaction contained 50 mM TRIS-HCl buffer (pH 8.0), 3 mM ATP, 
15 mM MgCl2 (30 or 105 mM), 1.5 mM phosphoenol pyruvate, 0.25 mM NADH, 2 µM 
protein, 12.6 units of lactate dehydrogenase, 8.4 units of pyruvate kinase, 4 units of 
myokinase, 75 mM L-serine and various concentration of citrate (buffered at pH 8.0). 
 
Figure 2.6: Schematics for AMP activity assay for detecting and monitoring of AcsD enzyme activity. AMP, 
liberated by AcsD reaction, is used as starting substrate in an enzyme coupled reaction to oxidize NADH. PEP and 
NADH are consumed, ATP is regenerated keeping its concentration constant. Abbreviations: DABA: L-2,4-
diaminobutyric acid; EA: ethanolamine; PEP:  phosphoenolpyruvate; NADH/NAD+: reduced and oxidized form of 
nicotinamide adenine dinucleotide   
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The total volume per reaction was 140 µL. Reactions were pre-incubated at 20 °C for 
5 min and started by adding AcsD to a final concentration of 2 µM. Kinetic data were 
converted and  fitted using Origin 7 (OriginLab) with the Michaelis-Menten equation 
v = vmax· [S]·([S] + KM)
-1 (see also section 2.3.2.5). 
2.2.7 Activity test for nucleophilic substrates 
AcsD substrate specificity (wt and mutated protein) for various nucleophiles were 
tested using the previous described AMP activity assay (see section 2.2.5). Reactions 
were prepared as usual, but contained 75 mM of the respective nucleophile. 
Samples were pre-incubated for 5 min at 20 °C and reaction started with 2 µM wt or 
mutated AcsD. Fluorescence data were acquired corresponding to reactions with L-
serine. Each data set was normalized by dividing starting intensity value when 
enzyme was added (at 5 min). Slopes of normalized data were determined with 
Origin 7 (OriginLab). 
2.2.8 Mass spectroscopic analysis citric acid derivatives  
AcsD products with various nucleophiles were confirmed by MS and MS/MS analysis. 
Enzymatic reactions were carried out in ammonium acetate buffer (10 mM, pH 8.0) 
containing 10-30 µM wt AcsD, 30 mM MgCl2, 20 mM citrate and 40 mM of various 
nucleophiles (each buffered at pH 8). The mixtures were incubated at 20 °C and the 
reactions were initiated by adding 20 mM ATP.  
At certain time points 1 μL aliquots were removed, diluted into 50:50 acetonitrile: 
water (100 μL) and centrifuged at 12,000 rpm for 1 min. The samples were analyzed 
using continuous syringe infusion (Harvard syringe pump, Harvard Apparatus, Kent, 
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UK) into a LCT (Micromass, Manchester, UK) ESI MS instrument or a Q-Star XL 
(Applied Biosystems, Foster City, USA) ESI-QTOF instrument using the appropriate 
ionization mode. M/zs of interest were subjected to collisionally induced dissociation 
(CID) on the Q-Star XL instrument, with collision energy adjustment to give some 
intact signal. The operation of mass spectrometry instruments and acquisition of 
data were carried out by Dr Catherine H Botting (BMS Mass spectrometry and 
Proteomics Facility, University of St Andrews). 
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2.3 Results 
2.3.1 Protein purification 
2.3.1.1 Immobilized-metal affinity chromatography  
Over expressing His6-AcsD E. coli cells were grown, induced and lysed as described in 
section 2.2.1. The first purification step after cell lysis was carried out using 
immobilized-metal affinity chromatography (IMAC) (Figure 2.7 a). His6-AcsD was 
detectable in the crude protein solution (lane 1) at the level of the 75 kDa standard 
protein marker (lane S). Expression trails of His6–AcsD at 37 °C yielded only smaller 
amounts of soluble protein (data not shown). It was found that this effect could be 
minimized by decreasing the temperature to 15 °C after induction. However, still a 
large amount of insoluble protein was found in the cell pellet (lane 3) compared to 
the supernatant (lane 2). Elution with 500 mM imidazole indicates that most of His6–
AcsD was eluted in the first fraction (lane 6) and less in the later ones (lane 7 and 8). 
Other than crude protein solution (lane 2) eluted His6-AcsD (lane 6-8) was relatively 
pure.  
2.3.1.2 Desalting and tag removal 
The high imidazole concentration from the IMAC purification had a negative effect 
on AcsD when kept at RT for several hours. Therefore protein solution was directly 
desalted on a HiPrep 26/10 column. The elution profile indicates a peak (10 – 15 mL) 
corresponding to AcsD protein (Figure 2.7c). A smaller peak at 55-70 mL contains the 
separated ions, such as imidazole and salts. TEV-cleavage was carried out O/N at RT 
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and verified by SDS-PAGE (Figure 2.7b). Cleavage was successful with a protease to 
protein ratio of 1:50. TEV protease and cleaved tag were removed by a second IMAC 
purification step using a 5 mL HisTrap column (GE Healthcare). Protein and washing 
buffer contained 50 mM imidazole to avoid AcsD binding to the column.  
a 
 
b 
 
c 
 
Figure 2.7: First step in His6-AcsD purification and TEV cleavage. (a) First purification of AcsD with immobilized-
metal affinity chromatography (IMAC): standard; 1 crude protein solution after cell breakdown; 2 supernatant 
(S/N); 3 pellet dissolved in 8 M urea; 4 flow through of IMAC column; 5 protein eluted by the washing step; 6 
elution I;  7 elution II; 8 elution III; (b) Cleaving of His6-tag with 1:50 TEV protease; S standard; 1 His6-AcsD; 2 
cleaved AcsD  treated with 1:50 TEV protease ; 3 cleaved AcsD  treated with 1:10 TEV protease. (c) Elution 
profile of the desalting step on a HiPrep 26/10 desalting column to remove imidazole used for elution in the 
IMAC purification step. 
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2.3.1.3  Gel filtration 
In a final gel filtration step, AcsD was separated from remaining impurities, such as 
potential breakdown products or E. coli proteins. The elution profile shows that AcsD 
elutes from fraction B4 to C6 (Figure 2.8a). Protein containing fractions (10 µL each) 
were analyzed by SDS-PAGE to examine their purity (Figure 2.8b). Purest fractions 
(B4-C6) were combined and concentrated to 6 – 9 mg/mL. Fractions with impurities 
or degraded AcsD (B6 and B5) were discarded. A second smaller peak (D5-E4) 
contained no detectable protein (Figure 2.8a, b). The high molecular weight band 
(~140 kDa) in fraction B4-C5 was confirmed by mass spectrometry to be AcsD and is 
likely to be dimeric.   
a 
 
 
b 
 
Figure 2.8: Last purification step of AcsD. (a) Elution profile of gel filtration step on a Superdex 200 (GE 
Healthcare) column, the last AcsD purification step.  (b) SDS-polyacrylamide gels of AcsD gel filtration showing 
the collected fractions. Highest purity of protein is found in fraction B4-C6. 
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2.3.2  AcsD activity assay and kinetics 
Activity of wt and mutated His6-AcsD was determined in a coupled enzyme assay 
(see section 2.2.5). The AcsD activity assay is based on coupling the AcsD dependent 
formation of AMP to the LDH catalyzed oxidation of NADH to NAD+. The coupled 
enzymes used in the assay are myokinase (MK), pyruvate kinase (PK) and lactate 
dehydrogenase (LDH), whereas later two enzymes were purchased combined in one 
solution. The reduced form of nicotinamide adenine dinucleotide can be excited at 
376 nm, which emits at 462 nm, whereas the oxidized form does not. Hence, 
enzymatic conversion of NADH to NAD+ can be monitored by fluorescence. Data 
were used to compare mutant with wt enzyme activities and calculate kinetic 
parameters. 
a b  c 
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Figure 2.9: AcsD activity assay setup. (a) Calibration of the fluorescence based AcsD activity assay. At high NADH 
concentrations (>1 mM) fluorescence intensity decreases due to fluorescence quenching. (b) At lower NADH 
concentrations the relation is not precisely linear. This effect occurs in water (black) as well as in reaction buffer 
(minus AcsD) (blue). (c) Comparison of raw data (fluorescing units) with normalized data (NADH concentration) 
shows that normalization improves the linear relationship.  
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2.3.2.1 Data evaluation 
In order to obtain an appropriate concentration regime for accurate NADH 
detection, reactions lacking AcsD were measured with NADH concentrations up to 
2 mM (Figure 2.9a). Above 1 mM NADH fluorescence intensities decreased when 
more NADH was added, presumably due to self-quenching. The concentration range 
employed from 50 to 300 µM NADH (in reaction buffer and in water) still showed a 
non-linear relationship (Figure 2.9b). If one assumes a linear relationship, the fit of 
kinetic curves was acceptable, but shows deviations from the “normal” shape. 
Therefore the fluorescence intensity was converted to NADH concentration using a 
calibration curve, which resulted in a much smoother graph (Figure 2.9c). The 
regression is exponential and the fitting function, obtained by Origin, was used to re-
calculate and convert the raw fluorescent intensity data to NADH concentration 
using Microsoft Excel (Figure 2.9b). Standard calibration graphs were obtained (on a 
daily basis before each set of experiments) to ensure reliable conversion. These 
derived values for NADH concentration improved the fit to standard kinetic curves. 
Data for kinetics were fitted with Michaelis-Menten equation using Origin software 
with the background rate (no AcsD) subtracted.  
2.3.2.2 Stability and verification of AMP activity assay  
Since the spectroscopic assay by Wu and Hill (Wu and Hill 1993) was modified (see 
section 2.2.5), verification of its liability and usability is important. Initial tests of 
AcsD reaction at 37 °C were completed within minutes. In reactions lacking AcsD 
background signal was observed. To obtain more stable and reproducible data, the 
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reaction temperature was dropped to 20 °C and a 5 min pre-incubation time added 
and recorded. At this temperature reactions with 2 µM wt AcsD were completed 
within 15 min. No background reaction was detected in samples were AcsD was 
omitted (Figure 2.10a).  
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Figure 2.10: Control reactions for AMP activity assay. (a) Used negative and positive controls to verify stability 
of AMP assay. Reactions with 2 µM of AcsD wt protein (black ) finished (consumption of all NADH) within 
15 min. Reactions where L-serine (orange ), citrate (turquoise ),  ATP (blue ) , AcsD (red ),  myokinase 
(MK) (yellow-green ⊳) or MK/AcsD (grey ) was omitted, were not active. Samples with 2 µM AMP, but no 
AcsD (dark blue --) were 6 fold faster. (b) AMP assay with different concentrations of AcsD provides additional 
proof that AcsD is rate limiting. (c) Reaction rates plotted over AcsD concentration used in (b) show a linear 
regression. (d) Reactions with halved or doubled concentration of myokinase (MK) and pyruvate kinase/ lactate 
dehydrogenase (PK/LDH) have no significant effect on turnover rates of NADH. Reactions with 1xMK/ 1xPK/LDH 
(black ) and 2xMK (red ) show slight faster turnover rates than reactions with 0.5 MK (turquoise ), 2x 
PK/LDH (orange ) or 0.5x PK/LDH (blue ). A negative control without MK (yellow-green ⊳) is not active, 
while the positive control with 2 µM AMP (where AcsD was omitted) is the fastest reaction (dark blue  --).   
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When at least one AcsD substrate (either L-serine, citric acid or ATP) was omitted, no 
significant decrease in NADH levels was detected. Similar observations were made in 
reactions lacking AcsD and/or myokinase. Addition of exogenous AMP (2 μM) to 
reactions where AcsD was omitted resulted in a rate of NADH consumption over six 
fold faster than AcsD (Figure 2.10a). This indicates that the coupled enzymes are not 
rate limiting even at artificially high concentrations of AMP. Hence, AcsD must be the 
rate limiting enzyme. This was tested with increasing or decreasing protein 
concentrations, which reflected in increasing or decreasing NADH turnover rates, 
respectively (Figure 2.10b). Plotted rates over protein concentrations show a linear 
regression and indicate that AcsD in this concentration range (0.5-3.5 µM) is not yet 
saturated (Figure 2.10c). These experimental data suggested that 2 µM AcsD per 
reaction is reasonable and was chosen to obtain consistent data. 
The influence of coupled enzymes on reaction rates by varying their protein 
concentration was studied and compared with the AMP reaction. No significant 
effect was observed by doubled or halved MK or PK/LDH concentrations (Figure 
2.10d). Reactions containing 4 units of MK, 8.4 units of PK and 12.6 units of LDH 
showed the fastest conversion and were used in all further samples. Reactions 
lacking MK showed no change in NADH levels and indicate that AcsD is producing 
AMP and PPi and not ADP, which could have been used by subsequent PK and hence 
would lead to fluorescence decrease. All these control reactions support and confirm 
that AcsD is the rate limiting enzyme. They also verify the stability and usability of 
AMP activity assay as a tool to obtain kinetic parameters. 
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2.3.2.3 Testing of proposed nucleophiles 
As mentioned in section 1.5, AcsD is proposed to perform a condensation reaction 
between citric acid and L-2,4-diaminobutyric acid (DABA) or ethanolamine (EA) 
(Challis 2007). The activity was tested with a variety of nucleophiles, including 
L-serine, D-serine, ethanolamine and DABA which could in theory act as the substrate 
of AcsD. Reactions containing L-serine or hydroxylamine were more active than these 
with ethanolamine or DABA (Figure 2.11). D-serine turns over with a similar rate as 
ethanolamine, but twice as fast as DABA. All other tested nucleophiles have activities 
similar to reactions where no nucleophile (other than water) was present (Figure 
2.11a). Control reactions where AcsD was omitted showed no detectable activity 
(Figure 2.11b). 
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Figure 2.11: Activity assay with likely natural substrates. (a) L-serine is more reactive than D-serine, 
ethanolamine or hydroxylamine. Hydroxylamine, the second smallest nucleophile (water would be the 
smallest), accelerates the reaction much faster as reactions lacking any nucleophiles (except water). L-alanine, 
β-alanine or glycine have activity similar to reactions where no nucleophile (other than water) was present. 
Reactions lacking His6-AcsD (wt) but containing L-serine showed no detectable activity. (b) Raw data for (a). L-
serine (black ), D-serine (orange ), ethanolamine (olive ), L-2,4-DABA (blue ), hydroxylamine (grey ), 
L-alanine (purple ), β-alanine (dark yellow ), glycine (dark cyan ), no nucleophile (except water) (blue ), 
no His6-AcsD (wt) but L-serine (red ).  
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L-serine, the fastest nucleophile, reacts 5 to 10 fold quicker than ethanolamine or 
DABA, respectively. Since the carboxylate moiety of serine is not incorporated in the 
final siderophore it must be removed in subsequent synthesis steps.  
2.3.2.4 AcsD reaction generates AMP and PPi 
ATP has recently been shown to be converted to AMP by other NIS synthetases (Kadi 
et al. 2007; Oves-Costales et al. 2007). The decomposition of citryl-adenylate by AcsD 
should therefore liberate AMP, a citrate derivative and pyrophosphate. No NADH 
consumption (with L-serine as nucleophile) was detected when myokinase was 
omitted (Figure 2.12). Thus AcsD cannot form ADP (and generate Pi) on its own, as 
ADP is the substrate of pyruvate kinase (the next enzyme in the coupled assay, see 
also section 2.2.5 ). Formation of ADP by AcsD would have caused NADH oxidation 
and led to a decrease in fluorescence signal. Myokinase converts AMP and ATP into 
two molecules ADP, which are then used by pyruvate kinase to recycle ATP by PEP 
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Figure 2.12: AMP production by AcsD. NADH consumption using His6-AcsD with and without MK demonstrates 
AMP (and by implication PPi) formation by AcsD. Omitting myokinase (orange circles) results in no detectable 
activity. Myokinase converts AMP and ATP to ADP. ATP is present in the reaction mixture and AMP must 
therefore be produced by AcsD.  
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dephosphorylation. ATP is present in the reaction mixture and AMP must therefore 
be generated by AcsD (Figure 2.6).   
2.3.2.5 Kinetic data 
Kinetic parameters for AcsD were obtained by varying the concentration of buffered 
citric acid (pH 8.0) from 0 to 90 mM. To ensure Michaelis-Menten enzyme kinetics 
the second substrate (L-serine) was added in excess (75 mM) to the reaction, while 
all other parameters were kept constant as described in section 2.2.6.  
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Figure 2.13: Enzyme kinetics for citrate. (a) Data obtained with 15 and 30 mM MgCl2 were fitted with Michaelis-
Menten equation (dotted lines) and corrected for background. (b) Same as in (a), but including data with 
105 mM MgCl2. At high citrate concentrations reaction rate increases when artificially high concentration of 
Mg2+ are present. Error bars were generated by three independent measurements.  
 
Data were converted (see section 2.3.2.1) and rates (slopes) determined by fitting 
each data set with a linear function using Origin (Origin Labs). Rates (NADH 
consumption in µM min-1) were plotted over citric acid concentrations (Figure 2.13a). 
With a Mg2+ concentration of 30 mM the apparent kinetic parameters for citrate are 
Km = 14.7 ± 0.002
 mM, kcat = 2.2 x 10
3 s-1 and kcat/KM = 1.5 x 10
5 M-1s-1 (Table 2.6). 
Repeating the assay with 15 mM MgCl2 shows, as citrate concentration increases 
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beyond 15 mM, that reaction rate decreases rapidly. This can be attributed to Mg2+ 
citrate complexation, which is supported by the fact that additional Mg2+ increases 
the reaction rate (Figure 2.13b). However, high concentrations of Mg2+ also 
significantly diminish AcsD performance at low citric acid concentrations. 
 
Table 2.6: Derived apparent kinetic parameters for citric acid. The values were corrected by subtracting the 
background rate where AcsD was omitted. 
MgCl2 KM (mM) Vmax (µM/min) kcat (s
-1) kcat/KM (M
-1 s-1) 
15 mM 5.96 ± 0.86 71.44 ± 4.06 2.14 x 103 3.6 x 105 
30 mM 14.67 ± 0.02 73.24 ± 0.046 2.20 x 103 1.5 x 105 
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2.3.3 Screening and optimization of co-crystals 
Due to problems in obtaining good diffracting co-crystals with the published sodium 
tartrate condition (McMahon et al. 2008), a new screening series was carried out 
and revealed a new crystallization condition in the JMAC Screen, well 92  (0.1 M 
TRIS-HCl pH 8.5, 20 % (w/v) PEG 8000). Though crystals were thin clustered plates 
(Figure 2.14a), optimization for each co-complex by varying salt, precipitant, buffer 
and substrate concentration improved clusters to rather large and well diffracting 
crystals (Figure 2.15). For more information on each condition see section 2.2.2.  
a 
 
b 
 
 
Figure 2.14: Initial crystal condition of AcsD co-complex. (a) Initial crystal clusters obtained after a couple of 
days from JMac Crystal Screen tube 92. (b) Experimental detail used for the crystallization robot (Cartesian 
HoneyBee) condition: 0.1 M TRIS-HCl pH 8.5, 20 % (w/v) PEG 8000 
While structures of apo, citrate co-complex (overlapping with ATP) and ATP co-
complex show P212121 symmetry (Figure 2.15a-c), the AMP and SO4
2-, adenosine-
citrate-SO4
2 and ethylenediamine co-complex were solved in P1 space group. Other 
than the P212121 crystals, P1 crystals have a rhombic morphology with sharp edges 
(Figure 2.15d-f). The data set for the ethylenediamine co-complex was collected 
from a very large crystal, joined with a smaller fragment as seen in Figure 2.15f.  
Careful centering on the top edge using a beam size of 100 x 100 µm (ID29, ESRF) 
helped to avoid an overlapping diffraction pattern during data collection. 
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2.3.4 NIS conserved residues in active site 
A ClustralW alignment of selected type A, B and C NRPS-independent siderophores 
shows that in comparison with the active site region of AcsD several conserved 
residues are found (Figure 2.16a). Residues S279, R281, K293, R305, E341, R369, 
H444, N447 and D464 are strongly conserved, while H170, T282, T301, E341, H444, 
Q446, N447, E466 and N509 are partly conserved in the superfamily of NIS 
siderophores. Interestingly, all but not E341 are involved in coordination of ATP or 
Mg2+ in AcsD (Figure 2.16b, c). Most of these residues (S279, R281, T282, K293, T301, 
R305 and R369) are located in the middle domain (red), while the remaining residues 
are located in the C-terminal domain (green) (Figure 2.16a). 
 
Figure 2.15: Crystal gallery of AcsD crystals. (a) AcsD apo crystals (modified from McMahon et al. 2008). (b) Co-
complex with citrate (overlaps with ATP). (c) Co-complex with ATP. (d) Co-complex with AMP and SO4
2-. (e) Co-
complex with adenosine, citric acid and SO4
2-. (f) Co-complex with ethylenediamine and ATP. 
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a 
 
b  c 
        
Figure 2.16: Conserved active site residues. (a) Alignment of type A, B and C NIS synthetases. Highlighted in red 
are residues absolutely conserved in the active site of AcsD, residues highlighted in blue are partly conserved 
within NIS. Residues highlighted in red and blue coordinate ATP in AcsD. (: AcsD residues mutated) Protein 
sequences and Genbank references used in constructing the alignment: Type A AcsD - Pectobacterium 
chrysanthemi gi|16118732; PvsD - vibrioferrin biosynthesis protein Vibrio parahaemolyticus gi|23307118; IucA - 
IucA protein E. coli CFT073 gi|26109870. Type B AcsA - P. chrysanthemi gi|16118729; SbnC - Staphylococcus 
aureus gi:32441989; PvsB - vibrioferrin biosynthesis protein PvsB V. parahaemolyticus gi:23307116. Type C IucC - 
E. fergusonii gi|22034306; DesD - hypothetical protein SCO2785 Streptomyces coelicolor A3(2) gi|21221236; 
AcsC - P. chrysanthemi gi|16118727). AcsD domains are colored in blue (N-terminal domain), red (middle domain) 
and yellow (C-terminal domain). (b) AcsD monomer structure with ATP bound (balls and stick model) in cartoon 
representation color coded and annotated as above. (c) Absolutely conserved (highlighted in red) and partly 
conserved (highlighted in blue and green) active site residues in NIS enzymes coordinating ATP (colored in white 
carbons) and Mg2+ (colored in green). 
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2.3.5 Co-complex structures 
The native protein and all co-complex structures are essentially identical with a root 
mean square deviation (rmsd) for 573 Cα atoms of 0.4 Å. No large conformational 
changes were observed upon ligand binding. The active site is created by the 
arrangement of the three domains which form a deep cavity. In this cavity ATP is 
coordinated between the middle, C-terminal domain and loops 4 and 7. It is cradled 
in a position perpendicular to β-strands 10, 11 and 12 (Figure 2.17a). AMP and 
sulfate are located in the same position as ATP (Figure 2.17b). 
a  
 
b 
 
c  
 
d  
 
Figure 2.17: Complex structures of AcsD from Pectobacterium chrysanthemi. (a) Monomer of AcsD in cupped 
hand representation cradling ATP. N-terminal domain is colored in blue; middle domain in red and C-terminal 
domain in green. Carbons of ATP are shown in white. Key secondary structure elements are labeled from the N-
terminus. (b) AMP sulfate co-complex, coloring as above. (c) Citric acid artifact (bound at high citrate 
concentrations) mimicking the triphosphates of ATP. Coloring as above. (d) Coordination of citrate in its “real” 
binding site. Color and labeling as above; carbons of citric acid are yellow and for adenosine in white; oxygen 
atoms of sulfate are colored in dark grey. 
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Initial attempts to co-crystallize AcsD with citrate and ATP-γ-S led to a complex in 
which citrate is bound in the ATP site mimicking the triphosphate (Figure 2.17c). No 
density was observed for the ATP analogue. As this co-complex was obtained in 
artificially high citric acid concentrations (300 mM) it was considered to be an 
artifact. AcsD was therefore co-crystallized with adenosine, sulfate and citrate. This 
was intended to lock the protein into the correct conformation by imitating bound 
ATP but still leave space (at the α phosphorous) for citrate to bind in its true location 
(Figure 2.17d). In this co-complex, a sulfate ion binds at the γ phosphate position and 
adenosine binds in the same pocket as seen in the ATP structure. A citrate molecule 
was found bound in subunit B adjacent to the ATP binding site. 
2.3.5.1 ATP coordination 
ATP is coordinated almost exclusively through interactions with conserved residues 
(Figure 2.16, Figure 2.18a). Residues S279, R281, T282, K293, R305, R369, H444 and 
D464 all interact with the phosphates of ATP or with citrate (R305, H444) in the 
respective structures. Only K293, R369 and E466 are located on secondary structure 
motifs (β10, β12 and L10 respectively). T282 (totally conserved in C, partly in A) and 
H444 (conserved in Type A and C but not B) are the only residues not highly 
conserved in all groups of NIS. A further five conserved residues, H170, T301, H444, 
Q446 and N509, one Mg2+ ion and six bridging water molecules make additional 
contacts to the adenosine moiety of the ATP structure. In both subunits, the Mg2+ 
ion is bound to the α and γ phosphates of ATP and the side chains of Q446, N447 and 
D464 in an approximate octahedral environment (Figure 2.18a). There is no Mg2+ in 
the apo or citrate bound structures. In this position the adenine purine ring is 
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stabilized by a π-π interaction network between H170 and H444 whilst making 
additional interactions with N509. Interestingly N509 is only conserved among type A 
enzymes. The ribose ring is twisted relative to the adenine purine ring and is 
stabilized in this conformation through interactions with T301 and Q446. 
a b 
           
 
c d 
                  
Figure 2.18: AcsD substrate coordination.  Important secondary structure elements such as loops (e.g. L4 or L7) 
or sheets are labeled from the N-terminus. (a) ATP binding site with ATP (b) citrate artifact, binding position 
overlaps with ATP phosphates (superposed in wireframe). (c) AMP - sulfate co-complex overlaps with ATP 
(superposed in black wireframe). Carbons of AMP colored in white. (d) Citrate adenosine sulfate complex, true 
binding position. 
 
Q446 adopts a different rotamer in the ATP coordinated structure relative to the apo 
and citrate (artifact) bound structures to accommodate ATP and Mg2+ ion (Figure 
2.18a, b). From currently 250 deposited structures that contain ATP and a 
coordinating Mg2+, only 7 structures show an α- γ phosphate coordination. By far the 
  
— 67 — 
most common is the coordination of the β and γ phosphates. Interestingly, the ATP 
conformer in AcsD, which is shaped akin to a horse shoe, has not been observed in 
the protein data bank. Binding of AMP and sulfate in the AMP-sulfate co-complex 
shows a similar coordination as ATP (Figure 2.18c). Only T301 adopts a different 
rotamer.  
    
Figure 2.19: Surface representation of the water filled cavity in monomer B adjacent to the ATP binding 
pocket. AcsD is rotated by 180° compared to the view in Figure 2.17a. The atoms of ATP are colored as above, 
the water molecule in monomer B is colored in red. 
 
The binding site for ATP is larger than ATP. The bottom end of the ligand binding site 
extends into a water filled cavity (Figure 2.19). Monomer B binds a single water 
molecule, but in monomer A three water molecules are located in this pocket. 
Hence, this cavity is likely to accommodate generated pyrophosphate (PPi) during 
catalysis by replacing these water molecules. 
  
— 68 — 
2.3.5.2 Citric acid coordination 
First attempts to co-crystallize citrate with ATP-γ-S (as a non-cleavable ATP analogue) 
showed that citric acid was coordinated in a similar position as the triphosphates of 
ATP (Figure 2.18b). No electron density for ATP-γ-S was observed. The high 
concentrations of citric acid (300 mM) used in the crystallization condition probably 
led to this artifact structure. The “correct” citrate structure was obtained by co-
crystallization with adenosine and sulfate imitating bound ATP. Citrate was only 
found bound in monomer B. The electron density in monomer A was not distinct 
enough to model another molecule of citric acid. Citrate binds to residues located 
mainly on loops (Figure 2.18d). The electron density shows that the central 
carboxylate of citrate is recognized by T301 and R305. The hydroxyl group makes a 
hydrogen bond to Q302. These interactions serve to unambiguously position the 
citrate with the pro-R carboxylate pointing towards the ATP site making hydrogen 
bonds to H444 and R305. The pro-S carboxylate makes hydrogen bonds with H170, 
K563 and Y504. Real space refinement of citrate in all possible orientation was used 
to select and determine its correct and final position (Figure 2.18d).  
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2.3.6 AcsD shares part of the cAPK fold of kinases 
A structure similarity search in DALI (Holm and Sander 1993) and SSM (Krissinel and 
Henrick 2004) reveals that AcsD has an overall novel topology, with no match to any 
known protein. Superimposing ATP molecules of all 250 in the PDB deposited ATP 
co-complex structures to the AcsD bound ATP revealed that only 7 structures show 
an α and γ ATP phosphate coordination with Mg2+. These seven structures are mostly 
kinases (1csn, 1phk, 1qmz, 1ql6) (Owen et al. 1995; Xu et al. 1995; Brown et al. 1999; 
Skamnaki et al. 1999) including two cAMP-kinases (1atp, 1rdq) (Zheng et al. 1993; 
Yang et al. 2004) and one ribonucleotide transformylase which is involved in the 
purine biosynthesis (1kj9) (Thoden et al. 2002).  
a 
 
b 
 
Figure 2.20: Similarity between AcsD and the cAPK fold. (a) Partly secondary structure match of AcsD colored in 
grey and 1e8x (a cAPK kinase) colored in blue. The position of ATP is shown in yellow (AcsD) or magenta (1e8x). 
(b) Close up of the matching region of secondary structure. 
 
Furthermore, a domain similarity search reveals, that the central two domains (palm 
and fingers) do have partial structural match to several cyclic AMP-dependent 
protein kinases (cAPK) which bind nucleotide triphosphates (NTPs) including 1e8x 
(Walker et al. 2000), 2gqr (Ginder et al. 2006) and 1cja (Steinbacher et al. 1999). The 
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structures superimpose with rmsd between 3.30 and 3.55 Å for around 130 matching 
Cα atoms (Figure 2.20).  
a 
 
 
 
b 
 
c 
 
Figure 2.21: Essential features of the cAPK fold required for catalysis. (a) The similar structural region of AcsD 
(grey) compared with 1e8x (blue) showing ATP bound in different orientation with key residues (b) ATP binding 
site of 1e8x as an example of the cAPK fold, the position of residues involved in tethering ATP are conserved in 
AcsD. ATP binding in 1e8x is shown in magenta. Superimposed in yellow is the position of ATP in AcsD. 
Secondary structure elements (loops (L5, L7, L9 and L10) and sheets) are labeled from the N-terminus. (c) Space 
fill diagram illustrating the different environment of the conserved ATP binding pocket, orange is ATP from 
1e8x and yellow is ATP from AcsD. i 1e8x binding pocket ii AcsD binding pocket iii different orientation than ii; 
iv AcsD pocket with 1e8x ATP superimposed shows that it clashes with Y159 and F372. 
 
NTP in the cAPK fold is bound in a conservative manner and the adenosine moiety 
extends deep into a neutrally charged pocket sitting almost parallel to β-strands 10, 
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11 and 12 (Figure 2.21). Residues on analogous loops to those in AcsD (L5, L9 and 
L10) bind NTP through interactions with the exposed phosphate(s) (Figure 2.21b). 
Other than the adenosine rings, the phosphates occupy the same space as those in 
AcsD, but the vectors from α to γ phosphates have opposite directions (Figure 
2.21a,b). Additional residues in the neutral pocket make interactions with the 
adenosine moiety. Although these structures share a common fold and phosphate 
coordination with AcsD, coordination of the adenosine moiety in AcsD is strikingly 
different (Figure 2.21b).  
The cAPK adenosine moiety binding pocket in AcsD has a basic charge and is 
sterically occluded compared to the neutral pocket in the cAPK fold. In 1E8X residues 
E880, V882 and M953 are found in a neutral pocket. In the AcsD pocket they are 
replaced by Y159, F291 and F372 and also occupied by conserved residues R369 and 
semi conserved R463 (alternative is K) (Figure 2.21c). As a result, the triphosphates 
of ATP in AcsD sit in a position normal to β-strands 10, 11 and 12 and bind to 
residues on two insertions, L4 and L7, found in AcsD relative to the classic cAPK fold. 
L4 and L7 extend across the top of the ATP binding site effectively sealing the site 
from above. In the cAPK fold L4 is not found and L7 is typically much shorter. As a 
result only one route (in and out) for large molecules exists and directly exposes the 
α phosphate of ATP in AcsD for incoming substrates (Figure 2.19).  
2.3.7 Mutational studies 
Active site and conserved residues in AcsD were mutated as described in section 
2.2.4. In Table 2.2 (section 2.2.4.1) all created mutants including progress in 
purification and testing are summarized. In the sequence alignment (Figure 2.16a) all 
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mutated sites of AcsD are marked with a star (). Five of the 23 planned mutants 
failed in PCR, expression or later purification steps. This was mainly caused by 
inefficient primers or mutations which caused more inclusion bodies and hence led 
to insoluble protein. To ensure correct folding of each purified mutant, circular 
dichroism (CD) spectroscopy analysis was carried out (see appendix B, Figure 4.7). 
The previously described AcsD activity assay was used for activity detection with L-
serine (Figure 2.22) and/or other substrates (Figure 2.34).  
Any mutation in T301, R305, H444 and D464 led to total loss in activity (<1 %) and 
hence are likely to be crucial for AcsD activity. T301 and R305 recognize the central 
carboxylate of citrate and H444 binds to the pro-R carboxylate of citrate (Figure 
2.18d). D464 binds to the β and γ phosphates of ATP and is involved in Mg2+ 
coordination. H444A and R305K mutants still have a residual activity of ~1 % and 
~1.5 %, respectively. All other tested mutants show activity above 5 % (compared to 
wt activity). Remarkably, mutation of R576 residue had only little (R576A, ~90 %) or a 
minor (R576K, ~47 %) effect on enzyme activity. This residue is not conserved and 
located on a flexible loop on top of the active site. It was thought to be involved in 
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Figure 2.22: AMP activity assay for wt AcsD and active site mutants. 
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coordination of citric acid (Schmelz et al. 2009). If so, R576 is not crucial or important 
for catalysis.  
a b 
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Figure 2.23: Mutation in ATP binding cavity. (a) At the bottom of ATP binding cavity three water molecules (red) 
are located. A model of F291 mutation (colored in red) to tyrosine (carbons in white) shows, that it may lead to 
displacement of water and therefore decreases space for generated pyrophosphate. (b) Though F291 is far 
away from the α phosphate of ATP, a simple mutation to tyrosine leads to a 10 fold decrease in AcsD activity. 
Mutants H170A, E193Q, H242N and S279A show that they are important, but not 
lethal for catalysis since they still have a remaining activity of ~5-25 % compared to 
the wt protein. E193 and H242 are not located in the active site. Glu193 stabilizes 
the secondary structure of L4 by forming salt bridges with other conserved residues 
K177 and R179. His242 is located on the β6-α5 turn and binds weakly to a water 
molecule (W229 in ATP structure) and the backbone of I280 and V244 on L5 and α5-
helix, respectively. The polar H242N mutant is still able to maintain the binding to 
V244 backbone but not to W229 or I280 on L5, which contains the conserved and 
ATP coordinating residues S279 and R281 (Figure 2.16). Hence the H242N mutation 
may lead to a more flexible L5 resulting in a reduced enzyme rate. Mutation of 
conserved H170 to alanine is more critical and reduces the reaction ~7 fold. This 
residue facilitates a π-stacking interaction with adenosine ring of ATP and binds to 
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the pro-S carboxylate of citric acid and a mutation therefore is likely to weaken 
binding of ATP and citric acid. F291, located at the bottom of ATP binding cavity, 
does not interact with ATP (Figure 2.23a). However, mutation to tyrosine results in a 
10 fold loss of activity (Figure 2.23b). The larger tyrosine (-OH) is likely to displace 
one of the nearby coordinated water molecules and hence reduces available space in 
the bottom of ATP binding cavity (Figure 2.23a). 
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2.3.8 Mass spectroscopy of AcsD reaction product 
2.3.8.1 Timeline of AcsD reaction 
Although AMP production in AcsD reaction was demonstrated in the AMP activity 
assay (see section 2.3.2.4), mass spectroscopic analysis was used to characterize and 
verify AMP and final product formation. Different time points of AcsD reaction with 
ATP, Mg2+, citric acid and L-serine were analyzed with a LCT-ESI MS instrument in 
negative mode (section 2.2.8).  
          
Figure 2.24: Mass spectroscopy of AcsD reaction with L-serine. (a) Time line of AcsD with L-serine measured 
with LCT-ESI MS. Two peaks increase over time corresponding to AMP ([M-H+] m/z =346) and citryl-L-serine 
([M-H+] m/z =278). (b) Control reactions, where ATP was omitted or only solvent was tested, show not the 
additional peaks detected in (a). 
 
Two new mass peaks, not detected in control reactions, were observed with m/z 
values of 277.9 and 345.9 after 30 min incubation. These peaks get more prominent 
as subsequent time points show (Figure 2.24a). These mass peaks were not observed 
in control solutions or reactions where ATP was omitted (Figure 2.24b). AMP has a 
theoretical m/z value of 346 for [M-H]- which is close to the detected mass of 
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m/z=345.9. The lower mass peak (m/z=277.9) can be attributed to citryl-L-serine 
which has a theoretical mass of m/z=278.05. These results support the obtained 
assay results (section 2.3.2.4) and verify that AcsD is able to utilize ATP, Mg2+, citric 
acid and L-serine producing citryl-L-serine and AMP. 
2.3.8.2 Tandem mass spectrometry of citryl-L-serine 
Isolated and purified large scale enzymatic derived citryl-L-serine was identified as N-
citryl-L-serine (carried out in the group of Prof. G. Challis). This was surprising as it 
was thought that L-serine would catalyze ester bond formation with its hydroxyl, 
rather than amide formation with its α-amino group and the pro-R carboxylate of 
citric acid. The fragmentation pattern of enzymatic derived citryl-L-serine, isolated N-
citryl-L-serine and chemically synthesized O-citryl-L-serine (by group of G. Challis) 
were tested and compared using tandem mass spectrometry (section 2.2.8). Directly 
injected AcsD product (no isolation or purification) of N-/O-citryl-L-serine led to four 
major daughter ions with m/z = 260.05, 198.08, 173.04 and 111.03 (Figure 2.25a). 
Each of these ions result from loss of water alone (m/z = 260.05), two water plus 
carbon dioxide (m/z = 198.08), loss of serine (C3H5NO2, m/z = 173.04) and loss of 
serine plus two waters plus carbon dioxide (m/z=111.03) (Figure 2.26, see also Table 
2.7), respectively. 
Isolated N-citryl-L-serine has only three major daughter ions with m/z = 260.05, 
198.05 and 110.07 (Figure 2.25b). The m/z = 260.05 and 198.05 daughter ions are 
identical to those produced of directly injected citryl-L-serine. The m/z = 110.07 
daughter ion could result by loss of serine (C3H4O3) plus two waters plus carbon 
dioxide (Figure 2.26). However the m/z = 173.04 daughter ion for N-citryl-L-serine is 
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barely detectable. The amide bond is significantly stronger (compared to ester) and 
hence might not undergo cleavage as readily. Furthermore, the chemically 
synthesized O-citryl-L-serine ester shows the same fragmentation pattern (Figure 
2.25c) as directly injected enzymatic product or citric acid (Figure 2.25a, d), 
identifying it as O-citryl-L-serine.  
        
Figure 2.25: MS/MS analysis of AcsD and control reactions. (a) Tandem mass spectroscopy of enzymatic derived 
(but not purified) citryl-L-serine with a strong m/z = 111 peak typical for O-citryl-ester (see also Figure 2.26). (b) 
The fragmentation pattern for isolated and purified N-citryl-L-serine has the m/z=110 peak which can be 
attributed to a citryl-amide linkage (see also Figure 2.26). (c) Fragmentation pattern of chemical synthesized O-
citryl-L-serine ester shows like (a) and (d) the characteristic m/z=111 peak. Other daughter ions are identical 
with (a), identifying the enzymatic product as O-citryl-L-serine and not as N-citryl-L-serine. (d) Daughter 
fragments of citric acid show a similar pattern compared to O-citryl-L-serine (a) and (c).  
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Figure 2.26: Possible O-citryl-L-serine (ester) and N-citryl-L-serine (amide) MS/MS fragments. The fragmentation 
scheme shows that a simple fragmentation generated the ester specific m/z=111 and the amide specific m/z= 
110 fragments. 
 
Interestingly, the MS/MS fragmentation produces a specific pattern for authentic 
ester or amide citrate-L-serine (Figure 2.26). Simple fragmentation of the AcsD ester 
product with L-serine leads to a daughter ion of m/z = 111, as seen for directly 
injected citrate-L-serine and the chemical synthesized O-citrate-L-serine. On the 
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other hand fragmentation of the amide yields an ion with m/z = 110, as seen for 
isolated N-citryl-L-serine (Figure 2.26, Table 2.7). This is strong evidence that AcsD 
catalyzes ester formation and liberates O-citryl-L-serine, consistent with lack of 
reactivity demonstrated with β-alanine (Figure 2.11). Hence N-citryl-L-serine from 
the preparative scale most likely results from re-arrangement of O-citryl-L-serine (the 
product of the enzymatic reaction) during the purification (for more experimental 
detail see Schmelz et al. 2009). 
 
Table 2.7: MS/MS fragmentation pattern of O- and N-citryl-L-serine 
 
 
2.3.9 Catalysis of ester, amide and thioester bond formation 
2.3.9.1 Systematic screening for possible nucleophiles 
L-serine and sixteen other related small molecules (Figure 2.27) were tested using 
the fluorescence based activity assay as described in section 2.2.5. All tested 
nucleophiles were purchased from chemical suppliers, such as Sigma Aldrich or 
Fluka. Most nucleophiles are common and essential metabolic products or 
substrates, such as glycine, L-alanine, L-isoserine or L-lactic acid. In section 2.3.2.3 it 
Fragments structure enzymatic 
O -citryl-L -serine 
(direct injection, 
ester)
isolated 
N -citryl-L -serine 
(amid)
synthetic 
O- citryl-L -serine 
(ester)
citric acid
O-
 or N -citryl-L -serine  C9H12NO9 278.10 278.07 278.06
O-
 or N -citryl-L -serine -H2O C9H10NO8 260.05 260.05
O - or N -citryl-L -serine -2H2O C9H8NO7 242.04
O- or N-citryl-L -serine -2H2O -CO2 C8H8NO5 198.08 198.05 198.05
citrate C6H7O7 191.06 191.03 191.03
citrate -H2O C6H5O6 173.04 173.02 173.02
O - or N -citryl-L -serine  -2H2O -2CO2 C7H8NO3 154.08 154.06
O - or N- citryl-L -serine  -3H2O -2CO2 C7H6NO2 136.05
citrate -H2O -CO2 C5H5O4 129.03
O -citryl-L -serine (ester)  -C3H5NO2  -2H2O -CO2 C5H3O3 111.03 111.01 111.02
N -citryl-L -serine (amide)  -C3H4O3   -2H2O -CO2 C5H4NO2 110.07
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was already demonstrated that water is capable of hydrolyzing citrate adenylate at a 
detectable rate. This background rate was assigned to zero for nucleophilic activity.  
a b 
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Figure 2.27: Nucleophilic specificity of AcsD: (a) AcsD rates with tested nucleophiles in triplicate. (b) Schematic 
representation of L-serine and role of each chemical moiety. (c) Chemical structures of tested nucleophiles with 
numbers indicating their reactivity in reference to L-serine (100). Nucleophiles which were tested twice as fast 
as water (5) are highlighted in grey and considered to form a citrate derivative. MS and MS/MS analysis were 
carried out for underlined nucleophiles. Functional groups are highlighted in similar colors for clarity.  
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Analytic mass spectrometry (MS and MS/MS) was used to determine the chemical 
composition of the citrate nucleophile linkage where this could be ambiguous (Figure 
2.28, Figure 2.29). This approach was already used in section 2.3.8.2 to confirm that 
L-serine reacts through its hydroxyl, forming an ester linkage rather than an amide 
bond with its α-amino nucleophile. Ten substrates (including L-serine) showed 
significant higher activity than that of water (designated active nucleophiles) whilst 
seven nucleophiles have activity equal to water (within error). 
The most striking observation of the active nucleophiles is that all but one have an α-
amino group or are simple diatomics (non hydrogen atoms). Replacing this functional 
group with a hydroxyl or omitting it, leads to loss in activity as seen for L-2,3-
dihydroxy-propionic acid, 3-hydroxy propanoic acid or β-alanine. This suggests that 
the α-amino group of L-serine plays a crucial role in recognizing and orienting the 
incoming nucleophilic hydroxyl.  
The other immediate observation is that compounds which have a nitrogen 
nucleophile, rather than hydroxyl seen in L-serine, are more reactive. This is 
exemplified by the compound L-2,3-diaminiopropionic acid which differs from L-
serine only in that it has an amine rather than a hydroxyl, however it is over twice as 
reactive in the assay. The enhanced reactivity is also apparent in ethanolamine 
compared to ethylenediamine (or 1,2-diaminopropane). In this context it should be 
pointed out that L-isoserine, which lacks the α-amino group, is still active. This 
activity can be attributed to the enhanced nucleophilic ability of the amine group 
which has replaced the hydroxyl and overcomes the substitution of the α-amino 
group with hydroxyl. The preference for an amine nucleophile is also reflected in the 
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MS/MS fragmentation pattern of the product between hydroxylamine (which has 
both nitrogen and oxygen nucleophiles) and citric acid (Figure 2.29). While most of 
the fragments can be derived from either N- or O-citryl-hydroxylamine, the m/z=126 
fragment corresponding to N-citryl-hydroxylamine is far more dominant than the 
m/z=127 fragment belonging to O-citryl-hydroxylamine (Figure 2.30). Ethanolamine 
forms an ester linkage to citric acid, rather than an amide, since the distinct citryl-
ester fragment with m/z=111 is present (see also section 2.3.8.2). 
The results indicate that whilst the carboxylate function of L-serine is important for 
recognition it is not critical and a number of compounds lacking this group are still 
active (e.g. ethanolamine or ethylenediamine). The stereochemistry of the 
nucleophilic group is important, adding an additional carbon (-CH2-CH2-NH2) as in 
L-2,4-diaminobutyric acid (DABA) dramatically decreases activity. However, 
decarboxylated DABA, 1,3-diamionopropane, was reported to be a suitable L-serine 
surrogate and found to be incorporated in a functional achromobactin derivative 
(Berti and Thomas 2009). Shortening the nucleophilic moiety to a methyl group 
(-CH3), as seen for L-lactic acid or L-alanine, results in loss of function. Replacing the 
nucleophilic hydroxyl with sulfhydryl (L-cysteine) decreases the rate seven fold 
(compared to L-serine) but is still significantly above water. Mass spectrometry on 
the LCT ESI MS instrument indicates that the product is citryl-L-cysteine (Figure 2.31). 
It was not possible to obtain convincing tandem mass spectrometry of the thioester 
bond on the Q-Star XL ESI-QTOF instrument. However, no evidence was observed for 
a peptide bond either. The absence of amide and the known reactivity of thioester 
linkages imply that reactions with L-cysteine proceeds through the S nucleophile.  
  
— 83 — 
 
Figure 2.28: MS spectra of AcsD catalyzed citric acid ester and amides. In all tested reactions formation of AMP 
(m/z =346 [M-H]-) was observed, while ATP (m/z =506 [M-H]- and m/z =528 [M-2H+Na]-) was consumed. 
Product peaks were highlighted with light blue circles. For citryl-L-DAPA or citryl-EDA a second peak 
corresponding to m/z= [M-2H+Na]- (dark blue circle) could be assigned. 
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Figure 2.29: MS/MS spectra of AcsD citric acid ester and amide products. Respective product peaks are labeled 
with light blue circles. Fragmentation pattern including lost fragments and masses were assigned (as far as 
possible). For hydroxylamine the daughter fragments corresponding to N-citryl-hydroxylamine (blue) or O-
citryl-hydroxylamine (red) were assigned, whereas peaks originated from N-citryl-hydroxylamine are dominant. 
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a 
 
 
 
 
b 
 
Figure 2.30: Theoretical fragmentation pattern of citryl-hydroxylamine (a) Possible fragments for N-citryl-
hydroxylamine. (b) Possible fragments for O-citryl-hydroxylamine. 
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a 
 
 
 
 
 
 
 
 
 
 
 
 
b 
 
Figure 2.31: MS analysis of AcsD reaction with L-cysteine on the LCT ESI MS instrument (Micromass, 
Manchester, UK). (a) Only in reactions where AcsD was present a new peak with an m/z value of 294.11 was 
detected. This peak corresponds to the theoretical m/z= 294.03 [M-H]- value of citryl-L-cysteine. (b) Time points 
(O/N and 48h) of reaction with L-cysteine. While the m/z=294.1 peak is not increasing significantly, a second 
peak corresponding to citryl-L-cysteine Na+ adduct (m/z=[M-2H+Na]-) increases slowly. 
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2.3.9.2 Structural studies  
Attempts to co-crystallize AcsD with enzymatic derived O-citryl-L-serine or O-citryl-
ethanolamine have not been successful. However, the ability of AcsD producing 
amides by utilizing L-2,3-DAPA or ethylenediamine (this work and Berti and Thomas 
2009) was used to obtain a co-complex structure. AcsD co-crystallization trials were 
set up with supernatant of incubated AcsD reactions containing L-2,3-DAPA or 
ethylenediamine, as well as Mg2+ and ATP. While both experiments resulted in good 
diffracting crystals (up to 2Å), only those grown from pre-incubated ethylenediamine 
reactions showed clear additional electron density for a molecule larger than citric 
acid and then only in subunit B. This density was interpreted and refined as N-citryl-
ethylenediamine (Figure 2.32 and Figure 2.4).  
 
 
Figure 2.32: AcsD citryl-ethylenediamine (EDA) co-complex. Electrostatic surface representation of AcsD with 
bound ATP (colored in yellow), citryl-EDA (colored in white) and Mg2+ ion (colored in green).  
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Data collection and refinement statistics of N-citryl-ethylenediamine (citryl-EDA) co-
complex structure are shown in Table 2.1. Akin to the ATP co-complex (Figure 2.18a) 
ATP and Mg2+ are also bound in the citryl-EDA structure (Figure 2.33a). Most of the 
citryl moiety of citryl-EDA is coordinated in the same manner as citric acid in the 
AcsD citrate co-complex (Figure 2.18d, Table 4.2 and Table 4.4). However, there is 
one crucial difference: the carbon atom involved in forming the amide bond to 
ethylenediamine has moved away from its position in the citrate co-complex (Figure 
2.33b). This change is presumably driven by the presence of the α phosphorous of 
ATP which would otherwise clash with ethylenediamine. The EDA moiety of citryl-
EDA is mainly coordinated by the charged residues E442 and R501 (Figure 2.33a).  
a b 
       
 
Figure 2.33: AcsD citryl-ethylenediamine coordination. (a) Coordination of citryl-EDA; carbons of EDA colored 
white. (b) Superposition of citryl-EDA (colored in white) and citric acid (colored in green) demonstrating the 
different position of pro-R carboxylate in relation to the amide bond of citryl-EDA. 
  
— 89 — 
2.3.9.3 Mutational studies 
Based on the obtained structural citryl-EDA data, R501 and E442 were mutated and 
tested for enzyme activity with selected nucleophiles (Figure 2.34a). All tested 
nucleophiles have the crucial α-amino group and a nucleophilic hydroxyl or amino 
group, only L-serine comprised the additional carboxylate group. E442D and R501A 
mutants are inactive for all tested nucleophiles. However, E442Q did show activity 
(almost halved but above water) with one nucleophile, hydroxylamine. R501K utilizes 
both ethylenediamine and hydroxylamine at approximately the native rate. Most 
notably R501K is less active with L-serine, but 1,2-diaminopropane is utilized at a 
slightly higher rate (~120 %) than with wt AcsD.  
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Figure 2.34: Mutational studies of nucleophile binding site. Mutation of residues involved in coordinating 
distinct functional groups of L-serine. 
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2.4 Discussion 
2.4.1 Structural aspects 
AcsD is a new member of adenylate-forming enzymes. A defining characteristic of 
adenylate-forming enzymes is that they activate the carbon atom of carboxylic 
groups by making an adenylate ester. The adenylate ester is a highly reactive leaving 
group which enhances the electrophilic nature of the carbon atom to be attacked by 
a nucleophilic substrate. Comparison of AcsD active site with the superfamily of 
adenylate-forming enzymes and the structurally distinct family of aminoacyl-tRNA 
synthetases, which perform a similar adenylation reaction (Chang et al. 1997), 
reveals some common chemical themes in catalysis such as the use of Mg2+ and 
positively charged residues to facilitate catalysis. There are however significant 
differences regarding Mg2+ coordination and spatial configuration of active site 
residues.  
In the adenylation domain of GrsA, a NRPS involved in the biosynthesis of 
gramicidin S (Conti et al. 1997), a Mg2+ ion is bound to the α phosphate of AMP. In 
contrast, no Mg2+ ions were found in the active site of the crystal structure of Acyl-
CoA synthetase or luc (Nakatsu et al. 2006). In the adenylate-forming enzymes 
superfamily Arg (R526 in Acetyl-CoA synthetase (Gulick et al. 2003)) or Lys (Lys517 in 
GrsA) or His (H247 in luc) are in close proximity to the α phosphate of ATP. In 
contrast AcsD has two conserved residues, H444 and R305, proximate to the 
α phosphate. Interestingly, the AcsD residues do not superimpose with those in the 
superfamily. tRNA synthetases can be split in two classes, class I uses one Mg2+ and 
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class II uses three Mg2+ ions which bridge α, β (class I, class II) and β, γ (class II) 
phosphates of ATP. Similar to the adenylating superfamily, a single positively charged 
residue is proximate to the α phosphate of ATP. These differences in structure and 
catalytic site organization suggest that AcsD represents a new class of adenylating 
enzyme superfamily. 
2.4.2 AcsD is capable of assembling enantioselective citrate 
amides and esters 
AcsD activates citrate for condensation with the second substrate L-serine. The 
hydroxyl group of L-serine functions as the nucleophile. Previous work had shown 
that amines could function in this second step, decomposing the citrate adenylate to 
generate an amide (Berti and Thomas 2009). Our data suggest that amines can 
function much more readily (as might be expected from simple chemical 
considerations) as nucleophiles. In biology this would present a problem as all amino 
acids have a free primary amine group (except proline). However, the combination of 
structural and biochemical data suggests that the enzyme solves the problem by 
strongly recognizing the α-amino group. Only two exceptions are found to this rule, 
the first is a simple molecule with only two non-hydrogen atoms one of which is an 
amine (hydroxylamine) and the second one is the compound L-isoserine. Neither of 
these molecules are expected to exist at significant concentrations in biological 
systems. The requirement for the α-amino group appears to be so strong that the 
compound ethanolamine (which has both an amine and hydroxyl moiety) reacts 
(within error) exclusively with the hydroxyl function rather than the more reactive 
amine. The carboxyl group is important but not essential and several compounds 
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(ethanolamine being one example) react without having this functionality. The data 
also suggest (but do not conclusively show) that the enzyme is capable of catalyzing 
the formation of the thioester linkage, but at a much slower rate than L-serine. 
Although sulfur is a stronger nucleophile, the enzyme apparently disfavors its 
presence. As a result of the much lower activity, it is unlikely to be a significant 
competitor in biology.  
In order to better understand the enzyme requirements for this activity, the complex 
of N-citryl-ethylenediamine was determined (Figure 2.33a). This experimental guide 
for the recognition of the incoming nucleophile identifies two important residues, 
E442 and R501. Both mutants E442D and R501A are inactive with all substrates. 
Interestingly E442Q is weakly active with hydroxylamine but inactive with all the 
other substrates. R501K can utilize several amine nucleophiles but not L-serine. For 
E442, both the position and charge of the side chain are crucial, suggesting the 
residue is important for catalysis (Figure 2.34). The activity of the hydroxylamine can 
be explained by noting that its pKa (< 8.0) is significantly below that of the other 
substrates. E442 might act as a general base deprotonating the incoming nucleophile 
and activating it. The situation with R501 is more complex, the data suggest that a 
positive charge is essential (R501A is inactive) but the spatial position is not 
important for nucleophiles which lack the carboxylate group as they react with 
essentially the same rate as native. Interestingly 1,2-diaminopropane reacts more 
readily with R501K than wt, an observation which can be attributed to the larger 
volume at the active site tolerating a secondary amine at the α-amino position. The 
spatial position is important but is not critical for L-serine which is still utilized by 
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R501K (but with 14 fold reduced rate). The likely role of R501 is to provide a positive 
charge which helps to bind and orient L-serine, but has no direct role in catalysis. 
Remarkably, R501K seems to favor nucleophiles forming amides over those resulting 
in esters, as seen for the low activity of L-serine or ethanolamine (Figure 2.34a). 
 
The structural data of N-citryl-EDA was used to design a model for a O-citryl-L-serine 
complex (in essence adding a carboxylate group to the observed crystal structure) 
(Figure 2.35). This model suggests that R501 and K563 might coordinate the 
carboxylate enhancing the reactivity of carboxylate containing nucleophiles. K563 is 
involved in the recognition of citrate as well. A K563A mutant was constructed, but 
expresses only poorly and not all impurities could be removed during purification. 
The results on this crude material show that the mutant has no activity above water 
for any nucleophile (Figure 2.34). This suggests that the water rate has increased but 
this may simply be a feature of impurities. Nevertheless one can see that K563 is an 
 
 
Figure 2.35: Model of coordinated O-citryl-L-serine. Coordination is based on the N-citryl-ethylenediamine data 
adding the carboxylate of L-serine, which is coordinated by K563 and R501. Note the different orientation of 
pro-R carboxylate of citric acid (colored in grey, facing the α phosphate) and the ester bond in the final product 
(moved away to avoid clashing with ATP). 
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important residue for activity, its precise role other than in the recognition of 
carboxylate groups (citrate and L-serine) is unclear and still remains to be explored. 
2.4.3 Molecular mechanism  
2.4.3.1 AcsD forms an enzyme bound citrate adenylate intermediate 
Superposition of the protein atoms of the ATP and adenosine citrate complexes of 
AcsD assist in constructing a model for the ternary complex (Figure 2.36a-c). This 
model indicates that the essential Mg2+ ion will polarize the α phosphorus oxygen 
bond, enhancing its electrophilicity. Furthermore, Mg2+ will stabilize the generated 
pyrophosphate as well. Interestingly, the α - γ phosphate coordination of Mg2+ in 
AcsD is rare and only found in seven out of 250 ATP containing structures. The 
absolutely conserved residues R305 and H444 make contacts with the α phosphate 
and pro-R carboxylate of citric acid. H444 seems a likely candidate to act as a general 
base to deprotonate the pro-R carboxylate of citric acid creating a nucleophile. Both 
residues (H444 and R305) will further polarize the phosphorus oxygen-bonds 
(enhancing the electrophilicity of the α phosphate) and also stabilize the negatively 
charged (deprotonated) form of the citrate carboxylate. Once activated, the citric 
acid nucleophile is able to attack the exposed α phosphate of ATP in an SN2 type 
reaction, creating an enzyme coordinated citrate-AMP intermediate and PPi (Figure 
2.36d). 
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2.4.3.2 AcsD liberates O-citryl-L-serine and AMP 
The second step in AcsD reaction is the decomposition of the adenylate intermediate 
by L-serine. The attack of L-serine has to occur from the face of citrate which is 
exposed to the solvent, as the other face is shielded by the ribose of ATP. On this 
face E442, R501 and K563 are positioned to recognize L-serine as a model of the 
likely second ternary complex demonstrates (Figure 2.37a). The nucleophilic hydroxyl 
of the manually docked serine is located in a similar position as a water molecule 
a 
 
b  
 
c 
 
d 
 
Figure 2.36: First step of AcsD mechanism. (a) Adenosine (carbon colored white) and sulfate (yellow/grey) from 
the citrate adenosine AcsD complex overlap with ATP (carbon colored yellow) from the ATP AcsD complex 
(based on superposition of protein atoms). (b) A model of ternary complex of AcsD, generated by 
superimposing the ATP and citrate complex. The color scheme is preserved, except H444 and R305 which are 
highlighted in red. (c) Schematic representation of the ternary complex. Hydrogen bonds are shown with doted 
lines. Catalytic residues are colored in red. (d) Reaction of citrate and ATP via a pentavalent transition state 
forming the enzyme coordinated citryl-adenylate intermediate. 
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found in the ATP co-complex structure (W140). This location is optimal for the 
nucleophilic attack at the carbonyl group required for the decomposition of citrate 
adenylate. Interestingly, the docked model superimposes well with the EDA moiety 
of the N-citryl-EDA co-complex (Figure 2.37b). Mutational studies show that E442 
could be the crucial catalytic residue for the second part of AcsD reaction, polarizing 
and coordinating the respective nucleophile (Figure 2.33). The polarized hydroxyl of 
L-serine attacks the pro-R carbonyl of the citryl-adenylate intermediate liberating O-
citryl-L-serine and AMP (Figure 2.37c). 
  
a b 
              
c 
 
Figure 2.37: Second step in AcsD reaction. (a) Model of the second ternary complex. (b) Superposition of L-
serine model and the N-citryl-EDA co-complex. The docked L-serine superposes well with the EDA moiety. (c) 
Chemical representation of second AcsD reaction step. The generated citryl-adenylate intermediate (Figure 
2.36d) is attacked by L-serine forming O-citryl-L-serine and AMP. 
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2.4.3.3 The fate of pyrophosphate 
Most adenylate-forming enzymes release pyrophosphate immediately after 
formation of their adenylate such as GrsA or luc, two Acyl CoA synthetases (Conti et 
al. 1997; Gulick et al. 2003; Nakatsu et al. 2006). However acetyl-CoA synthetases 
and class II tRNA synthetases bind the PPi in a pocket using conserved His and Arg 
(H270 and R480 in Acetyl-CoA synthetase) residues to stabilize it. In AcsD, candidates 
for this role are the conserved residues R369 and R469. These residues are located in 
a hydrophilic pocket, which could accommodate PPi (Figure 2.19). Though F291 in 
AcsD is far away from the active site a mutation to tyrosine reduces the catalytic 
activity (Figure 2.23). The larger tyrosine most likely displaces a water molecule at 
the bottom of ATP cavity and hence confines the possible space to accommodate 
pyrophosphate. These results suggest that in contrast to other adenylate-forming 
enzymes AcsD may keep PPi in this cavity after the first reaction step and liberate it 
after formation and release of O-citryl-L-serine. 
2.4.4 Mechanistic link to kinases 
Like AcsD, kinases catalyze nucleophilic attack at and cause breakage of phosphate 
ester bonds. Kinases however catalyze the attack of a nucleophilic substrate at the 
γ phosphate. But in AcsD the citrate carboxyl group attacks at the α phosphate. 
Structurally the ATP binding site of AcsD shares elements of the cAPK template, 
including a metal binding site but crucially lacks the characteristic mobile glycine rich 
loop (Taylor et al. 1999).  
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The cAPK fold binds the triphosphate in roughly the same position relative to the 
secondary structure (Figure 2.20). However, the vectors from α to γ phosphates have 
opposite directions and the adenosine rings do not superimpose (Figure 2.21b). As a 
result the key phosphate atoms are located in the same relative position in both 
AcsD and cAPK (Figure 2.38 and Figure 2.21). Hence both AcsD and kinases may 
share a similar reaction mechanism.  
 
Based on these similarities it is possible that AcsD may have an evolutionary link to 
kinases. In this context it has to be noted that PurT, a ribonucleotide transformylase 
involved in purine biosynthesis (Thoden et al. 2002), transfers the γ phosphate to a 
formyl group creating a reactive intermediate. Thus the enzyme combines kinase like 
activity (attack at γ phosphate) with AcsD like activity (creation of a reactive 
intermediate) and may represent a physical link between these families. 
 
Figure 2.38: Comparison of AcsD and kinase ATP. Schematic illustration of the ATP orientation in AcsD (in red) 
and in kinases (in blue). The key electrophilic α phosphate in AcsD and γ phosphate in kinases superimpose. 
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2.5 Conclusion 
The finding that AcsD catalyzes highly stereoselective desymmetrization of citrate by 
adenylation of one of its prochiral carboxylate groups indicates that AcsD and other 
type A NIS synthetases may find use as novel biocatalysts for the preparation of 
homochiral citric acid derivatives. The obtained structural information for AcsD 
provides the opportunity for rational mutagenesis to alter or broaden its substrate 
specificity, further increasing its potential for use in enantioselective biocatalysis. 
Mutational and structural studies revealed two catalytic residues H444 and R305. 
The histidine deprotonates (as a general base) the incoming citric acid, but may also 
stabilize the pentavalent transition state in addition to R305 and Mg2+.  
It was shown that AcsD is able to utilize other nucleophiles than L-serine or 
ethanolamine. The systematic screening for potential substrates unveiled certain 
roles for each functional group of the nucleophilic substrate. While the α-amino 
group is crucial for coordination, the less important carboxyl moiety enhances 
nucleophilic binding. However, the nucleophilic moiety was shown to be variable. 
Three nucleophilic groups were tested (-OH, -NH2, -SH) generating citrate esters, 
amides or thioesters that were verified by MS and MS/MS analysis. However, 
fragmentation of the thioester product resulting from reaction with cysteine was not 
successful. Instead, a new mass peak corresponding to citryl-L-cysteine was detected 
on the LCT ESI MS instrument. The N-citryl-ethylenediamine complex identified a 
possible binding site for the nucleophilic substrate. Mutational studies confirmed 
that E442 is a key catalytic residue for the second step in AcsD reaction. Along with 
R501 it also coordinates the crucial α-amino group of the nucleophile. A docked 
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model of O-citryl-L-serine, based on the N-citryl-EDA complex, shows that K563 and 
R501 are likely to coordinate the nucleophilic carboxylate.  
Interestingly the R501K mutant shows a surprising preference for amide forming 
nucleophiles and utilizes 1,2-diaminopropane 20 % faster than wt enzyme. Such 
changes in specificity are often useful for biotransformations. Hence, AcsD and other 
NIS synthetases have great potential for mutational engineering to broaden their 
substrate range and specificity. Harnessing the ability of AcsD to desymmetrize 
organic acids by making amides or esters would have valuable applications in organic 
chemistry. Such a rational design has always been a challenge. Furthermore, a clear 
understanding of the substrate recognition sites could assist in the development of 
AcsD inhibitors. These are likely to affect also homologues of human pathogens. One 
feasible target is AsbA, which is catalyzing the initial step in petrobactin biosynthesis 
in Bacillus anthracis (Oves-Costales et al. 2007). Thus AcsD inhibitors may be the 
starting point for designing novel antibiotics used to treat anthrax or other bacterial 
infections. 
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2.6 Future work 
AcsD generates enantioselective citrate amide and ester derivatives. This could be 
useful in commercial biotransformation or biosynthetic chemistry. This was 
exemplified by one mutant, R501K, which is able to utilize 1,2-diaminopropane faster 
than the wt enzyme producing N-citryl-diaminopropane. Rational mutagenesis of the 
nucleophilic binding site will be one of the future targets. Another yet unanswered 
question is due to the fact that E442Q is inactive for all tested nucleophiles, but not 
for hydroxylamine. So far only six of approximately twenty nucleophiles have been 
tested. The remaining ones have to be analyzed to finally reveal if hydroxylamine is 
the only nucleophile utilized by E442Q.  
AcsD is specific for the first substrate, citric acid (Berti and Thomas 2009; Schmelz et 
al. 2009). Hence, modification of citrate binding site may enlarge AcsD specificity for 
other carboxylic acid substrates. In this study, T301 (coordinating the central citrate 
carboxylate) was mutated leading to an inactive enzyme (T301A) when tested with 
citrate. Possible other candidates for rational mutagenesis are K563, Y504 and N302. 
Especially, substitution of Y506 and K563 (coordinate the citrate pro-S carboxylate) 
with a smaller amino acid would generate more space for a larger and longer 
carboxylic acid such as 2-hydroxy-1,2,4-butanetricarboxylic acid or 2-hydroxy-1,2,5-
pentane-tricarboxylic acid (Figure 2.39). Mutagenesis of these substrate binding sites 
is an opportunity to alter or broaden AcsD substrate specificity and further increase 
its potential for use in enantioselective biocatalysis. 
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Figure 2.39: Likely citrate analogues for future AcsD mutants. 
 
Finally, it was shown that AcsD favors L-serine over the proposed substrate 
ethanolamine. However, recently Berti et al. (2009) demonstrated that citryl-
ethanolamine or N-citryl-1,3-diamionpropane, but not O-citryl-L-serine, is 
incorporated in a functional siderophore, which is able to restore growth of a 
siderophore-deficient Pseudomonas syringae strain (Berti and Thomas 2009). In their 
experiment combination of all three biosynthesis enzymes (AcsD, AcsC and AcsA) 
were used with several likely substrates to assemble achromobactin or its derivatives 
in-vitro. Products were analyzed by mass spectrometry and added to plated cultures 
of a siderophore-deficient strain. They showed that reactions with L-serine result in 
formation of α-ketoglutaryl-diaminobutyryl-citryl-serine. This product still lacks a 
final α-KG moiety to be added by AcsA to yield achromobactin. This reaction seems 
not to take place probably due to the not yet eliminated carboxyl group introduced 
by L-serine. AcsE, a postulated PLP-dependent decarboxylase, could catalyze 
decarboxylation of α-ketoglutaryl-diaminobutyryl-citryl-serine or a prior product 
such as O-citryl-L-serine to allow assembling of the final siderophore. This could be 
examined by addition of AcsE in the experiment described early (Berti and Thomas 
2009). This would finally make it clear whether ethanolamine or L-serine is the 
natural product of AcsD.  
b 
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Chapter 3 -  AlcC 
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3.1 Introduction 
3.1.1 Summary 
In this chapter the structural and biochemical work on the type C NIS enzyme AlcC is 
reported. AlcC is involved in biosynthesis of alcaligin, a hydroxamate siderophore 
synthesized by iron-starved Bordetella pertussis and B. bronchiseptica, both being 
mucosal pathogens of the upper respiratory tract of mammals (Moore et al. 1995). 
While B. pertussis is a human pathogen causing whooping cough, B. bronchiseptica 
causes endemic respiratory diseases in other mammalian hosts such as swine, cats 
and dogs (Goodnow 1980). AlcC is a processive enzyme performing the final two 
steps in alcaligin biosynthesis (Challis 2005; Brickman et al. 2007). AlcC is predicted 
to dimerize N-(4-Amino-3-hydroxy-butyl)-N-hydroxy-succinamic acid in an ATP driven 
reaction. This product then is cyclized in a second AlcC reaction liberating alcaligin.  
The co-complex of adenosine and ATP were obtained. The ATP structure shows that 
the ATP phosphate binding site is conserved within NIS enzymes and the adenosine 
moiety is coordinated by a network of water molecules. The fluorescence based AMP 
activity assay used for AcsD establishes that AlcC also performs an adenylation 
reaction. Detailed analysis of the MS/MS fragments of AlcC reaction products with 
the substrate analogue N-hydroxy-N-succinylputrescine identified not only substrate 
dimers, but also the dimer macrocycle. AlcC is also able to generate N-hydroxy-N-
succinylputrescine trimers and a trimer macrocycle. It was not possible to obtain any 
substrate co-complexes (apart from ATP and adenosine structure). Hence, binding 
models of N-(4-Amino-3-hydroxy-butyl)-N-hydroxy-succinamic acid, alcaligin and a N-
hydroxy-N-succinylputrescine trimer macrocycle were developed. The modeled 
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substrate fits perfectly in a cavity and faces the α phosphate of ATP to perform a 
nucleophilic attack. Models of alcaligin and the trimer macrocycles demonstrate that 
there is enough space in the active site to accommodate them. 
3.1.2 AlcC apo structure 
The apo structure of AlcC was solved, built and partly refined before I started 
working on this project. A monomeric poly-alanine model of AcsD apo-structure was 
used as molecular replacement model. The unit cell of AlcC contains one monomer 
per asymmetric unit. PISA (Krissinel and Henrick 2007) identifies a stable head-to-
a  
 
b 
 
 
Figure 3.1: AlcC apo-structure. (a) AlcC dimer in stereo view shown in cartoon and surface representation. N-
terminal domain is colored in blue, middle domain in orange and C-terminal domain in green (b) The AlcC apo 
structure binds five sulfate ions, one located in the active site (shown in ball and stick representation).  
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head dimer with a complexation significance score (CSS) of 1 (Figure 3.1a).  
The active site of each monomer is formed by three domains: N-terminal, middle and 
C-terminal domain. The N-terminal domain (colored in blue, residues 7 – 138) forms 
a three helix bundle flanked by five anti-parallel β-sheets (Figure 3.1b). The middle 
domain (colored in orange, residues 193-389) is linked to the opposite N-terminal 
domain by loop L4 (residues 156-192). It is folded into a 9 stranded anti-parallel β-
sheet interspersed with 5 α-helices and conserved loops L5 and L7. The C-terminal 
domain (colored in green, residues 390 – 601) is predominantly α-helical (8 helices) 
and leads back to the N-terminal domain. In the apo-structure five SO4
2- ions are 
bound, one of them is located in the active site (Figure 3.1b). The AlcC topology 
shows significant similarities to the previously discussed AcsD structure. 
3.1.3 AlcC substrates  
In alcaligin biosynthesis AlcB is proposed to carboxylate N-hydroxy-putrescine with 
succinic acid to form N-hydroxy-N-succinylputrescine (Sub204) (Figure 1.10c). In the 
subsequent reaction, AlcE adds a hydroxyl and generates N-(4-Amino-3-hydroxy-
butyl)-N-hydroxy-succinamic acid (Sub220), the proposed substrate of AlcC. In a 
subsequent AlcC reaction an internal amide bond is formed generating the 
macrocycle alcaligin (Figure 3.11a). AlcC was also tested to utilize Sub204, the 
product of AlcB, as a substrate analogue. Other than with Sub220 just Sub204 dimers 
are formed, but not the final macrocycle putrebactin (Figure 3.11b) (Challis, 
unpublished data). Therefore, alcaligin biosynthesis shares parallels with the recently 
described putrebactin biosynthesis from Shewanella species (Kadi et al. 2008).  
 
  
— 107 — 
 a  b 
 
Figure 3.2: AlcC substrate consumption. (a) Two molecules of the proposed substrate N-(4-Amino-3-hydroxy-
butyl)-N-hydroxy-succinamic acid (Sub220) are dimerized and then the “open” ends are joined to form alcaligin. 
(b) AlcC was shown to utilize N-hydroxy-putrescine (Sub204) generating dimers, but not the macrocycle 
putrebactin (Challis, unpublished data).  
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3.2 Materials and methods 
3.2.1 Overproduction and purification of AlcC 
The pET151/D-TOPO alcC construct was provided by Prof. Challis, University of 
Warwick. It codes for the protein fused with an N-terminal TEV cleavable His6-tag. 
For protein over-production the alcC plasmid was transformed into BL21(DE3) E.coli 
cells. 1L cultures were launched from 10 mL O/N starter cultures as described for 
AcsD (section 2.2.1). When cell density reached an optical density A600=0.8 protein 
overproduction was started by adding 0.5 mM IPTG. The temperature was lowered 
to 15 °C and cultures further incubated O/N. For cell harvest, subsequent protein 
purification and tag-removal the evolved AcsD protocol was adopted and employed. 
For detailed information see section 2.2.1.  
After tag removal AlcC has six additional residues at the N-terminus (GIDPFT) with a 
final weight of 70604 Da. Purified AlcC was concentrated to 5.6 mg/mL in 50 mM Tris 
pH 7.5, 500 mM NaCl, 10 % (v/v) glycerol using protein concentrating devices (50 kDa 
Vivaspin). Concentrated protein was divided into 25 µL aliquots that were flash 
frozen in liquid nitrogen and stored at –80 °C. The purification progress was 
monitored by SDS-PAGE. The identity and integrity of AlcC was confirmed by mass 
spectrometry. From one liter of cell cultures ~1.9 mg pure AlcC protein was purified.  
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3.2.2 Crystallization, data collection and refinement of AlcC  
3.2.2.1 AlcC apo structure 
Apo crystals were grown by Xiaoxuan Qi during her MRES studies in SPoRT, March 
2007. Her optimized crystal condition was 1.4 MgSO4, 0.1 M sodium cacodylate 
(pH 6.0) and 0.1 M Li2SO4. Crystals were cryo-protected by transferring into 2.25 M 
MgSO4 and 100 mM sodium cacodylate (pH 6.0). Data were indexed and scaled using 
XDS and XSCALE (Kabsch 1993). The apo structure was solved with a poly-alanine 
model of AcsD molecule A as a molecular replacement model. This work, the manual 
fit to various maps and the initial refinement were carried out by Dr Kenneth 
Johnson, a former member in SPoRT, before I started working on this project. A final 
refinement was performed to meet the criteria of the structure validation tool 
MolProbity (Davis et al. 2007). The structure was refined using REFMAC5 
(Murshudov et al. 1997) and COOT (Emsley and Cowtan 2004) was used for manual 
manipulation. The apo structure shows electron density for five sulfate ions, one 
located in the bottom of the active site. Data collection and refinement statistics are 
displayed in Table 3.1. Electron densities of ligands (discussed in the following 
sections) are shown in Figure 3.3. 
3.2.2.2 Adenosine-SO42- co-complex structure 
Adenosine-SO4
2- complex crystals grew in hanging drops from equal mixtures of 
0.1 M MES pH 6.5, 1.6 M MgSO4, 0.14 M Li2S04 and protein solution (2.5 mg/mL AlcC, 
45 mM MES pH 6.5 and 5 mM adenosine, pre incubated for 30 min on ice) to full size 
in 2 weeks at 20 °C. Crystals were cryo-protected by increasing the MgSO4 
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concentration to 2.3 M and cryo-cooled at -173 °C. A data set was collected at a 
beam wavelength of 0.9835 Å on ID14-4 at European Synchrotron Radiation Facility 
(ESRF, Grenoble). The detector was set to a distance of 288 mm. Data collection was 
carried out with an exposure time of 1.0 s  (14 % transmission) over 125° starting at 
20.0° phi with an oscillation range of 0.5° and no overlap. The data set was indexed 
and integrated using DENZO and scaled with SCALEPACK (both implemented in the 
HKL2000 suit (Otwinowski and Minor 1997)) to 2.1 Å. The 2.4 Å apo structure was 
used to phase the 2.1 Å adenosine SO4
2- complex. The structure was refined using 
REFMAC5 (Murshudov et al. 1997) and COOT (Emsley and Cowtan 2004) was used 
for manual manipulation. 
3.2.2.3 ATP co-complex structure 
Crystals grew in hanging drops from equal mixtures of 0.1M MES pH 6.5, 1.7 M 
MgSO4, 0.18 M Li2SO4 and protein solution (2.5 mg/mL AlcC, 45 mM MES pH 6.5 and 
5 mM adenosine, 5 mM N-hydroxy-N-succinylputrescine (Sub204), pre incubated for 
30 min on ice) to full size (approx. 0.2 x 0.4 mm) in 2 weeks at 20 °C. Crystals were 
soaked in 25 mM ATP, 25 mM substrate 204 and 4 M sodium formate for 30 seconds 
and flash-frozen in liquid nitrogen. A data set was collected at a wavelength of 
0.9796 Å on the IO2 beam line at Diamond Light source Ltd, UK. The detector was set 
to a distance of 288 mm. Data collection was started at 75° phi for 180° with an 
oscillation range of 0.5°. Data were indexed and integrated using DENZO and scaled 
with SCALEPACK (both implemented in HKL2000 (Otwinowski and Minor 1997)) to 
1.96 Å. The 2.4 Å native structure was used for phasing the 1.96 Å ATP complex 
structure, which was refined using REFMAC5 (Murshudov et al. 1997) and COOT 
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(Emsley and Cowtan 2004). In the active site extra electron density was only 
observed for ATP, but not for Sub204.  
 
Table 3.1: AlcC data collection and refinement statistics. 
 
 Apo Adenosine –SO4
2- ATP 
Data collection    
Space group P21212 P21212 P21212 
Cell dimensions 
(Å) 
 
a= 93.7, 
b= 129.0, 
c= 48.3 
a= 92.9, 
b= 128.9, 
c= 48.2 
a= 94.6, 
b= 129.4, 
c= 46.5 
Resolution (Å) 
(high resolution) 
40.0-2.4 
(2.49-2.4) 
45.2 -2.1 
(2.18-2.1) 
50.0-1.96 
(1.96-2.03) 
Rmerge 8.6 (49.4) 11.2 (58.7) 9.3 (55.2) 
I/σ(I) 17.1 (3.3) 12.54 (2.1) 20.8 (3.5) 
Completeness ( %) 97.9 (99.1) 99.6 (99.9) 99.9 (99.8) 
Aver. redundancy 4.1 (3.7) 4.8 (4.3) 7.2 (6.8) 
Vm(Å
3/Da) 2.1 2.1 2.0 
Solvent ( %) 41 41 40 
Software XDS/XSCALE HKL2000 HKL2000 
Refinement Phenix.refine Refmac5 Refmac5 
Unique reflections 23068 34630 41914 
Rwork /  Rfree 18.2/23.6 19.9 / 24.8 18.2 / 22.1 
No. atoms 
     Protein  
     Water  
     ATP 
     Adenosine  
     Mg2+ 
     SO4
2- 
 
4631 
180 
0 
0 
0 
25 
 
4601 
285 
0 
19 
0 
20 
 
4726 
257 
31 
0 
2 
0 
B-factors (Å2) 
     Protein 
     Water 
     ATP 
     Mg2+ 
     Adenosine 
     SO4
2- 
 
32 
31 
0 
0 
0 
57 
 
28 
32 
0 
0 
39 
56 
 
21 
27 
17 
20 
0 
0 
Rmsd bonds (Å)  
/ angles (°) 
0.003 / 0.725 0.011 / 1.261 0.009 / 1.173 
B-factor deviation 
Bond/angle (Å2) 
Main chain 
Side chain 
 
 
 
 
 
0.754 / 1.256 
1.808 / 2.760 
 
 
0.554 / 1.070 
1.665 / 2.795 
MolProbity score  
(percentile) 
96 99 93 
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a 
 
b 
 
c 
 
d 
 
Figure 3.3: Electron density of AlcC co-complex structures. (a) Stereo Fo-Fc map of ADN-sulfate co-complex at 
2.5 σ. (b) Stereo Fo-Fc map of ATP co-complex at 2.5 σ. (c) 2Fo-Fc map of ADN and SO4
2- contoured at 1 σ. The 
electron density for C5 of the ribose moiety is weak and the C5 hydroxyl less well ordered. (d) 2Fo-Fc map of 
ATP contoured at 1 σ.  
 
3.2.3 AMP production assay  
AlcC activity was tested in the AMP production assay, previously described for AcsD 
(section 2.2.5). The reaction contained 50 mM Tris-HCl buffer (pH 8.0), 3 mM ATP, 
15 mM MgCl2, 1.5 mM phosphoenol pyruvate, 0.25 mM NADH, 2.4 µM AlcC, 
12.6 units of lactate dehydrogenase, 8.4 units of pyruvate kinase, 4 units of 
myokinase and 2.5 mM Sub204 at a total volume of 140 μL. The mixture was 
incubated at 20 °C for 5 min and the reaction started by adding 2.4 µM AlcC. 
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3.2.4 Mass spectrometry  
Products of the AlcC timeline experiment with Sub204, a substrate analogue of AlcC 
was characterized by MS and MS/MS analysis. Enzymatic reactions were carried out 
in 50 mM ammonium acetate buffer (pH 8.0) containing 20-40 µM wt AlcC, 30 mM 
MgCl2 and 5 mM Sub204. The mixtures were incubated at 20 °C and the reactions 
were initiated by adding 20 mM ATP. At certain time points 1 μL aliquots were 
removed, diluted into 50:50 acetonitrile:water (100 μL) and centrifuged at 
12,000 rpm for one minute. The samples were analyzed using continuous syringe 
infusion (Harvard syringe pump, Harvard Apparatus, Kent, UK) into a LCT 
(Micromass, Manchester, UK) ESI MS instrument or a Q-Star XL (Applied Biosystems, 
Foster City, USA) ESI-QTOF instrument using the appropriate ionization mode. M/zs 
of interest were subjected to collisionally induced dissociation (CID) on the Q-Star XL 
instrument, with collision energy adjustment to give some intact signal remaining. 
The operation of instruments and data acquisition was carried out by Dr Catherine H 
Botting (BMS Mass spectrometry and Proteomics Facility, University of St Andrews).  
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3.3 Results 
3.3.1 Protein purification 
3.3.1.1 Immobilized-metal affinity chromatography  
His6-AlcC plasmid containing E. coli cells were grown, induced and lysed as described 
in section 3.2.1. The first purification step after cell lysis was carried out using Ni-
beads (Figure 3.4a). His6-AlcC was eluted with 500 mM imidazole in three fractions 
(lane 7-8). Most protein eluted in the first fraction (lane 7) at around 75 kDa and 
contained a lot of additional proteins that had to be removed in subsequent 
purification steps. 
 a b c 
                        
Figure 3.4: His6-AlcC purification and TEV cleavage. (a) First purification of AlcC with immobilized-metal affinity 
chromatography (IMAC): S standard; 1 crude protein solution after cell breakdown; 2 supernatant (S/N); 3 pellet 
dissolved in 8 M urea; 4 flow through of IMAC column; 5 wash step 1; 6 wash step 2; 7 elution I;  8 elution II; 9 
elution III; (b) TEV digestion with 1:50 TEV protease. S standard; 1 His6-AlcC from elution I; 2 cleaved AlcC from 
elution I; 3 His6-AlcC from elution II; 4 cleaved AlcC from elution II. (c) Second IMAC purification to remove the 
tag and impurities. 1 cleaved AlcC from EI where TEV protease and tag was removed; 2 Cleaved AlcC from EII 
where TEV protease and tag was removed; 3 Elution from 2nd nickel column. It contains a lot of impurities, which 
have been removed from cleaved protein in lane 1 and 2. 
 
  
— 115 — 
3.3.1.2 Desalting, tag removal and gel filtration 
Eluted protein was directly desalted on a HiPrep 26/10 column to avoid protein 
degradation caused by imidazole. The elution profile indicates a peak (14 – 30 mL) 
corresponding to AlcC protein (Figure 3.5a). TEV-cleavage was carried out over night 
at RT and verified by SDS-PAGE (Figure 3.4b). Cleavage was successful with a 
protease to protein ratio of 1:50. TEV protease and cleaved tag were removed by a 
second IMAC purification step using a 5 mL pre-packed HisTrap column (GE 
Healthcare). Protein and wash buffer contained 50 mM imidazole to avoid TEV-
cleaved AlcC from binding to the column. It was collected directly in the flow-
through. Several impurities (E. coli proteins and non cleaved AlcC) have been 
removed through this purification step (Figure 3.4c).   
a b  
 
Figure 3.5: Desalting and gel filtration elution profiles for AlcC. (a) Elution profile of the desalting step on a HiPrep 
26/10 desalting column to remove imidazole used for elution in the IMAC purification step. (b) Elution profile of 
the gel filtration step on a Superdex S200 column. Fractions A4 – A8 is aggregated protein found in the void 
volume. Protein in A9-B5 was identified as AlcC by mass spectrometry (see also Figure 3.6). 
After tag removal, AlcC protein was concentrated and finally purified on a Superdex 
S200 (GE Healthcare) gel filtration column. The elution profile shows a Gaussian 
shape with its peak at a retention volume of 55 mL (Figure 3.5b). A second smaller 
peak that eluted in the void volume (~40 mL) is aggregated AlcC (Figure 3.6). The 
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purest fractions (A9-B12) were kept separate from less pure fractions (B11-B7). Both 
set of fractions were combined and concentrated for crystallization trails (see also 
section 3.2.1) 
                       
Figure 3.6: SDS-PAGE of AlcC gel elution profile. Fractions analyzed from gel filtration (Figure 3.5b) show that A5 
(fraction of the void volume) contains degraded AlcC protein. Purest AlcC protein is found in fraction A9-A12, 
while fractions B11-B6 still contain impurities.  
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3.3.2 Crystallization of AlcC 
3.3.2.1 Co-crystallization of various substrates 
AlcC was found to form single, large orthorhombic crystals by using high 
concentrations of MgSO4 as a precipitant. Five SO4
2- binding sites were identified in 
the apo structure, whereas one is located in the active site. This high sulfate 
concentration made it rather difficult to co-crystallize any AlcC substrates in the 
active site. While most co-crystals still grew in perfect shape and reasonable size 
(some smaller and some larger than 0.2 x 0.4 mm), it was not possible to coordinate 
ATP, AMP, ADP or the substrate analogue Sub204 alone or in combination (e.g. ATP + 
Sub204, or AMP + Sub204). However, co-crystallization with 5 mM adenosine was 
successful (Figure 3.7a, Figure 3.3a,c), but not in combination with Sub204 (Figure 
3.7b). Attempts to find a sulfate free crystal condition with commercially available 
crystal screens were not successful, even though parameters like protein 
concentration were changed or different buffers were tested. Screening in 
combination with micro-seeding of AlcC apo-crystal seeds failed as well.  
a  b 
          
 
Figure 3.7: Co-complex crystals of AlcC. (a) AlcC adenosine – co-crystals grown with 5 mM adenosine. (b)  Crystals 
grown with 5 mM Sub204 and 5 mM adenosine sill have a perfect shape, but don’t coordinate any substrates, 
but sulfate.  
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3.3.2.2 Soaking of AlcC crystals 
Since co-crystallization was shown to be not successful, other methods had to be 
tested. To enhance success of a soaking experiment, the possible binding site which 
was blocked by sulfate had to be “emptied” prior binding of substrate. This was 
obtained by transferring crystals into 4 M sodium formate. Thereafter, AlcC crystals 
were transferred into the soaking solution containing 10-200 mM substrate and 4 M 
sodium formate for a few seconds and flash-frozen in liquid nitrogen. This approach 
was successful when crystals were soaked with 25 mM ATP and 25 mM Sub204, 
binding ATP in the active site (Figure 3.3b, d), but not Sub204. Attempts to increase 
the soaking time (up to 22 h) or the concentration of Sub204 (with and without ADN 
or ATP) resulted only in electron density for ADN or ATP, but not for Sub204. Soaking 
with 15 mM ATP and 15 mM of desferrioxamine B (Figure 3.8), a substrate analogue 
for a final ring formation, failed. Here again only density for ATP was detected.  
 
 
Figure 3.8: Chemical structure of desferrioxamine B mesylate.  
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3.3.3 Co-complex structures 
The native protein and all co-complex structures are essentially identical with a root 
mean square deviation (rmsd) for 577 Cα atoms of 0.32 Å. No large conformational 
changes have been observed upon ligand binding. AlcC forms a deep cavity alike the 
AcsD active site. In this cavity ATP is coordinated between middle, C-terminal domain 
and loops 4 and 7 and is cradled in a position perpendicular to β-strands 12, 15 and 
14 (Figure 3.9a, b).  
 
a b 
    
c  d 
       
Figure 3.9: Coordination of AlcC ligands. (a) Soaked ATP complex. (b)  ATP binding site. ATP carbons are colored 
in yellow. (c) Adenosine and SO4
2- co-complex. (d) Adenosine and SO4
2- coordination. L7 is less well coordinated 
and no electron density has been observed for residues 310-312.  
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Adenosine and sulfate of the ADN-SO4
2- co-complex show a similar coordination 
(Figure 3.9c, d). Adenosine adopts position of the ATP adenine ring and the ribose 
while sulfate is coordinated in the γ phosphate position of ATP. 
Upon ATP binding, loop L7 seems to be more ordered as in the apo structure or ADN-
SO4
2-co-complex which is lacking residues 310 – 312 (Figure 3.9b, d). This primarily 
affects the highly conserved R312. Upon ATP binding R312 moves in from a remote 
position to coordinate the α-phosphorous of ATP (Figure 3.10). Interestingly, ATP in 
AlcC is coordinated by two Mg ions rather than one as seen in AcsD (Figure 2.18a). 
The second Mg is coordinated by residues D469, E472 and E473 and bridges the α 
and β phosphates in AlcC. E451 adopts a different rotamer in both co-complex 
structures to allow adenosine or ATP binding. In the ATP co-complex E451 is involved 
in coordination of the first Mg2+ ion (Figure 3.10). 
 
 
Figure 3.10: AlcC active site is more ordered upon ATP coordination. ATP binding helps to stabilized loop L7. R312 is 
moved in (indicated by a blue arrow) to bind the α phosphate of ATP. E451 adopts a different rotamer to allow 
adenosine or ATP to bind. AlcC apo structure is colored in grey, AlcC ATP structure as in Figure 3.9.  
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3.3.4 AlcC structure comparison with AcsD 
Although AlcC has only 24 % sequence identity to AcsD (39 % similarity, for more 
detail see Appendix B, Table 4.5) it has a three domain topology that is similar to 
AcsD (Figure 3.1a). In contrast to AcsD in AlcC a 10 residue extended N-terminal loop 
is found (Figure 3.11a). But L1 in AlcC comprises only 7 residues compared to 28 
residues in AcsD and connects the first two β-sheets, but is not involved in AlcC 
dimerization.  
a b                
         
 
NIS family 
sequence 
identity to 
AlcC 
sequence 
similarity to 
AlcC 
A 20-26 % 35-43 % 
B 21-25 % 36-42 % 
C 24-52 % 43-70 % 
c d 
        
Figure 3.11: AlcC and AcsD have a similar topology. (a) AlcC monomer in cartoon representation. Striking 
differences to AcsD (b) are the extended N-terminal loop, the shorter L1 and the inserted 15 residue long helix 
α5. (b) Secondary structure elements of AcsD. (c) Sequence identity and similarity of NIS family members in 
relation to AlcC (detailed analysis in appendix B, Table 4.5). (d) AlcC active site shows structural similarities with 
AcsD, which is shown in lighter, transparent colors. AcsD secondary structure elements are labeled in black/white 
colors and AcsD elements in light blue colors.  
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The middle domain of AlcC contains 198 residues and is 15 residues longer than that 
one in AcsD. These additional residues form helix α5, which is flanked by α4 and β8. 
Helices α5 and α6 in AcsD are merged to helix α6 in AlcC. The C-terminal domain 
leads back to the N-terminal domain as seen for AcsD. The main difference in the C-
terminal domain is found in L10. It extends a further 14 residues and replaces the 
two helices α12 and α13 found in AcsD (Figure 3.11a, b). Though AlcC has only ~40 % 
sequence similarity to type A NIS synthetases (Figure 3.11c) the ATP binding motif, 
the five stranded anti-parallel beta sheets and loops L5, L7, L9 and L10 (Figure 3.11d) 
are conserved.  
3.3.5  Comparison of AlcC and AcsD ATP coordination 
Superposition of AlcC and AcsD co-complex structures reveals that ATP in both 
structures is preliminary coordinated by matching residues (Figure 3.12). These are 
strongly conserved throughout NIS family A and C (Table 3.2) and are basically 
involved in the coordination of ATP tri-phosphates. The adenosine moiety of ATP in 
AlcC however adopts a slightly different position and is coordinated differently.  
 
Figure 3.12: Comparison of ATP coordination in AlcC and AcsD. Cartoon representation in stereo view. ATP in 
both enzymes is preliminary coordinated by conserved residues. AlcC ATP co-complex is colored as in Figure 3.9. 
AcsD residues and Mg2+ are colored in dark grey and the backbone in transparent grey.  
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a 
 
 
 
 
b  
 
 
 
 
 
c 
 
Figure 3.13: Coordination of ATP adenosine moiety in AlcC and AcsD. (a) The adenosine moiety in AlcC is 
coordinated by interaction with several water molecules. The different ATP position in AcsD (superposed based 
on active site residues) is shown in black wireframe. (b) The AcsD adenosine moiety is coordinated by less 
water molecules. Here the family A conserved N509 is involved in coordination of the adenine ring. AlcC ATP is 
superposed in black wireframe. (c) Adenosine in AlcC is coordinated in a similar water network as seen for ATP 
in (a). AlcC ATP is superposed based on active site residues and shown in black wireframe. Hydrogen bonds are 
indicated by dotted lines. 
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The most striking observation is that adenosine moiety in AlcC is essentially 
coordinated by a network of 13 water molecules (eight in direct contact with 
adenosine) (Figure 3.13a). In AcsD four adenosine binding waters are found (Figure 
3.13b).  
 
Since the AlcC ATP complex was derived from a soak, these water molecules could 
be an artifact. However the ADN co-complex derived from co-crystallization shows a 
similar water coordination network and demonstrates that this is not the case 
(Figure 3.13c). Another difference in ATP coordination is that in AcsD the adenine 
ring is stacked between two histidines (H444 and H170). H449 in AlcC adopts a 
similar position to H444 in AcsD, but H162 is found in a less ideal position for 
Table 3.2: ATP coordination in AlcC and AcsD. The table compares matching residues of AlcC and AcsD involved in 
ATP coordination. Each set of residues was defined as “conserved” when totally conserved in NIS family A, C. 
Number of family members carrying the same amino acid of partly conserved residues are shown in brackets (e.g 
(4/17)), whereas the last number is the total number of known family members. 
 
AlcC AcsD conserved conserved in family partly conserved in family 
not 
conserved 
H162 H170 x A,C B( 4/17) 
 
S284 S279 x A,C B(9/17) 
 
R286 R281 x A,C B(8/17) 
 
T287 T282 
 
C A (most T, but some S) B 
K300 K293 x A,C B (9/17) 
 
M308 T301 
 
A 
 
B,C 
N307 
  
C 
 
A,B 
R312 R305 x A,C B(9/17) 
 
R379 R369 
 
C, most A  (R/Y/V) B (G/L/S/Y) 
 
H449 H444 
 
A,C B ( 6/17) 
 
E451 Q446 
 
A, C (Q/E) B (9/17) 
 
N452 N447 x A,C B (9/17) 
 
K468 R463 
 
A (R conserved), 
C (K conserved)  
B 
D469 D464 x A,C B (D/E) 
 
E472 E466 
  
A (E/Q), C (E/D/G) B 
E473 G467 
 
A (G conserved), 
 
C (E,D,G) B 
 N509 
 
A 
 
B,C 
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stacking. N509 in AcsD (only conserved in family A members) coordinates the N1 and 
N6 atoms of the adenine moiety (Figure 3.13b). The matching G450 in AlcC is not 
close and binding of N1 and N6 is maintained by two water molecules (W20 and W6) 
instead (Figure 3.13a). Interestingly G450 is strongly conserved in type C enzymes 
(see also appendix D). 
ATP in AlcC is polarized by two Mg ions. The first one is coordinated by AlcC residues 
E452, N452 and D469, the analogue residues of AcsD (Q446, N447, D464), bridging 
the α and γ phosphate of ATP. The second Mg in AlcC is positioned by residues D469, 
E473 and E473 binding to the α and β phosphorous (Figure 3.12). Only the first two 
residues (D469, E472) are found in AcsD (D464 and E466). The third residue E473, 
which is weakly conserved in NIS family C (other possibilities are D or G), is replaced 
by G467 in AcsD. Interestingly G467 is conserved within family A. Why AlcC 
coordinates a second Mg ion is still unclear. R312 and H449 in AlcC (conserved 
residues in NIS enzymes) face the α phosphate of ATP akin the catalytic important 
residues H444 and R305 in AcsD.  
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3.3.6 Activity assay for AlcC 
Since AlcC is proposed to perform a similar reaction as AcsD, it presumably liberates 
AMP as well. Therefore its activity could be examined by the AMP activity assay, 
which was extensively tested for AcsD (see also chapter 2). Preliminary experiments 
with Sub204 as substrate analogue showed that this is the case and AlcC leads to 
NADH conversion in the coupled assay, while reactions without AlcC showed no 
decrease in NADH concentrations (Figure 3.14).  
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Figure 3.14: AMP production by AlcC. NADH consumption is observed using AlcC and substrate analogue 
Sub204. Reactions with Sub204 were AlcC was omitted showed no decrease in NADH levels. The positive 
control with AMP, but no AlcC enzyme, shows that the coupled enzymes are not rate limiting, but AlcC. 
These first results indicate that the fluorescence based AMP activity assay is 
transferable to other AMP forming enzymes and could be used to obtain kinetic data 
for AlcC. However, due to the relatively large quantities of substrate analogue 
(Sub204) (synthesized by group of Prof. Challis, Warwick) required for this assay, only 
a few experiments were carried out to test the proof of principle. Tests with Sub220, 
the proposed substrate, were not possible. Unfortunately, Sub220 is not 
commercially available and synthesis optimization to yield adequate amounts is still 
in progress.  
  
— 127 — 
3.3.7 Mass spectroscopic analysis 
3.3.7.1 AlcC forms a Sub204 dimer 
The processive enzyme AlcC is proposed to perform dimerization and 
macrocyclization of Sub220. The substrate analogue Sub204 was tested to be active 
and to synthesize more easily in adequate amounts. As mentioned earlier, 
preliminary tests indicated that AlcC utilizes Sub204 catalyzing its dimerization, but 
not its macrocyclization. Mass spectroscopic analysis of AlcC product formation with 
Sub204 revealed two new mass peaks with an m/z value of 391.2 and 413.2 that 
increase over time (Figure 3.15). The theoretical mass of Sub204 dimer is 390.2, 
which correlates well with the observed m/z=391.2 peak in positive TOF mode 
(M+H+). The second mass m/z=413.2 could be a dimer sodium adduct (M+Na+).  
 
Figure 3.15: AlcC mass spectrometry analysis of Sub204 dimer formation. Two new peaks have been observed 
after 3 h incubation. The observed m/z values 391.2 and 413.2 correspond to Sub204 dimer (inset) and a 
Sub204 Na+ adduct, respectively in positive TOF mode. A third mass peak at m/z=373.2 is observed after 26 h 
incubation that would match with the theoretical mass of a Sub204 dimer macrocycle (M+H+) (inset). 
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3.3.7.2 AlcC forms a Sub204 dimer macrocycle 
The mass spectrometry spectra of Sub204 product formation shows a third mass 
peak at m/z=373.2 after 26 h of reaction incubation (Figure 3.15). On closer 
examination, one can detect the 373.2 peak already after 3h of reaction initiation. 
The peak increases steadily over time if compared to the 371.11 peak (Figure 3.16). 
The 373.2 peak is 18 Daltons lighter than the Sub204 dimer peak (m/z=391.2) and 
hence could be the mass of the Sub204 dimer macrocycle, formed in a second AlcC 
reaction by losing water and forming an ester linkage. The observed mass (M+H+ 
m/z=373.2) matches the theoretical mass of a Sub2042 macrocycle (M=372.2) in 
positive TOF mode. The Sub204 derived macrocycle is also known as putrebactin in 
the literature (Kadi et al. 2008). This was surprising as it was thought that AlcC could 
only form Sub204 dimers. 
 
 
Figure 3.16: AlcC mass spectrometry analysis of Sub204 macrocycle formation. The 373 peak is detectable after 
3 h of incubation and increases to dominate the spectra after 26 h in this m/z range. The m/z value of 373.19 
(M+H+) correlates well with the theoretical mass of a Sub204 dimer macrocycle (M=372.2) shown in the inset. 
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3.3.7.3 MS/MS analysis of Sub204 dimer and Sub2042 macrocycle 
Fragmentation of the three new peaks with an m/z value of 373.2, 391.2 and 413.2 
in tandem mass spectrometry experiments led to several daughter ions for each 
species (Figure 3.17a, Figure 3.18a, Figure 3.19a). Interestingly daughter ions from 
Sub204 dimer (m/z= 291.2, 287.1, 269.1 and 187.1) and the dimer sodium adduct 
(m/z= 327.1, 313.2, 227.1 and 127.1) do not have the same masses. This was 
unexpected as one would think that the fragmentation of the same or related 
compounds would lead to at least some identical daughter ions, as seen for the 
fragments of Sub204 dimer and the Sub204 macrocycle which share the m/z=269.1 
and 187.1 daughter ions (Figure 3.17a and Figure 3.19a).  
a 
 
b 
 
Figure 3.17: MS/MS fragmentation pattern of Sub204 dimer product. (a) Fragmentation of Sub204 dimer 
results in four main daughter ions. (b) Possible fragmentation of Sub204 generating the four daughter ions. 
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To verify that the Na+ adduct fragmentation pattern is related and derives from 
Sub204, a theoretical fragmentation was performed. The software ChemDraw Ultra 
(CambridgeSoft) was used for drawing and calculation of fragmentation masses. In 
all three cases simple fragmentation of amide bonds led to the observed fragments 
(Figure 3.17b, Figure 3.18b and Figure 3.19b).  
 
 
 
a 
 
b 
 
Figure 3.18: MS/MS fragmentation pattern of Sub204 dimer sodium adduct. (a) MS/MS spectra of dimeric 
Sub204 sodium adduct shows four daughter ions. (b) Possible fragmentation of Sub204 dimer adduct to 
generate the daughter ions in (a). No simple fragmentation of the sodium adduct yield a fragment with 
m/z=327.1. 
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For the Sub204 dimer, the three major fragments (m/z= 291.2, 287.1 and 187.1) can 
be generated by cleaving one of the three amide bonds. The fourth fragment 
(m/z=269.1) is possibly created in a second event from fragment m/z=287.1 by 
eliminating a water molecule (Figure 3.17b). Theoretical fragmentation of the 
sodium adduct results in three daughter ions (m/z=313.2, 227.1 and 127.1), but not 
in the m/z=327.1 fragment (Figure 3.18b). All daughter ions are also sodium adducts 
and therefore 23 Dalton heavier than the actual fragment. Hence, the m/z values of 
313.2, 227.1 and 127.1 correlate to fragments with a mass of 290.2, 204.1 and 104.1 
Daltons, respectively. Interestingly, these masses/fragments correlate with the non-
charged fragments of the dimer in the theoretical fragmentation scheme and are not 
detectable (Figure 3.17b), apart from 290.2 which is observed as the protonated 
daughter ion 291.2 in the MS/MS spectra (Figure 3.17a).  
Fragmentation of the Sub204 macrocycle results in two major daughter ions with 
m/z =269.1 and 187.1 and three minor ions with m/z =169.1, 151.1 and 140.06 
(Figure 3.19a). An initial fragmentation is mandatory to break and linearize the 
macrocycle. This event presumably takes place by cleaving one of the four amide 
bonds. However the linearized macrocycle has no mass difference and is therefore 
not distinguishable from the closed ring in an MS/MS analysis (Figure 3.19b). In a 
second event, the linearized macrocycle is cleaved at another amide position 
resulting in fragments m/z =269.1 or 187.1 (Figure 3.19b). Two of the minor 
observed fragments (m/z=169.1 and 151.1) could be derived by two successive 
eliminations of water from fragment 187.1. Fragment m/z=140 is likely to be 
generated by losing N-methyl-hydroxylamine (OH-NH-CH3) from fragment 187.1 
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(Figure 3.19b). Both major fragments (m/z =269.1 or 187.1) are also observed in the 
fragmentation pattern of dimeric Sub204 (Figure 3.17b). These results indicate that 
all three peaks (m/z= 373, 391 and 413) are related to each other and most likely 
originate from a Sub204 product generated by AlcC. This also shows that AlcC is 
capable of synthesizing the macrocycle putrebactin, which lacks the two additional 
OH-groups in alcaligin (Figure 3.2). 
 
a 
 
b 
 
Figure 3.19: MS/MS fragmentation pattern of Sub204 dimer macrocycle. (a) Fragmentation results in six main 
daughter ions. (b) Possible fragmentation scheme of Sub2042 macrocycle to generate the observed daughter 
ions. 
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3.3.7.4 AlcC forms a Sub204 trimer and trimer macrocycle 
Long incubations of AlcC reaction (~3 days) showed that AlcC incubated with ATP, 
Mg2+ and Sub204 results in three additional mass ions (along the previous discussed 
dimeric peaks) with an m/z value of 559.3, 577.3 and 599.3 (Figure 3.20a). These 
masses correlate with the theoretical masses of a Sub204 trimeric macrocycle 
(558.3 Da), Sub204 trimer (576.3 Da) and Sub204 trimeric Na+ adduct (599.3 Da) in 
positive acquisition mode (Figure 3.20b).  
a 
 
b 
 
Figure 3.20: AlcC is capable of producing Sub204 trimers. (a) MS/MS analysis of AlcC reactions incubated for 
three days with Sub204 show three additional peaks that correlate with the masses of trimeric Sub204 in open 
(576.3 and 599.3 (Na+ adduct)) and in ring formation (558.3). (b) Chemical structure of a Sub204 trimer and its 
conversion catalyzed by AlcC into a trimer macrocycle. Each Sub204 moiety is highlighted in a different color.  
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a 
 
b 
 
Figure 3.21: MS/MS analysis of Sub204 trimer peak. (a) MS/MS fragmentation pattern of Sub204 trimer peak 
577.3. (b) Theoretical fragmentation to reproduce the daughter ions observed in (a). Each Sub204 moiety is 
highlighted in a separate color. The fragmentation sites are indicated by red dotted lines.  
The detected MS/MS daughter ions of these three peaks indicate that they are 
related to the fragmentation patterns observed for dimeric Sub204 products (Figure 
3.21a, Figure 3.23a, Figure 3.22a). All daughter ions of dimeric macrocycle, Sub204 
dimer or the Na+ adduct are found in the fragmentation pattern of the three peaks 
m/z=559.3, 577.3 and 599.3, respectively. Only fragment m/z=140 of the dimeric 
macrocycle has not been observed in the pattern of peaks 577.3 and 559.3 (Figure 
3.19, Figure 3.21, Figure 3.22). As for the dimeric species, theoretical fragmentation 
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of each trimer species was performed to see if the resulting fragments correlate with 
the respective MS/MS spectrum. 
a 
 
b 
 
Figure 3.22:  MS/MS analysis of Sub204 trimer sodium adduct peak. (a) MS/MS fragmentation pattern of Sub204 
trimer peak 599.3. (b) Theoretical fragmentation of the trimer sodium adduct to reproduce the observed 
daughter ions in (a). Coloring as in Figure 3.21. No simple fragmentation of the trimer Na+ adduct led to the 
observed fragment 513.2.  
 
As for dimeric Sub204, the observed fragments could be reproduced in all three 
cases by simple fragmentation of amide bonds or by elimination of water molecules 
(Figure 3.21b, Figure 3.23b, Figure 3.22b). These results strongly suggest that AlcC is 
capable of extending a Sub204 dimer with another Sub204 molecule forming a 
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trimeric molecule. The data also suggest that AlcC catalyzes cyclization of this 
compound, liberating a trimeric macrocycle (Figure 3.17b). 
a 
 
b 
 
Figure 3.23: MS/MS analysis of Sub204 trimer macrocycle peak. (a) MS/MS fragmentation pattern of Sub204 trimer 
peak 559.3. (b) Theoretical fragmentation of the trimer macrocycle to reproduce the observed daughter ions in (a). 
Coloring as in Figure 3.21.  
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3.4 Discussion 
3.4.1 AlcC dimerization interface 
AlcC and AcsD form both dimers, but involve different dimerization domains. The 
AcsD interface is formed by L1, which comprises a four residue helix located in the N-
terminal domain (Figure 2.1c, Figure 3.24a). The four residues involved in hydrogen 
bonds in the AcsD interface are not conserved in AlcC, and L1 in AlcC is much smaller 
and cannot establish the AcsD dimerization interface (Figure 3.24b). Instead residues 
mainly located on helices (α1-α3, α6 and α8), L4 and a longer N-terminal loop are 
involved in forming the AlcC dimer interface (Figure 3.25). Twelve hydrogen bonds 
and two salt bridges (K255-D123 in each monomer) are found. The interface buries 
2130 Å2 per monomer and is more than 2.5 times larger than that of AcsD, which 
buries 821 Å2 per monomer as analysis with PISA shows (Krissinel and Henrick 2007).  
a  b                
        
 
Figure 3.24: AcsD and AlcC dimer interface comparison. (a) Dimerization domain of AcsD (b) Model of an AcsD 
like dimerisation domain for AlcC. The model was generated by superposing two AlcC monomers independently 
with monomer A and B of AcsD. It demonstrates that AlcC cannot form a “side-by-side” dimer of AcsD due to its 
shorter L1 loop.  
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The AlcC dimer interface contains three family C conserved motifs (Figure 3.26a) 
comprising half of all hydrogen bond forming residues. They are located on α3, α6 
and α8. D123 and K255 form two intermolecular salt bridges and are situated on α3 
and α6, respectively. Both residues are weakly conserved and D123 is substituted by 
E or Q or in the case of K255 by several other amino acids (Figure 3.26a).  
 
Figure 3.25: AlcC dimer interface. The “real” AlcC dimer is a head-to-head dimer. The interface is formed by 
residues located on helices (colored in blue) in the N-terminal and C-terminal domain. L4 and the long N-
terminal loop are also involved in forming the interface.   
PISA analysis (Krissinel and Henrick 2007) of AlcC dimerization shows that the 
interface area decreases by ~500 Å2 per monomer if one deletes residues 7-17 of the 
N-terminal loop and that the dimer would be formed by six hydrogen bonds rather 
than by twelve (Figure 3.26b). As a result the free energy (ΔiG) released upon 
dimerization would be 10 kcal/mol less than for full length AlcC. This indicates that 
the additional N-terminal residues in AlcC (10 more than in AcsD) may help to 
interlock the two monomers and stabilize the dimer as demonstrated in Figure 3.26c. 
These dimerization motifs suggest that type C enzymes presumably form “head-to-
head” rather than “site-by-site” dimers as observed in AcsD. Whether these 
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differences in dimer formation have specific function in catalysis or any other role is 
still unclear and needs further investigation.  
a  b 
                
AlcC PISA analysis Apo structure N-term. loop 
removed
complexation 
significance score (CSS) 1 1
interface area (Å2) 2129.9 1606.3
hydrogen bonds 12 6
salt bridges 2 2
∆iG (kcal/mol) -34.4 -24.5
  
  
 c 
 
Figure 3.26: Conserved motifs of the AlcC dimer interface. (a) AlcC contains three partly conserved motifs 
located on α3, α6 and α8 which comprise six hydrogen bond forming residues in the dimer interface. D123 and 
K255 form also two salt bridges. (b) PISA analysis of AlcC apo structure and of a model, lacking the N-terminal 
loop (residues 6-17). The interface area per monomer decreases by 500 Å2 and less energy (~10 kcal/mol) upon 
dimerization is released. (c) The extended N-terminal loop (colored in red) interlocks the two AlcC monomers. 
AlcC is shown from its front (facing the active site) and its back in surface representation. N-terminal domain is 
colored in blue, middle domain in green and C-terminal domain in orange.  
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3.4.2 Conserved ATP binding motifs in NIS family C 
Coordination of ATP in AlcC and AcsD involves several conserved residues. It was 
shown that most of these residues are close to the phosphates of ATP. However the 
adenosine moiety is bound differently. In AcsD the adenine ring is stacked between 
two conserved histidines (H444 and H170). H162 in AlcC is placed in a suboptimal 
position for stacking. Instead, a network of water molecules organizes the binding of 
the adenosine moiety as observed in the adenosine co-complex or the ATP complex 
structure (Figure 3.13). A sequence alignment of 27 NIS family C members shows 
that they have five conserved ATP binding motifs located on L5, L7, L9, L10 and on 
β12 and β15 (Figure 3.27). 
 
Figure 3.27: Conserved ATP binding motifs of NIS synthetase family C. Schematic representation of motifs and 
their binding association to ATP moieties. Labeled residues are conserved residues found in AlcC. Motifs and 
structural elements are numbered from the N-terminus. Upper cases are family conserved, lower cases are partly 
conserved and positions labeled with “x” are not conserved residues. 
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Remarkably, all five motifs are involved in phosphate coordination and contain the 
likely catalytic key residues R312 and H449. The most conserved motif is motif I 
(aqqSiRT) which contains three highly conserved residues (S284, R286 and T287 in 
AlcC) located on L5 that are involved in β and γ phosphate coordination (Figure 3.27). 
These three residues are also found in NIS family A members. Motif II is fifteen 
residues long and contains three highly, nine weakly and three non conserved 
residues on β12 and L7. This motif is involved in the binding of all ATP phosphates 
and the 2’-OH of the ribose and contains the presumed catalytic arginine (R312 in 
AlcC).  
Motif III (WR(E/Q)sp) contains two highly conserved residues (W378 and R379 in 
AlcC), whereas only arginine is involved in the coordination of the γ phosphate. Motif 
IV contains three family conserved residues (H449, E451 and N452 in AlcC). These 
residues coordinate the α phosphate and the first Mg ion. A NIS superfamily 
conserved histidine (H449 in AlcC), which was shown to be one of the catalytic 
residues in AcsD (H444 in AcsD), is located in motif IV. Motif V is less well conserved 
and is involved in binding the γ phosphate and the first Mg ion. The binding site of 
the first Mg is conserved between AlcC and AcsD, in contrast to the second Mg 
coordination which is not conserved. Only a few other type C enzymes have 
matching residues (see also appendix D). This suggests that not all family C members 
bind a second Mg ion. These binding motifs indicate that the phosphates of ATP in 
family C but also in family A may be coordinated in a similar manner.  
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3.4.3 AlcC is a processive enzyme and forms macrocycles 
Although AcsD and AlcC have a conserved ATP binding pocket (described in detail in 
the previous section), their substrate binding site must be different. AcsD, a type A 
enzyme, uses citric acid and L-serine, but AlcC, a type C enzyme, consumes and 
performs dimerization of the succinic acid derivatives Sub204 or Sub220. For AcsD, 
the co-complex of citric acid and the final product citryl-EDA assisted in elucidation 
of the AcsD reaction mechanism. Unfortunately no such co-complex structures were 
obtained for AlcC. However, one still can infer substrate binding from the AcsD co-
complex structures for a possible ligand location in AlcC. The O1 atom of the citric 
acid is facing the α-phosphorous in an angle of 151° which is a consistent position for 
a nucleophile attack to form an enzyme bound citryl-adenylate. Furthermore, two 
conserved catalytic residues (R305 and H444) are in close proximity to the 
carboxylate of citric acid. Bearing all these facts in mind the first ternary complex 
with Sub220 can be modeled in the AlcC ATP co-complex. Sub220 perfectly fits in a 
small active site pocket and would be coordinated by R312, H162, M447, H449 and 
D506 (Figure 3.28a). The Sub220 carboxylate and not its amino group would face the 
α-phosphorous of ATP allowing a nucleophilic attack of the carboxylate. A conserved 
histidine (H162 in AlcC, H170 in AcsD) is close to coordinate Sub220. In AcsD, H170 is 
involved in binding of citric acid as well as stacking the adenosine ring of ATP with 
H444. However in AlcC, H162 is in a less favored position for stacking. The remaining 
Sub220 binding residues M447 and D506 are only weakly conserved (found in nine 
other type C enzymes, see also appendix D, Figure 4.5). 
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Figure 3.28: Docked models of Sub220 and final products in AlcC active site. (a) The docked Sub220 (colored in 
green) faces with its carboxylate the α phosphate of ATP. Sub220 is coordinated by three conserved residues 
(H162, R312 and H449) and two weakly conserved residues (M447 and D506). (b) A second Sub220 molecule 
(colored in purple) faces the Sub220-AMP intermediate (Sub220 moiety colored in green, AMP in yellow) from 
the solvent accessible face and binds to E473. (c) The Sub220 dimer has to bind in a permutated orientation to 
allow macrocyclization. (d) The Sub220 dimer is activated by adenylation and a Sub220 dimer intermediate and 
PPi is generated. (e) A docked alcaligin molecule superposes well with a docked Sub220 dimer (shown in black 
wireframe).  
 
Similar to AcsD where the L-serine attack must occur on the solvent exposed face of 
citric acid, in AlcC only one position for the second substrate molecule is conceivable. 
In the second ternary complex another Sub220 molecule presumably is coordinated 
by E473 facing the ester bond of the Sub220-adenylate with its nucleophilic amino 
group (Figure 3.28b). The Sub220 carboxylate binds to the free amino group of the 
Sub220-adenylate intermediate. After dimer formation the product has to be 
released. This would be consistent with mass spectrometry results where a mass 
peak corresponding to Sub204 dimer is detected although the enzyme was removed 
by filtration prior analysis. The Sub2042 macrocyclization can happen in two different 
ways: enzyme catalyzed or autocatalytically. Reactions with Sub204, where AlcC was 
removed after O/N incubation (to yield sufficient Sub204 dimer product), showed 
that the ratio of Sub204 dimer (+ Na+ adduct) to dimer macrocycle peak levels do not 
change significantly over a period of 13 days (see appendix E, Figure 4.8). This 
indicates that AlcC catalyzes the macrocyclization and that the macrocycle is not 
formed autocatalytically. Therefore a generated dimer would have to bind in a 
permutated orientation in the active site facing the α-phosphorous of ATP with its 
free carboxylate (Figure 3.28c). As for the first reaction the dimer has to be activated 
by adenylation generating an enzyme bound Sub220 dimer intermediate and 
pyrophosphate (Figure 3.28d). A model of the resulting alcaligin superimposes well 
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with both substrate position and the macrocycle does not clash with active site 
residues (Figure 3.28e).  
AlcC was shown to form a Sub204 trimer in an open and a closed ring formation. This 
was quite surprising since the actual biosynthesis model proposes AlcC to form 
alcaligin, a dimeric macrocycle (Challis 2005; Brickman et al. 2007). A docked model 
of alcaligin and Sub204 trimer macrocycle shows that the larger macrocycle is still 
able to fit in the AlcC active site. This is demonstrated by the space filled models of 
each macrocycle (Figure 3.29a, b). A model of AlcC dimer with two trimeric 
macrocycles bound reveals that each active site has to work independently since 
 
Figure 3.29: Docked models of alcaligin and the Sub204 trimer in AlcC active site. (a) Space filling model of 
alcaligin. (b) Space filling model of Sub204 trimer demonstrates that there is still enough room to bind the large 
trimeric macrocycle. (c) Docked model of two Sub204 trimer macrocycles in both AlcC monomers.  
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they are too far apart to interact with each other. These models suggest that both 
reactions (dimerization and macrocyclization) are likely to happen in the same place.  
a 
                                  
         
b 
     
Figure 3.30: Similarities between AlcC and DesD. (a) Chemical structure of N-hydroxy-N-succinylcadaverine and 
desferrioxamine E, substrate and product of DesD. (b) A sequence analysis of AlcC and DesD shows that key 
active site residues (H162, R312, M447, H449, E472, E473, D506 etc.) are conserved in both enzymes.  
 
DesD, another type C enzyme, is involved in biosynthesis of desferrioxamine in 
Streptomyces coelicolor (Kadi et al. 2007). It has 51 % sequence identity (69 % 
sequence similarity) with AlcC (see also appendix C, Table 4.5). DesD is proposed to 
perform trimerization and macrocyclization of N-hydroxy-N-succinylcadaverine to 
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generate desferrioxamine E (Figure 3.30a). The DesD substrate is a 10-
aminocarboxylic compound and differs only by an additional carbon compared to 
Sub204 (Figure 3.2b), which is a 9-aminocarboxylic substrate. A sequence alignment 
of both enzymes shows that residues involved in ATP coordination as well as the 
possible catalytic residues R312 and H449 are found in both enzymes (Figure 3.30b). 
Residues H162, M447, D506 and E473 which are likely to coordinate Sub220 in AlcC 
are also present in DesD. Hence the active site must be organized in a similar way. 
Therefore it is likely that AlcC is able to utilize DesD substrate catalyzing not only 
dimerization, but also trimerization and macrocyclization. 
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3.5 Conclusion 
The apo and co-complex structure of AlcC are the first structural insights into a NIS 
family C member. While the adenosine structure was acquired by co-crystallization, 
the ATP structure was only obtained after replacing the active site bound sulfate. 
This was accomplished by soaking apo crystals in high concentrations of sodium 
formate, followed by an ATP/sodium formate solution. The most prominent 
observation is that ATP is coordinated in a “similar” manner to ATP in AcsD, and that 
two conserved residues, R312 (that moves in from a remote position) and H449, are 
found in close proximity to the α-phosphorous. This indicates that these residues, as 
it was shown for AcsD, are the catalytic residues. Sequence analysis of family C 
members showed that coordination of the tri-phosphates and the first Mg ion is 
partly conserved in five binding motifs. The binding site of the second Mg is not 
conserved and is presumably not found in many other type C enzymes. 
AlcC and AcsD share a three domain topology. There are only minor differences in 
secondary elements such as an added helix (α5) or the extended N-terminal loop in 
AlcC. Even though they share a similar topology, AlcC has a “head-to-head” dimer 
and is not able to form the “side-by-side” dimer seen for AcsD due to its shorter L1 
loop. The extended N-terminal loop (missing in AcsD) was shown to interlock the two 
AlcC monomers and stabilize them. It still remains unclear whether dimerization is 
functionally significant.  
In biochemical analysis with the substrate analogue N-hydroxy-N-succinylputrescine 
(Sub204) it was demonstrated that AlcC is capable of forming dimers, trimers and 
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their macrocycles. This was unexpected, since preliminary tests in the group of Prof. 
Challis indicated that with this substrate analogue only a dimer but not a macrocycle 
was formed. A detailed fragmentation analysis of the MS/MS data illustrated that 
simple cleavage at amide bonds or elimination of water reproduces the observed 
fragments. Since no substrate or product co-complex was obtained substrate binding 
models were created. The docked model of Sub220 substrate perfectly fits in a small 
cavity facing the α phosphate of ATP with its carboxylate similar to citric acid in AcsD 
allowing a SN2 like attack to generate a Sub220 adenylate. The model of alcaligin and 
the trimer macrocycle demonstrate that the active site of AlcC is large enough to 
accommodate both without any domain movements. This would be consistent with 
the AcsD structure where no structural movement upon nucleophile binding was 
observed. A model of AlcC dimer with two coordinated (Sub204)3 macrocycles 
demonstrates that the two active sites of AlcC are too far apart to interact with each 
other and are not likely to form one “large” active site. Interestingly DesD, another 
type C enzyme, performs a similar trimerization and macrocyclization and shows a 
high sequence similarity to AlcC. Key active site residues including the likely 
substrate coordinating residues are found in both enzymes. DesD is involved in 
desferrioxamine biosynthesis, a substance also used as a FDA approved drug in 
medical applications such as iron chelating therapies after repetitive blood 
transfusions or treatment of chronic iron overload or acute iron intoxications (Hua et 
al. 2008; Suzuki 2008). But so far no structural data of DesD are published and the 
acquired structural results on AlcC might help in developing new or modified iron 
chelating compounds used in medical or commercial applications.  
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3.6    Future work 
AlcC and AcsD have a similar three domain topology, but don’t share the same dimer 
interface. The dimer interface in AlcC seems at least partly conserved in family C. Site 
directed mutagenesis of hydrogen bond forming residues involved in stabilizing the 
dimer and their effect on enzyme activity is required to probe their role. Additional 
biochemical data such as kinetic parameters or mutational studies on H449 and R312 
are desirable.  
Structural models of AlcC substrate and product coordination were developed based 
on structural information of AlcC and AcsD co-complex structures. Hence future 
work will concentrate on obtaining substrate or product co-complexes. Since soaking 
has not been successful, a different method or a revised protocol is needed. One 
possible approach is mutation of likely coordinating residues to enhance substrate 
binding and/or test substrate analogues that act as active inhibitors. However the 
main problem seems to be the sulfate containing crystallization condition, which 
does not allow binding of ATP until sulfate is removed or diluted. So far intensive 
screening for a sulfate-free condition has failed. Surface reduction entropy (SER) 
approach has been shown to enhance crystallization of several proteins (Derewenda 
2004; Goldschmidt et al. 2007). The surface modified AlcC protein could be re-
screened with commercial or customized stochastic screens, where sulfate or 
phosphate is omitted.  
AlcC was shown to be capable of catalyzing trimerization of N-hydroxy-N-
succinylputrescine (Sub204). DesD also catalyzes a trimerization reaction. It utilizes 
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three molecules of N-hydroxy-N-succinylcadaverine to generate desferrioxamine E. 
Since both substrates are quite similar (just a carbon longer), AlcC might also be able 
to utilize the DesD substrate. The docked model of the Sub204 trimer shows that 
there is enough space for larger substrates and products. Hence, finding and testing 
of other natural or chemically synthesized substrates could increase its use in 
biotransformation.  
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Chapter 4 -   Adenylation 
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4.1 Introduction 
4.1.1 Summary 
Thioesters, amides and esters are common chemical building blocks in a wide array 
of natural products. The formation of these bonds can be catalyzed in a variety of 
ways. For chemists, the use of an activating group is a common strategy and 
adenylate-forming enzymes are examples of this approach in biology. Here the 
hydroxyl leaving group of the otherwise unreactive carboxylic acid is activated by 
adenosine monophosphate liberating pyrophosphate (the driving force). The 
resulting carboxylate adenylate is very reactive and would decompose in water. 
Necessarily the enzymes that forms this reactive intermediate also catalyze a second 
step, in which a nucleophile (either amine, alcohol or thiol) reacts with the 
intermediate to generate the desired product, liberating AMP (Figure 1.2a).  
 
Figure 4.1: Old and new classification system of adenylate forming enzymes.  
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In this chapter the structural relation of AcsD and AlcC to other adenylate-forming 
enzymes is investigated. Coordination of ATP and metal ions were compared and the 
different catalytic residues examined. Since the existing superfamily (Fulda et al. 
1994) did not include tRNA-synthetases or the new identified family of NIS 
synthetases (comprising AscD and AlcC), a new classification system for adenylate 
forming enzymes was desirable. A new superfamily is proposed comprising three 
basic classes (Figure 4.1). The first class constitutes the former superfamily with 
subclasses Ia, Ib and Ic. The second class comprises aminoacyl-tRNA synthetases with 
subclasses IIa and IIb, while class III contains the NIS enzymes with subclasses IIIa, IIIb 
and IIIc.  
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4.2 Results and discussion 
4.2.1 Same reaction but very different domain architectures 
All adenylate-forming enzymes catalyze the difficult condensation between a 
nucleophilic carboxylic acid and the electrophilic phosphate of ATP. This mechanism 
proceeds through a negatively charged phosphorus group which must be stabilized. 
Two different chemical mechanisms can perform such a reaction: a dissociative or an 
associative substitution.  
In the first step of a dissociative mechanism the leaving group is released, forming a 
trigonal planar transition state (Figure 4.2a). In the second step the carboxyl-
nucleophile attacks the phosphorous. The other alternative is an associative 
substitution. Here the nucleophilic carboxylate attacks the α-phosphorous on the 
opposite site (180°) of the pyrophosphate leaving group in a one step reaction. This 
mechanism proceeds through a trigonal-bipyramidal transition state and covalently 
binds the carboxyl and the leaving group to the pentacoordinated α-phosphorous 
(Figure 4.2b). The pyrophosphate leaving group is pushed out. The latter reaction 
 a b 
                                    
Figure 4.2: Comparison of the transition state of a dissociative and associative reaction.  
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mechanism is favored since pyrophosphate, a relatively big and bulky leaving group, 
is more suitable for an associative “back face” attack. The activated carboxyl-
adenylate intermediate is then attacked by a nucleophilic substrate liberating ester, 
amide or thioester products (depending on the utilized nucleophile) and adenosine 
monophosphate (Challis 2005; Abe et al. 2008).  
Class I adenylate-forming enzymes all have a large N-terminal domain with a small C-
terminal domain connected via a flexible hinge (see section 1.2.1). The relative 
orientation of the two domains varies presumably as a consequence of the hinge. 
The C- and N-terminal domain were described as a “hammer-and-anvil” structure. 
The N-terminal domain (anvil) is subdivided into three sub-domains with an α/β 
topology, topped by a αβαβα sandwich and a β-barrel (Conti et al. 1996). The C-
terminal domain (hammer) sits on top like a “lid” and is made up of five β-strands 
and three α-helices. The two-domain architecture is consistent for all class I 
enzymes. Class II enzymes do not show such conserved overall domain arrangement. 
Subclass IIa aminoacyl-tRNA synthetases (aaRSs) have four domains: a zinc-binding, 
central catalytic, anticodon-binding and an amino acid specific domain. Some aaRSs 
(as LeuRS, IleRS or ValRS) have an additional proofreading/editing domain, called CP1 
(connective polypeptide 1), which was reported to be important for enzyme fidelity 
(Figure 1.3c) (Mascarenhas and Martinis 2008). In contrast to class IIa enzymes, 
subclass IIb consists of an anticodon-binding domain and the central catalytic 
domain, although additional insertions are known (Figure 1.3) (Xie et al. 2007). While 
subclass IIa aaRSs are generally monomeric, subclass IIb aaRSs are dimeric or 
tetrameric (Cusack 1997). Class III enzymes have three domains (Figure 2.1 and 
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Figure 3.11), an N-terminal domain, a central domain and a C-terminal domain 
(Schmelz et al. 2009). Until more structures are solved in this class, consistency of 
their overall architecture remains to be proven. 
4.2.2 ATP binding 
The catalytic site in adenylate-forming enzymes varies from class to class. In class I 
enzymes the active site is formed by the interface between the N-terminal and C-
terminal domain, which are connected by a flexible hinge (Wu et al. 2009). The 
domains significantly alter their relative orientations to adjust the catalytic site 
depending whether the protein is catalyzing adenylate formation or the second 
reaction. For example in human acyl-CoA synthetase (Kochan et al. 2009) a 
conserved catalytic lysine important for adenylation is moved out after adenylate 
formation to facilitate thioester formation (Figure 4.3a) (Kochan et al. 2009; Osman 
et al. 2009).  
Class II enzymes locate the active site in the central catalytic domain. Other than in 
class I enzymes no large conformational changes are observed in the catalytic 
domain upon substrate binding. However significant domain movements of the 
editing and the leucine-specific domain in leucyl-aaRS upon leucyl-tRNA coordination 
were identified (Weimer et al. 2009) (Figure 4.3b). In ProRS and HisRS from T. 
thermophilus, subclass IIb aaRSs, conformational changes in the active site (such as 
ordering adjacent loops) coupled to global inter-domain and inter-subunit 
movements have been reported (Yaremchuk et al. 2001). 
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Figure 4.3: Domain movement in class I and II adenylating enzymes. (a) Domain movement in class I enzymes. 
Changing from adenylate-forming conformation (red) to thioester-forming conformation (blue) results in a 
domain rotation of up to 135°. A conserved catalytic lysine (K557 in human acyl-CoA synthetase, colored in 
green) is moved out while a glycine residue (G470, colored in purple) is moved in the active site when shifting 
from adenylate to thioester-forming state. The rotation axis is indicated as a dotted line. Used PDB codes are 
3c5e (adenylate-forming conformation) and 2wd9 (thioester-forming conformation). Residues 289-303 of the N-
terminal domain are hidden to allow view on active site. (b) Domain movement in class IIa enzymes upon tRNA 
coordination. While the central catalytic domain does not change conformation the editing and the leucine-
specific domain shift 35° and 19° in Leucyl-tRNA synthetase upon tRNA coordination, respectively. Used PDB 
codes are 1h3n (unbound conformation (colored in red), coordinating a leucyl-adenylate analogue) and 2byt 
(tRNA bound conformation, colored in blue). 
 
Class III enzymes employ all three domains to make a deep cavity in the middle of 
the protein (Schmelz et al. 2009), which, apart from limited ordering of surrounding 
loops, do not alter their structure upon substrate binding. Class I and IIa enzymes 
bind ATP in a Rossmann-fold, but class IIb and class III do not. In subclass IIb aaRSs 
ATP is bound by three conserved motifs within a seven folded anti-parallel β-sheet 
(Cusack 1995; Crepin et al. 2006), but in class III enzymes ATP is bound by a novel 
fold, which shares parts of the cAPK nucleotide triphosphates binding fold (see also 
section 2.4.4). 
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4.2.3 Role of metals 
All adenylate-forming enzymes are reported to be Mg2+ dependent (Airas 2007), but 
in at least one case Mn2+ can substitute for Mg2+ (Belrhali et al. 1995). Interestingly, 
biochemical studies show that human TyrRS requires K+ for catalysis. It is reported 
that it adopts the function of substrate activation, which is normally carried out by a 
missing but otherwise highly conserved lysine residue in subclass IIa aaRS enzymes 
(Austin and First 2002).  
In each structure with ATP bound, a Mg2+ is reported to coordinate the phosphate. 
The divalent metal ion will neutralize the charge of ATP, stabilize the transition state 
and neutralize the leaving pyrophosphate. With such an acknowledged central role, 
it is surprising that the coordination geometry and even more the number of Mg2+ 
ions varies across the superfamily. The NRPS synthetase DltA (class Ia) (3fcc) shows a 
β – γ coordination (Yonus et al. 2008). Mg2+ in tryptophanyl-tRNA synthetase from G. 
stearothermophilus (1m83) (class IIa) is coordinated by α-β-γ phosphates unlike the 
human homologue (2qui) (Shen et al. 2008), where an α-β coordination is found. In 
AcsD, a class IIIa enzyme, a single Mg2+ coordinates the α–γ phosphate, a geometry 
only found in seven other structures consisting of kinases and the ribonucleotide 
transformylase PurT (1kj9). In AlcC a second Mg is bound to the α and β phosphate 
of the tri-phosphate. In contrast lysyl-tRNA synthetase, a subclass IIb enzyme, binds 
3 metal ions, coordinating the α and β phosphate and the β and γ phosphates 
(Desogus et al. 2000).  
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4.2.4 Catalytic residues 
At the α phosphate of ATP it is possible to identify chemical similarities of 
surrounding amino acids despite the discussed differences in protein structure. In 
every structure an Arg, Lys or His (Figure 4.4 and Figure 4.5) residue contacts the α 
phosphate but not always in a conserved position. In many but not all enzymes an 
additional positively charged residue surrounds the phosphate.  
 
Figure 4.4: Coordination of α phosphate in different classes of adenylate-forming enzymes. In each member at 
least one positively charged residue, as lysine, arginine or histidine is present. Acetyl-CoA synthetase (2p2f) and 
Japanese firefly luciferase (2d1q) are class I; human tryptophanyl-tRNA synthetase (2qui) and lysyl-tRNA 
synthetase (1e24) are class II; AcsD and AlcC are class III adenylate-forming enzymes. ATP superposed in line 
representation is ATP of AcsD. 
Class I enzymes use either Arg (Acetyl-CoA synthetase (Gulick et al. 2003)), Lys (GrsA 
and firefly luciferases) or His (firefly luciferase) near the α phosphate. Here a highly 
conserved threonine is also found in all these enzymes (Figure 4.5a). In class III two 
conserved residues, His and Arg (Figure 4.5c), are close to the α phosphate but 
neither of these residues do superpose with those in class I. A strictly conserved 
arginine found in all class IIa or IIb type tRNA synthetases (R262 in LysU, Figure 4.5b) 
does superimpose with R305 in AcsD or R312 in AlcC. These residues (along with 
metal ion(s)) polarize the α phosphate of ATP enhancing the electrophilicity of the 
phosphorus. The positive charge will also polarize the negative charge of the 
  
— 161 — 
incoming carboxylate increasing its nucleophilicity. The surrounding positive charges 
crucially will stabilize the negatively charged pentavalent transition state.  
 
a b c 
    
Figure 4.5: Active site alignment of different classes of adenylate-forming enzymes. Alignment was carried out 
on α phosphate of ATP or AMP. a Alignment of class I enzymes of Acetyl-CoA synthetase (2p2f), gramicidin S 
synthetase 1 (1amu), Japanese firefly luciferase (2d1q) and 4-Chlorobenzoyl-CoA ligase (3cw8). b Alignment of 
class II enzymes tryptophanyl-tRNA synthetase (1m83), human tryptophanyl-tRNA synthetase (2qui) and lysyl-
tRNA synthetase (1e24), alignment of α phosphate of ATP is shown, ATP in  grey line representation is ATP of 
2qui.  c Alignment of class III enzyme: AcsD colored in light blue (2w02) and AlcC colored in green,  Mg 1 ion in 
AcsD and AlcC show an α-γ phosphate coordination, while AlcC coordinates a second Mg ion (Mg 2) in the α-β 
position (green). In contrast to class I and II water in class III enzymes is close to the α phosphate. 
 
In all three classes point mutations of these positively charged residues show 
decreased enzyme activity. In class I enzymes mutations of the conserved lysine 
(K529R or K529Q in firefly luciferase) facing the α phosphate of ATP caused a ~1650 
fold reduction of activity when changed into glutamine (Branchini et al. 1999). In 
class II aaRSs K233 mutants (second lysine in the conserved ATP binding KMSKS 
motif) of tyrosyl-tRNA synthetase, have been reported to deteriorate the ability to 
form tyrosine-adenylate (Fersht et al. 1988; First and Fersht 1993). Similar results 
were obtained for AcsD, a class IIIa enzyme, loosing activity after mutation of 
positively charged R305 and H444 (see section 2.3.7). 
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4.2.5 The release of pyrophosphate 
The pyrophosphate leaving group in class III appears to be retained after adenylate 
formation in a pocket which extends beyond the γ phosphate. In class I enzymes 
pyrophosphate is released after forming the intermediate. This was examined in the 
adenylation domain of gramicidin S synthetase (Conti et al. 1996). In class II leucyl- or 
tyrosyl-tRNA synthetases, pyrophosphate is reported to be released after the amino 
acid adenylate was formed to mediate binding of tRNA which initiates the second 
step of tRNA amino-alkylation (Lin et al. 1975; Kuratani et al. 2006).  
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4.3 Conclusion 
Adenylate-forming enzymes have important and diverse roles in metabolic pathways 
of prokaryotes and eukaryotes. We suggest that an inclusive definition of the 
superfamily based on the commonality of the adenylation chemistry may be more 
useful than one limited to three dimensional structures. Adenylating enzymes show 
that the same chemistry can be catalyzed by very different structures. Despite the 
profound differences in structure and active site architecture, there are clear 
chemical similarities in the environment that surrounds the α phosphate. This 
chemical conservation is of course driven by the requirement to stabilize the 
pentavalent negatively charged transition state. From a chemical standpoint, the 
nucleophilic attack of the α or γ phosphate by a hydroxyl are closely related, because 
in both cases a negatively charged nucleophile attacks. For instance, class III enzymes 
and kinases (as discussed in chapter 2) share a similar coordination of the ATP tri-
phosphates, but not the same binding sites for the adenosine moieties, which are 
located opposite each other. This aligns the α-phosphorous of class III enzymes and 
the γ-phosphorous of kinases in identical position and hence allows a similar 
nucleophilic attack at the phosphate.  
Chemical conservation has been observed in other enzyme families such as 
proteases. Though the different families of proteases use different ways to activate a 
water molecule or another nucleophile to achieve the cleavage of peptide bonds, 
they all need to stabilize the tetrahedral transition state.    
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Figure 4.6: Chemical conservation of the serine protease triad. Serine proteases share a catalytic triad (His-Asp-
Ser), but are structurally and evolutionary distinct. (a) Trypsin protease (1S81, pork) with catalytic residues H57, 
D102 and S195. (b) Subtilisin (2ST1, Bacillus amyloliquefaciens) with catalytic residues D32, H64 and S221. (c) 
Prolyl oligopeptidase (3EQ7, pork) with residues S554, D641 and H680. (d) HCMV protease (1NJU, human 
herpesvirus 5) with a different catalytic triad: H63, S132 and H157. 
 
Serine proteases, which account for one third of all proteases, for instance comprise 
the well known catalytic triad (Asp-His-Ser). However serine proteases are 
structurally diverse as a comparison of trypsin, subtilisin and prolyl oligopeptidase 
shows (Figure 4.6a-c) (Page and Di Cera 2008). Interestingly, variations of the 
catalytic triad (e.g. His-Ser-His or Asp-Glu-Ser) are also found (Figure 4.6d) (Polgar 
2005). The nucleophilic serine attacks the carbonyl of the substrate (protein or 
peptide) and forms a covalent acyl-ester intermediate (Hedstrom 2002). The two 
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assisting residues in the triad are needed to act as a general base (histidine) and an 
acid (aspartic acid). During reaction the base accepts a proton from the serine 
hydroxyl moiety and the acid protonates the amino leaving group of the substrate. 
This arrangement and the oxyanion hole (formed by S221 and N155 in subtilisin) 
stabilize the formed negative charge of the tetrahedral intermediate (Polgar 2005).  
Akin to proteases, adenylating enzymes have utilized different spatial arrangements 
of residues to stabilize the transition state. This is primarily accomplished by the use 
of one or two positively charged residues such as His, Lys or Arg and the coordination 
of up to three Mg ions. It is likely that the requirement to activate carboxylic acids 
for condensation is particularly ancient (thioester, amide and ester bonds are 
extremely common chemical building blocks) and this may have driven the 
convergent evolution seen in the structures of the adenylate forming enzymes 
(Schmelz and Naismith 2009). Furthermore adenylate forming enzymes are not only 
interesting enzymes, but have utilities in commercial significant biotransformation or 
biosynthetic chemistry (Watanabe et al. 2006; Challis 2008; Fisch et al. 2009; Meier 
and Burkart 2009). 
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4.4 Future work 
Class III adenylate-forming enzymes have a three domain topology. Since only two 
structures (AcsD and AlcC) have been solved, it remains to be proven whether this 
topology is conserved or not. It therefore is essential to solve more structures of 
class III enzymes. So far preliminary work was carried out to obtain crystals for AcsA 
and DesD (see appendix F and G). DesD is another class IIIc and AcsA a class IIIb 
enzyme. The structure of AcsA would be interesting, since it would be the first 
structure of a class IIIb enzyme and would reveal whether class IIIb enzymes share a 
similar topology with class IIIa and IIIc enzymes. Another interesting, yet 
unanswered, point is the ability of AlcC (as a processive enzyme) to catalyze two or 
three reactions while AcsD, which shares a homolog topology, just catalyzes one. It is 
important to take a closer look at the substrate binding sites to identify which 
residues turns one enzyme into a processive and the other into a single reaction 
catalyzing one. 
Modification of the substrate specificity of other adenylate forming enzymes such as 
class I enzymes is interesting. For AcsD, a class III enzyme, it was shown that it is 
capable of utilizing a variety of different types of nucleophiles (-OH, -NH2 and –SH) 
and that mutation can shift its substrate specificity. The enzymatic synthesized 
products may have use in biotransformation. The question is whether class I 
enzymes can be modified to utilize artificial compounds as well. One focus might be 
on a class I enzyme: the benzoate CoA ligase from Burkholderia xenovorans (Bains 
and Boulanger 2007). Bains and Boulanger demonstrated that benzoate CoA ligase is 
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also capable of utilizing fluorinated benzoates but not chlorobenzoates. Modification 
of its active site might adapt its substrate specificity to allow oxidation of 
chlorobenzoates as well. Another potential enzyme could be 4-Chlorobenzoate ligase 
from Pseudomonas species (Chang et al. 1997). Engineered microorganisms 
“equipped” with such enzymes for instance would be valuable tools in 
bacteriological treatment approaches of chemically polluted areas.  
  
— 168 — 
5. Bibliography 
 
Abdalla, M. (2001). "Sudden decline of date palm trees caused by Erwinia chrysanthemi." 
Plant Disease 85(1): 24-6. 
Abe, T., Y. Hashimoto, H. Hosaka, K. Tomita-Yokotani and M. Kobayashi (2008). "Discovery of 
amide (peptide) bond synthetic activity in Acyl-CoA synthetase." J Biol Chem 
283(17): 11312-21. 
Airas, R. K. (2007). "Magnesium dependence of the measured equilibrium constants of 
aminoacyl-tRNA synthetases." Biophys Chem 131(1-3): 29-35. 
Atkin, C. L., L. Thelander, P. Reichard and G. Lang (1973). "Iron and free radical in 
ribonucleotide reductase. Exchange of iron and Mossbauer spectroscopy of the 
protein B2 subunit of the Escherichia coli enzyme." J Biol Chem 248(21): 7464-72. 
Austin, J. and E. A. First (2002). "Potassium functionally replaces the second lysine of the 
KMSKS signature sequence in human tyrosyl-tRNA synthetase." J Biol Chem 277(23): 
20243-8. 
Bains, J. and M. J. Boulanger (2007). "Biochemical and structural characterization of the 
paralogous   novel benzoate oxidation (box) pathway." J Mol Biol 373(4): 965-77. 
Baldwin, T. O. (1996). "Firefly luciferase: the structure is known, but the mystery remains." 
Structure 4(3): 223-8. 
Beaumont, F. C., H. Y. Kang, T. J. Brickman and S. K. Armstrong (1998). "Identification and 
characterization of alcR, a gene encoding an AraC-like regulator of alcaligin 
siderophore biosynthesis and transport in Bordetella pertussis and Bordetella 
bronchiseptica." J Bacteriol 180(4): 862-70. 
Belrhali, H., A. Yaremchuk, M. Tukalo, C. Berthet-Colominas, B. Rasmussen, P. Bosecke, O. 
Diat and S. Cusack (1995). "The structural basis for seryl-adenylate and Ap4A 
synthesis by seryl-tRNA synthetase." Structure 3(4): 341-52. 
Beri, R. and R. Chandra (1993). "Chemistry and biology of heme. Effect of metal salts, 
organometals, and metalloporphyrins on heme synthesis and catabolism, with 
special reference to clinical implications and interactions with cytochrome P-450." 
Drug Metab Rev 25(1-2): 49-152. 
Berti, A. D. and M. G. Thomas (2009). "Analysis of achromobactin biosynthesis by 
Pseudomonas syringae pv. syringae B728a." J Bacteriol 191(14): 4594-604. 
Branchini, B. R., R. A. Magyar, M. H. Murtiashaw, S. M. Anderson, L. C. Helgerson and M. 
Zimmer (1999). "Site-directed mutagenesis of firefly luciferase active site amino 
acids: a proposed model for bioluminescence color." Biochem 38(40): 13223-30. 
Brickman, T. J., M. T. Anderson and S. K. Armstrong (2007). "Bordetella iron transport and 
virulence." Biometals 20(3-4): 303-22. 
Brickman, T. J. and S. K. Armstrong (2009). "Temporal signaling and differential expression of 
Bordetella iron transport systems: the role of ferrimones and positive regulators." 
Biometals 22(1): 33-41. 
Brickman, T. J., T. Hanawa, M. T. Anderson, R. J. Suhadolc and S. K. Armstrong (2008). 
"Differential expression of Bordetella pertussis iron transport system genes during 
infection." Mol Microbiol 70(1): 3-14. 
Brown, N. R., M. E. Noble, J. A. Endicott and L. N. Johnson (1999). "The structural basis for 
specificity of substrate and recruitment peptides for cyclin-dependent kinases." Nat 
Cell Biol 1(7): 438-43. 
  
— 169 — 
Cendrowski, S., W. MacArthur and P. Hanna (2004). "Bacillus anthracis requires siderophore 
biosynthesis for growth in macrophages and mouse virulence." Mol Microbiol 51(2): 
407-17. 
Challis, G. L. (2005). "A widely distributed bacterial pathway for siderophore biosynthesis 
independent of nonribosomal peptide synthetases." Chembiochem 6(4): 601-11. 
Challis, G. L. (2007). "A Widely Distributed Bacterial Pathway for Siderophore Biosynthesis 
Independent of Nonribosomal Peptide Synthetases." Chembiochem 8(13): 1477. 
Challis, G. L. (2008). "Mining microbial genomes for new natural products and biosynthetic 
pathways." Microbiology 154(Pt 6): 1555-69. 
Challis, G. L. and J. H. Naismith (2004). "Structural aspects of non-ribosomal peptide 
biosynthesis." Curr Opin Struct Biol 14(6): 748-56. 
Chance, B. (1967). "The reactivity of haemoproteins and cytochromes." Biochem J 103(1): 1-
18. 
Chang, K. H., H. Xiang and D. Dunaway-Mariano (1997). "Acyl-adenylate motif of the acyl-
adenylate/thioester-forming enzyme superfamily: a site-directed mutagenesis study 
with the Pseudomonas sp. strain CBS3 4-chlorobenzoate:coenzyme A ligase." 
Biochem 36(50): 15650-9. 
Collaborative Computational Project Number 4. (1994). "The CCP4 suite: programs for 
protein crystallography." Acta Crystallographica Section D 50(5): 760-3. 
Conti, E., N. P. Franks and P. Brick (1996). "Crystal structure of firefly luciferase throws light 
on a superfamily of adenylate-forming enzymes." Structure 4(3): 287-98. 
Conti, E., T. Stachelhaus, M. A. Marahiel and P. Brick (1997). "Structural basis for the 
activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S." Embo 
J 16(14): 4174-83. 
Crepin, T., A. Yaremchuk, M. Tukalo and S. Cusack (2006). "Structures of two bacterial prolyl-
tRNA synthetases with and without a cis-editing domain." Structure 14(10): 1511-25. 
Crosa, J. H. and C. T. Walsh (2002). "Genetics and assembly line enzymology of siderophore 
biosynthesis in bacteria." Microbiol Mol Biol Rev 66(2): 223-49. 
Cusack, S. (1995). "Eleven down and nine to go." Nat Struct Biol 2(10): 824-31. 
Cusack, S. (1997). "Aminoacyl-tRNA synthetases." Curr Opin Struct Biol 7(6): 881-9. 
Cusack, S., C. Berthet-Colominas, M. Hartlein, N. Nassar and R. Leberman (1990). "A second 
class of synthetase structure revealed by X-ray analysis of Escherichia coli seryl-tRNA 
synthetase at 2.5 A." Nature 347(6290): 249-55. 
Davis, I. W., A. Leaver-Fay, V. B. Chen, J. N. Block, G. J. Kapral, X. Wang, L. W. Murray, W. B. 
Arendall, 3rd, J. Snoeyink, J. S. Richardson and D. C. Richardson (2007). "MolProbity: 
all-atom contacts and structure validation for proteins and nucleic acids." Nucleic 
Acids Res 35(Web Server issue): W375-83. 
de Lorenzo, V., A. Bindereif, B. H. Paw and J. B. Neilands (1986). "Aerobactin biosynthesis 
and transport genes of plasmid ColV-K30 in Escherichia coli K-12." J Bacteriol 165(2): 
570-8. 
de Lorenzo, V. and J. B. Neilands (1986). "Characterization of iucA and iucC genes of the 
aerobactin system of plasmid ColV-K30 in Escherichia coli." J Bacteriol 167(1): 350-5. 
Derewenda, Z. S. (2004). "Rational protein crystallization by mutational surface engineering." 
Structure 12(4): 529-35. 
Desogus, G., F. Todone, P. Brick and S. Onesti (2000). "Active site of lysyl-tRNA synthetase: 
structural studies of the adenylation reaction." Biochem 39(29): 8418-25. 
Dong, A., X. Xu, A. M. Edwards, C. Chang, M. Chruszcz, M. Cuff, M. Cymborowski, R. Di Leo, 
O. Egorova, E. Evdokimova, E. Filippova, J. Gu, J. Guthrie, A. Ignatchenko, A. 
Joachimiak, N. Klostermann, Y. Kim, Y. Korniyenko, W. Minor, Q. Que, A. Savchenko, 
T. Skarina, K. Tan, A. Yakunin, A. Yee, V. Yim, R. Zhang, H. Zheng, M. Akutsu, C. 
Arrowsmith, G. V. Avvakumov, A. Bochkarev, L. G. Dahlgren, S. Dhe-Paganon, S. 
  
— 170 — 
Dimov, L. Dombrovski, P. Finerty, Jr., S. Flodin, A. Flores, S. Graslund, M. 
Hammerstrom, M. D. Herman, B. S. Hong, R. Hui, I. Johansson, Y. Liu, M. Nilsson, L. 
Nedyalkova, P. Nordlund, T. Nyman, J. Min, H. Ouyang, H. W. Park, C. Qi, W. Rabeh, 
L. Shen, Y. Shen, D. Sukumard, W. Tempel, Y. Tong, L. Tresagues, M. Vedadi, J. R. 
Walker, J. Weigelt, M. Welin, H. Wu, T. Xiao, H. Zeng and H. Zhu (2007). "In situ 
proteolysis for protein crystallization and structure determination." Nat Methods 
4(12): 1019-21. 
Drechsel, H. and G. Jung (1998). "Peptide siderophores." J Pept Sci 4(3): 147-81. 
Drew, D. E., G. von Heijne, P. Nordlund and J. W. de Gier (2001). "Green fluorescent protein 
as an indicator to monitor membrane protein overexpression in Escherichia coli." 
FEBS Lett 507(2): 220-4. 
Du, L., C. Sanchez, M. Chen, D. J. Edwards and B. Shen (2000). "The biosynthetic gene cluster 
for the antitumor drug bleomycin from Streptomyces verticillus ATCC15003 
supporting functional interactions between nonribosomal peptide synthetases and a 
polyketide synthase." Chem Biol 7(8): 623-42. 
Emsley, P. and K. Cowtan (2004). "Coot: model-building tools for molecular graphics." Acta 
Crystallogr D Biol Crystallogr 60(Pt 12 Pt 1): 2126-32. 
Eriani, G., M. Delarue, O. Poch, J. Gangloff and D. Moras (1990). "Partition of tRNA 
synthetases into two classes based on mutually exclusive sets of sequence motifs." 
Nature 347(6289): 203-6. 
Fersht, A. R., J. W. Knill-Jones, H. Bedouelle and G. Winter (1988). "Reconstruction by site-
directed mutagenesis of the transition state for the activation of tyrosine by the 
tyrosyl-tRNA synthetase: a mobile loop envelopes the transition state in an induced-
fit mechanism." Biochem 27(5): 1581-7. 
First, E. A. and A. R. Fersht (1993). "Mutation of lysine 233 to alanine introduces positive 
cooperativity into tyrosyl-tRNA synthetase." Biochem 32(49): 13651-7. 
Fisch, K. M., A. F. Gillaspy, M. Gipson, J. C. Henrikson, A. R. Hoover, L. Jackson, F. Z. Najar, H. 
Wagele and R. H. Cichewicz (2009). "Chemical induction of silent biosynthetic 
pathway transcription in Aspergillus niger." J Ind Microbiol Biotechnol. 36(9): 1199-
213. 
Franza, T., B. Mahe and D. Expert (2005). "Erwinia chrysanthemi requires a second iron 
transport route dependent of the siderophore achromobactin for extracellular 
growth and plant infection." Mol Microbiol 55(1): 261-75. 
Franza, T., I. Michaud-Soret, P. Piquerel and D. Expert (2002). "Coupling of iron assimilation 
and pectinolysis in Erwinia chrysanthemi 3937." Mol Plant Microbe Interact 15(11): 
1181-91. 
Fulda, M., E. Heinz and F. P. Wolter (1994). "The fadD gene of Escherichia coli K12 is located 
close to rnd at 39.6 min of the chromosomal map and is a new member of the AMP-
binding protein family." Mol Gen Genet 242(3): 241-9. 
Galanis, E., A. S. King, P. Varughese and S. A. Halperin (2006). "Changing epidemiology and 
emerging risk groups for pertussis." CMAJ 174(4): 451-2. 
Gehring, A. M., I. Mori and C. T. Walsh (1998). "Reconstitution and characterization of the 
Escherichia coli enterobactin synthetase from EntB, EntE, and EntF." Biochemistry 
37(8): 2648-59. 
Giege, R., B. Lorber, J. P. Ebel, D. Moras and J. C. Thierry (1980). "[Crystallization of the 
complex formed between yeast aspartyl tRNA and its specific aminoacyl tRNA 
synthetase]." C R Seances Acad Sci D 291(4): 393-6. 
Giege, R., B. Lorber, J. P. Ebel, D. Moras, J. C. Thierry, B. Jacrot and G. Zaccai (1982). 
"Formation of a catalytically active complex between tRNAAsp and aspartyl-tRNA 
synthetase from yeast in high concentrations of ammonium sulphate." Biochimie 
64(5): 357-62. 
  
— 171 — 
Ginder, N. D., D. J. Binkowski, H. J. Fromm and R. B. Honzatko (2006). "Nucleotide complexes 
of Escherichia coli phosphoribosylaminoimidazole succinocarboxamide synthetase." 
J Biol Chem 281(30): 20680-8. 
Glanz, J. M., D. L. McClure, D. J. Magid, M. F. Daley, E. K. France, D. A. Salmon and S. J. 
Hambidge (2009). "Parental refusal of pertussis vaccination is associated with an 
increased risk of pertussis infection in children." Pediatrics 123(6): 1446-51. 
Goldschmidt, L., D. R. Cooper, Z. S. Derewenda and D. Eisenberg (2007). "Toward rational 
protein crystallization: A Web server for the design of crystallizable protein 
variants." Protein Sci 16(8): 1569-76. 
Goodnow, R. A. (1980). "Biology of Bordetella bronchiseptica." Microbiol Rev 44(4): 722-38. 
Gulick, A. M., V. J. Starai, A. R. Horswill, K. M. Homick and J. C. Escalante-Semerena (2003). 
"The 1.75 A crystal structure of acetyl-CoA synthetase bound to adenosine-5'-
propylphosphate and coenzyme A." Biochem 42(10): 2866-73. 
Hedstrom, L. (2002). "Serine protease mechanism and specificity." Chem Rev 102(12): 4501-
24. 
Hellenbrand, W., D. Beier, E. Jensen, M. Littmann, C. Meyer, H. Oppermann, C. H. Wirsing 
von Konig and S. Reiter (2009). "The epidemiology of pertussis in Germany: past and 
present." BMC Infect Dis 9: 22. 
Higgins, I. J., D. J. Best, R. C. Hammond and D. Scott (1981). "Methane-oxidizing 
microorganisms." Microbiol Rev 45(4): 556-90. 
Hisanaga, Y., H. Ago, N. Nakagawa, K. Hamada, K. Ida, M. Yamamoto, T. Hori, Y. Arii, M. 
Sugahara, S. Kuramitsu, S. Yokoyama and M. Miyano (2004). "Structural basis of the 
substrate-specific two-step catalysis of long chain fatty acyl-CoA synthetase dimer." J 
Biol Chem 279(30): 31717-26. 
Holm, L. and C. Sander (1993). "Protein structure comparison by alignment of distance 
matrices." J Mol Biol 233(1): 123-38. 
Hua, Y., R. F. Keep, J. T. Hoff and G. Xi (2008). "Deferoxamine therapy for intracerebral 
hemorrhage." Acta Neurochir Suppl 105: 3-6. 
Hugouvieux-Cotte-Pattat, N., G. Condemine, W. Nasser and S. Reverchon (1996). "Regulation 
of pectinolysis in Erwinia chrysanthemi." Annu Rev Microbiol 50: 213-57. 
Irwin, M. J., J. Nyborg, B. R. Reid and D. M. Blow (1976). "The crystal structure of tyrosyl-
transfer RNA synthetase at 2-7 A resolution." J Mol Biol 105(4): 577-86. 
Jogl, G. and L. Tong (2004). "Crystal structure of yeast acetyl-coenzyme A synthetase in 
complex with AMP." Biochem 43(6): 1425-31. 
Kabsch, W. (1993). "Automatic processing of rotation diffraction data from crystals of 
initially unknown symmetry and cell constants." J Appl Crystallogr 26(6): 795-800. 
Kadi, N., S. Arbache, L. Song, D. Oves-Costales and G. L. Challis (2008). "Identification of a 
gene cluster that directs putrebactin biosynthesis in Shewanella species: PubC 
catalyzes cyclodimerization of N-hydroxy-N-succinylputrescine." J Am Chem Soc 
130(32): 10458-9. 
Kadi, N. and G. L. Challis (2009). "Chapter 17. Siderophore biosynthesis a substrate specificity 
assay for nonribosomal peptide synthetase-independent siderophore synthetases 
involving trapping of acyl-adenylate intermediates with hydroxylamine." Methods 
Enzymol 458: 431-57. 
Kadi, N., D. Oves-Costales, F. Barona-Gomez and G. L. Challis (2007). "A new family of ATP-
dependent oligomerization-macrocyclization biocatalysts." Nat Chem Biol 3(10): 
652-6. 
Kang, H. Y. and S. K. Armstrong (1998). "Transcriptional analysis of the Bordetella alcaligin 
siderophore biosynthesis operon." J Bacteriol 180(4): 855-61. 
Kelly, S. M. and N. C. Price (1997). "The application of circular dichroism to studies of protein 
folding and unfolding." Biochim Biophys Acta 1338(2): 161-85. 
  
— 172 — 
Kiese, M. (1966). "The biochemical production of ferrihemoglobin-forming derivatives from 
aromatic amines, and mechanisms of ferrihemoglobin formation." Pharmacol Rev 
18(3): 1091-161. 
Kochan, G., E. S. Pilka, F. von Delft, U. Oppermann and W. W. Yue (2009). "Structural 
snapshots for the conformation-dependent catalysis by human medium-chain acyl-
coenzyme A synthetase ACSM2A." J Mol Biol 388(5): 997-1008. 
Köster, W. (2001). "ABC transporter-mediated uptake of iron, siderophores, heme and 
vitamin B12." Res Microbiol 152(3-4): 291-301. 
Köster, W. (2005). "Cytoplasmic membrane iron permease systems in the bacterial cell 
envelope." Front Biosci 10: 462-77. 
Krissinel, E. and K. Henrick (2004). "Secondary-structure matching (SSM), a new tool for fast 
protein structure alignment in three dimensions." Acta Crystallogr D Biol Crystallogr 
60: 2256-68. 
Krissinel, E. and K. Henrick (2007). "Inference of macromolecular assemblies from crystalline 
state." J Mol Biol 372(3): 774-97. 
Kuratani, M., H. Sakai, M. Takahashi, T. Yanagisawa, T. Kobayashi, K. Murayama, L. Chen, Z. J. 
Liu, B. C. Wang, C. Kuroishi, S. Kuramitsu, T. Terada, Y. Bessho, M. Shirouzu, S. Sekine 
and S. Yokoyama (2006). "Crystal structures of tyrosyl-tRNA synthetases from 
Archaea." J Mol Biol 355(3): 395-408. 
Lautru, S. and G. L. Challis (2004). "Substrate recognition by nonribosomal peptide 
synthetase multi-enzymes." Microbiology 150(Pt 6): 1629-36. 
Lin, C. S., R. Irwin and J. G. Chirikjian (1975). "Kinetic studies of leucyl transfer RNA 
synthetase from bakers' yeast. Order of addition of substrates and release of 
products." J Biol Chem 250(24): 9299-303. 
Liu, H. and J. H. Naismith (2008). "An efficient one-step site-directed deletion, insertion, 
single and multiple-site plasmid mutagenesis protocol." BMC Biotechnol 8: 91. 
Lorber, B., R. Giege, J. P. Ebel, C. Berthet, J. C. Thierry and D. Moras (1983). "Crystallization of 
a tRNA . aminoacyl-tRNA synthetase complex. Characterization and first 
crystallographic data." J Biol Chem 258(13): 8429-35. 
Mandal, K. and S. Maiti (2005). "Bacterial soft rot of aloe caused by Pectobacterium 
chrysanthemi: a new report from India." Plant Pathology 54(4): 573. 
Marahiel, M. A., L. O. Essen and A. H. David (2009). Chapter 13 Nonribosomal Peptide 
Synthetases: Mechanistic and Structural Aspects of Essential Domains. Methods 
Enzymol, Academic Press. Volume 458: 337-51. 
Marahiel, M. A., T. Stachelhaus and H. D. Mootz (1997). "Modular peptide synthetases 
involved in nonribosomal peptide synthesis." Chem Rev 97(7): 2651-73. 
Mascarenhas, A. P. and S. A. Martinis (2008). "Functional segregation of a predicted "hinge" 
site within the beta-strand linkers of Escherichia coli leucyl-tRNA synthetase." 
Biochem 47(16): 4808-16. 
May, J. J., N. Kessler, M. A. Marahiel and M. T. Stubbs (2002). "Crystal structure of DhbE, an 
archetype for aryl acid activating domains of modular nonribosomal peptide 
synthetases." Proc Natl Acad Sci U S A 99(19): 12120-5. 
McMahon, S. A., M. Oke, H. Liu, K. A. Johnson, L. Carter, N. Kadi, M. F. White, G. L. Challis 
and J. H. Naismith (2008). "Purification, crystallization and data collection of 
Pectobacterium chrysanthemi AcsD, a type A siderophore synthetase." Acta 
Crystallogr F Struc Biol and Cryst Com 64: 1052-5. 
Meier, J. L. and M. D. Burkart (2009). "The chemical biology of modular biosynthetic 
enzymes." Chem Soc Rev 38(7): 2012-45. 
Melo, N., A. C. Dias, L. Isidoro and R. Duarte (2009). "Bordetella pertussis, an agent not to 
forget: a case report." Cases J 2(1): 128. 
  
— 173 — 
Miller, D. A., L. Luo, N. Hillson, T. A. Keating and C. T. Walsh (2002). "Yersiniabactin 
synthetase: a four-protein assembly line producing the nonribosomal 
peptide/polyketide hybrid siderophore of Yersinia pestis." Chem Biol 9(3): 333-44. 
Moore, C. H., L. A. Foster, D. G. Gerbig, Jr., D. W. Dyer and B. W. Gibson (1995). 
"Identification of alcaligin as the siderophore produced by Bordetella pertussis and 
B. bronchiseptica." J Bacteriol 177(4): 1116-8. 
Münzinger, M., H. Budzikiewicz, D. Expert, C. Enard and J. M. Meyer (2000). "Achromobactin, 
a new citrate siderophore of Erwinia chrysanthemi." Z Naturforsch C 55(5-6): 328-32. 
Murshudov, G. N., A. A. Vagin and E. J. Dodson (1997). "Refinement of macromolecular 
structures by the maximum-likelihood method." Acta Crystallogr D Biol Crystallogr 
53(Pt 3): 240-55. 
Nakatsu, T., S. Ichiyama, J. Hiratake, A. Saldanha, N. Kobashi, K. Sakata and H. Kato (2006). 
"Structural basis for the spectral difference in luciferase bioluminescence." Nature 
440(7082): 372-6. 
Nishio, T., N. Tanaka, J. Hiratake, Y. Katsube, Y. Ishida and J. Oda (1988). "Isolation and 
structure of the novel dihydroxamate siderophore alcaligin." J Am Chem Soc 
110(26): 8733-4. 
O'Donoghue, P. and Z. Luthey-Schulten (2003). "On the evolution of structure in aminoacyl-
tRNA synthetases." Microbiol Mol Biol Rev 67(4): 550-73. 
Osman, K. T., L. Du, Y. He and Y. Luo (2009). "Crystal structure of Bacillus cereus D-alanyl 
carrier protein ligase (DltA) in complex with ATP." J Mol Biol 388(2): 345-55. 
Otwinowski, Z. and W. Minor (1997). Processing of X-ray Diffraction Data Collected in 
Oscillation Mode. Methods in Enzymol. J. R. M. Sweet and Eds. New York, Academic 
Press. 276: 307-26. 
Oves-Costales, D., N. Kadi, M. J. Fogg, L. Song, K. S. Wilson and G. L. Challis (2007). 
"Enzymatic logic of anthrax stealth siderophore biosynthesis: AsbA catalyzes ATP-
dependent condensation of citric acid and spermidine." J Am Chem Soc 129(27): 
8416-7. 
Owen, D. J., M. E. Noble, E. F. Garman, A. C. Papageorgiou and L. N. Johnson (1995). "Two 
structures of the catalytic domain of phosphorylase kinase: an active protein kinase 
complexed with substrate analogue and product." Structure 3(5): 467-82. 
Page, M. J. and E. Di Cera (2008). "Serine peptidases: classification, structure and function." 
Cell Mol Life Sci 65(7-8): 1220-36. 
Painter, J. and E. A. Merritt (2006). "TLSMD web server for the generation of multi-group TLS 
models." J App Cryst 39(1): 109-11. 
Palacio-Bielsa, A., M. A. Cambra and M. M. Lopez (2006). "Characterisation of potato isolates 
of Dickeya chrysanthemi in Spain by a microtitre system for biovar determination." 
Annals App Biol 148(2): 157-64. 
Perombelon, M. C. M. and A. Kelman (1980). "Ecology of the Soft Rot Erwinias." Annu Rev 
Phytopath 18: 361-87. 
Perona, J. J. and Y. M. Hou (2007). "Indirect readout of tRNA for aminoacylation." Biochem 
46(37): 10419-32. 
Polgar, L. (2005). "The catalytic triad of serine peptidases." Cell Mol Life Sci 62(19-20): 2161-
72. 
Rapp, M., D. Drew, D. O. Daley, J. Nilsson, T. Carvalho, K. Melen, J. W. De Gier and G. Von 
Heijne (2004). "Experimentally based topology models for E. coli inner membrane 
proteins." Protein Sci 13(4): 937-45. 
Rees, D. C. (2002). "Great metalloclusters in enzymology." Annu Rev Biochem 71: 221-46. 
Register, K. B., T. F. Ducey, S. L. Brockmeier and D. W. Dyer (2001). "Reduced virulence of a 
Bordetella bronchiseptica siderophore mutant in neonatal swine." Infect Immun 
69(4): 2137-43. 
  
— 174 — 
Rouault, T. A. (2003). "How mammals acquire and distribute iron needed for oxygen-based 
metabolism." PLoS Biol 1(3): E79. 
Schmelz, S., N. Kadi, S. A. McMahon, L. J. Song, D. Oves-Costales, M. Oke, H. T. Liu, K. A. 
Johnson, L. G. Carter, C. H. Botting, M. F. White, G. L. Challis and J. H. Naismith 
(2009). "AcsD catalyzes enantioselective citrate desymmetrization in siderophore 
biosynthesis." Nat Chem Biol 5(3): 174-82. 
Schmelz, S. and J. H. Naismith (2009). "Adenylate-forming enzymes." Curr Opin Struct Biol. 
Shen, N., M. Zhou, B. Yang, Y. Yu, X. Dong and J. Ding (2008). "Catalytic mechanism of the 
tryptophan activation reaction revealed by crystal structures of human 
tryptophanyl-tRNA synthetase in different enzymatic states." Nucleic Acids Res 
36(4): 1288-99. 
Skamnaki, V. T., D. J. Owen, M. E. Noble, E. D. Lowe, G. Lowe, N. G. Oikonomakos and L. N. 
Johnson (1999). "Catalytic mechanism of phosphorylase kinase probed by 
mutational studies." Biochem 38(44): 14718-30. 
Slawiak, M., E. Lojkowska and J. M. van der Wolf (2009). "First report of bacterial soft rot on 
potato caused by Dickeya sp (syn. Erwinia chrysanthemi) in Poland." Plant Patho 
58(4): 794. 
Steinbacher, S., P. Hof, L. Eichinger, M. Schleicher, J. Gettemans, J. Vandekerckhove, R. 
Huber and J. Benz (1999). "The crystal structure of the Physarum polycephalum 
actin-fragmin kinase: an atypical protein kinase with a specialized substrate-binding 
domain." Embo J 18(11): 2923-9. 
Suzuki, T. (2008). "[Iron overload and iron chelation therapy in transfusion-dependent 
patients]." Nippon Rinsho 66(3): 563-8. 
Tan, T., E. Trindade and D. Skowronski (2005). "Epidemiology of pertussis." Pediatr Infect Dis 
J 24(5 Suppl): S10-8. 
Taylor, S. S., E. Radzio-Andzelm, Madhusudan, X. Cheng, L. Ten Eyck and N. Narayana (1999). 
"Catalytic subunit of cyclic AMP-dependent protein kinase: structure and dynamics 
of the active site cleft." Pharmacol Ther 82(2-3): 133-41. 
Thoden, J. B., S. M. Firestine, S. J. Benkovic and H. M. Holden (2002). "PurT-encoded 
glycinamide ribonucleotide transformylase. Accommodation of adenosine 
nucleotide analogs within the active site." J Biol Chem 277(26): 23898-908. 
van Wageningen, A. M., P. N. Kirkpatrick, D. H. Williams, B. R. Harris, J. K. Kershaw, N. J. 
Lennard, M. Jones, S. J. Jones and P. J. Solenberg (1998). "Sequencing and analysis of 
genes involved in the biosynthesis of a vancomycin group antibiotic." Chem Biol 5(3): 
155-62. 
Walker, E. H., M. E. Pacold, O. Perisic, L. Stephens, P. T. Hawkins, M. P. Wymann and R. L. 
Williams (2000). "Structural determinants of phosphoinositide 3-kinase inhibition by 
wortmannin, LY294002, quercetin, myricetin, and staurosporine." Mol Cell 6(4): 909-
19. 
Warner, P. J., P. H. Williams, A. Bindereif and J. B. Neilands (1981). "ColV plasmid-specific 
aerobactin synthesis by invasive strains of Escherichia coli." Infect Immun 33(2): 540-
5. 
Watanabe, K., K. Hotta, A. P. Praseuth, K. Koketsu, A. Migita, C. N. Boddy, C. C. Wang, H. 
Oguri and H. Oikawa (2006). "Total biosynthesis of antitumor nonribosomal peptides 
in Escherichia coli." Nat Chem Biol 2(8): 423-8. 
Weber, G., K. Schorgendorfer, E. Schneider-Scherzer and E. Leitner (1994). "The peptide 
synthetase catalyzing cyclosporine production in Tolypocladium niveum is encoded 
by a giant 45.8-kilobase open reading frame." Curr Genet 26(2): 120-5. 
Weimer, K. M., B. L. Shane, M. Brunetto, S. Bhattacharyya and S. Hati (2009). "Evolutionary 
basis for the coupled-domain motions in Thermus thermophilus leucyl-tRNA 
synthetase." J Biol Chem 284(15): 10088-99. 
  
— 175 — 
Wilson, M. K., R. J. Abergel, K. N. Raymond, J. E. Arceneaux and B. R. Byers (2006). 
"Siderophores of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis." 
Biochem Biophys Res Commun 348(1): 320-5. 
Winn, M. D., M. N. Isupov and G. N. Murshudov (2001). "Use of TLS parameters to model 
anisotropic displacements in macromolecular refinement." Acta Crystallogr D Biol 
Crystallogr 57(Pt 1): 122-33. 
Woese, C. R., G. J. Olsen, M. Ibba and D. Soll (2000). "Aminoacyl-tRNA synthetases, the 
genetic code, and the evolutionary process." Microbiol Mol Biol Rev 64(1): 202-36. 
Wu, M. X. and K. A. Hill (1993). "A continuous spectrophotometric assay for the 
aminoacylation of transfer RNA by alanyl-transfer RNA synthetase." Anal Biochem 
211(2): 320-3. 
Wu, R., A. S. Reger, X. Lu, A. M. Gulick and D. Dunaway-Mariano (2009). "The mechanism of 
domain alternation in the acyl-adenylate forming ligase superfamily member 4-
chlorobenzoate: coenzyme A ligase." Biochem 48(19): 4115-25. 
Xie, W., L. A. Nangle, W. Zhang, P. Schimmel and X. L. Yang (2007). "Long-range structural 
effects of a Charcot-Marie-Tooth disease-causing mutation in human glycyl-tRNA 
synthetase." Proc Natl Acad Sci U S A 104(24): 9976-81. 
Xu, R. M., G. Carmel, R. M. Sweet, J. Kuret and X. Cheng (1995). "Crystal structure of casein 
kinase-1, a phosphate-directed protein kinase." Embo J 14(5): 1015-23. 
Yang, J., L. F. Ten Eyck, N. H. Xuong and S. S. Taylor (2004). "Crystal structure of a cAMP-
dependent protein kinase mutant at 1.26A: new insights into the catalytic 
mechanism." J Mol Biol 336(2): 473-87. 
Yaremchuk, A., M. Tukalo, M. Grotli and S. Cusack (2001). "A succession of substrate induced 
conformational changes ensures the amino acid specificity of Thermus thermophilus 
prolyl-tRNA synthetase: comparison with histidyl-tRNA synthetase." J Mol Biol 
309(4): 989-1002. 
Yonus, H., P. Neumann, S. Zimmermann, J. J. May, M. A. Marahiel and M. T. Stubbs (2008). 
"Crystal structure of DltA. Implications for the reaction mechanism of non-ribosomal 
peptide synthetase adenylation domains." J Biol Chem 283(47): 32484-91. 
Yu, S., E. Fiss and W. R. Jacobs, Jr. (1998). "Analysis of the exochelin locus in Mycobacterium 
smegmatis: biosynthesis genes have homology with genes of the peptide synthetase 
family." J Bacteriol 180(17): 4676-85. 
Zheng, J., E. A. Trafny, D. R. Knighton, N. H. Xuong, S. S. Taylor, L. F. Ten Eyck and J. M. 
Sowadski (1993). "2.2 A refined crystal structure of the catalytic subunit of cAMP-
dependent protein kinase complexed with MnATP and a peptide inhibitor." Acta 
Crystallogr D Biol Crystallogr 49(Pt 3): 362-5. 
  
— 176 — 
6. Appendix 
A. AcsD substrate coordination 
Table 4.1: Interactions between AcsD and ATP 
 
ATP atom phosphate 
moiety 
AcsD residue and 
atom 
Distance Å Domain 
O1G/1 γ Gln 446 NE2 3.17 3 – loop9 
O1G/1 γ Gln 446 OE1 3.20 3 – loop9 
O1G/1 γ Mg ion 2.04  
O1G/1 γ Asp 464 OD2 3.22 3 – loop10 
O2G/1 γ Arg 369 NH2 2.65 2 – β12 
O2G/1 γ Lys 293 NZ 2.84 2 - β10 
O2G/1 γ Asp 464 OD1 2.63 3 – loop10 
O2G/1 γ Asp 464 OD2 3.36 3 – loop10 
O3G/1 γ Arg 369 NH1 3.03 2 – β12 
O3G/1 γ Ser 279 OG 2.90 2 - loop5 
O3G/1 γ Thr 282 OG1 2.74 2 - loop5 
O3G/1 γ H2O 123 3.02  
O3B/1 γ Ser 279 OG 3.26 2 - loop5 
O1B/1 β Arg 281 NH2 3.24 2 - loop5 
O1B/1 β Arg 281 NE 2.76 2 - loop5 
O1B/1 β H2O  239 2.91 2 
O1B/1 β Asp 464 OD2 3.39 3 – loop10 
O2B/1 β Asp 464 OD2 2.91 3 – loop10 
O2B/1 β Asp 464 OD1 3.27 3 – loop10 
O2B/1 β Lys 293 NZ 2.90 2 - β10 
O2B/1 β Glu 466 OE1 3.47 3 – loop10 
O3A/1 β Asp 464 OD2 3.47 3 – loop10 
O3A/1 β Mg ion  2.51  
O1A/1 α Arg 305 NH2 3.04 2 – loop7 
O1A/1 α H2O  140 3.02  
O2A/1 α Asp 464 OD2 3.19 3 – loop10 
O2A/1 α His 444 NE2 2.92 3 – loop9 
O2A/1 α Mg ion 2.45  
O5/1 α Arg 305 NH2 3.01 2 – loop7 
O5/1 α H2O  139  3.07  
O4/1 ribose Gln 446 CB 3.23 3 – loop9 
O2/1 ribose Thr 301 OG1 2.85 2 – loop7 
O2/1 ribose Thr 301 CG2 3.04 2 – loop7 
O2/1 ribose H2O  6 3.08  
N1/1 base Asn 509 ND2 3.11 3 - α13 
N1/1 base Asn 509 ND1 3.48 3 - α13 
C2/1 base His 444 ND1 3.31 3 – loop9 
C2/1 base His 444 CE1 3.49 3 – loop9 
N6/1 base Asn 509 OD1 3.45 3 - α13 
N6/1 base H2O  56 2.52  
N6/1 base Leu 445 CD1 3.47 3 – loop9 
N7/1 base H2O  56 2.76  
N7/1 base His 170 CA 3.41 2 -  loop4 
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Table 4.2: Interactions between AcsD and citrate (overlap with ATP) 
 
atom label in 
structure 
citrate 
atom 
AcsD residue 
and atom 
Distance Å Domain 
CGC /0 C1 Asp 464OD2 3.64 3 – loop 10 
CB /0 C3 Asp 464OD2 3.22 3 – loop 10 
CA /0 C4 Asp 464OD2 3.18 3 – loop 10 
CA /0 C4 H2O 42 3.33  
CA /0 C4 Ser 279CB 3.68 2 - loop5 
CAC /0 C5 Asp 464OD2 3.54 3 – loop 10 
CBC /0 C6 Arg 281NE 3.37 2 - loop5 
CBC /0 C6 Arg 281NH2 3.54 2 - loop5 
CBC /0 C6 Ser 279CB 3.57 2 - loop5 
OG 2/0 O1 Arg 305 NH2 2.93 2 – loop7 
OG 1/0 O2 Asp 464OD2 2.68 3 – loop 10 
OG 1/0 O2 His 444NE2 3.65 3 – loop9  
OA 1/0 O3 Arg 369NH1 3.65 2 – β 12 
OA 1/0 O3 Lys 293CE 3.46 2 - β 10 
OA 1/0 O3 Thr 282OG1     3.16 2 - loop5 
OA 2/0 O4 Arg 369NH1 3.57 2 – β 12 
OB 1/0 O5 Arg 281CZ 3.26 2 - loop5 
OB 1/0 O5 Arg 281NE 2.80 2 - loop5 
OB 1/0 O5 Arg 281NH2 3.09 2 - loop5 
OB 1/0 O5 Lys 293CE 3.19 2 - β 10 
OB 2/0 O6 Arg 281NE 3.36 2 - loop5 
OB 2/0 O6 H2O 222 2.48  
OB 2/0 O6 Ser 279CB 3.24 2 - loop5 
OB 2/0 O6 Ser 279O        3.45 2 - loop5 
OHB /0 O7 Asp 464CG 3.28 3 – loop 10 
OHB /0 O7 Asp 464OD1 3.44 3 – loop 10 
OHB /0 O7 Asp 464OD2 2.45 3 – loop 10 
OHB /0 O7 Glu 466OE1 2.99 3 – loop 10 
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Table 4.3: Interactions between AcsD and citrate  
 
atom label in 
structure 
citrate 
atom 
AcsD residue 
and atom 
Distance Å Domain 
CGC /0 C1 His170 NE2 3.60 2 – loop4 
CGC /0 C1 Tyr504 OH 3.32 3 – α13 
CG /0 C2 ADN C2 3.60  
CG /0 C2 ADN N3 3.68  
CB /0 C3    
CA /0 C4 Arg576 NH1 3.38 3 
CAC /0 C5 ADN C5’ 3.08  
CAC /0 C5 Arg305 NH2 3.62 2 – loop7 
CAC /0 C5 Glu442 OE2 3.59 3 –  loop9 
CBC /0 C6 Arg305 NH1 3.57 2 – loop7 
CBC /0 C6 Thr301 OG1 3.12 2 – loop7 
OG 2/0 O1 Lys563 CD 3.42 3 – β16 
OG 2/0 O1 Lys563 CE 3.19 3 – β16 
OG 2/0 O1 Lys563 NZ 3.25 3 – β16 
OG 2/0 O1 Tyr504 CE2 3.57 3 – α13 
OG 2/0 O1 Tyr504 OH 3.27 3 – α13 
OG 1/0 O2 Asn565 ND2 3.60 3 
OG 1/0 O2 Asn565 OD1 3.59 3 
OG 1/0 O2 His170 CD2 3.63 2 – loop4 
OG 1/0 O2 His170 CE1 3.58 2 – loop4 
OG 1/0 O2 His170 NE2 2.64 2 – loop4 
OG 1/0 O2 Tyr504 OH 2.59 3 – α13 
OA 1/0 O3 ADN C5’ 3.08  
OA 1/0 O3 ADN O5’ 3.31  
OA 1/0 O3 Arg 305 NH2 2.75 2 – loop7 
OA 2/0 O4 ADN C5’ 3.47  
OA 2/0 O4 Glu442 OE2 3.27 3 –  loop9 
OA 2/0 O4 His444 CD2 3.34 3 –  loop9 
OA 2/0 O4 His444 CE1 3.58 3 –  loop9 
OA 2/0 O4 His444 NE2 2.62 3 –  loop9 
OB 1/0 O5 ADN C2’ 3.33  
OB 1/0 O5 ADN C3’ 3.09  
OB 1/0 O5 Arg305 CZ 3.21 2 – loop7 
OB 1/0 O5 Arg305 NH1 2.88 2 – loop7 
OB 1/0 O5 Arg305 NH2 2.80 2 – loop7 
OB 1/0 O5 Thr301 OG1 3.00 2 – loop7 
OB 2/0 O6 Asn302 CB 3.54 2 – loop7 
OB 2/0 O6 Asn302 N 3.63 2 – loop7 
OB 2/0 O6 Thr301 CB 3.26 2 – loop7 
OB 2/0 O6 Thr301 OG1 2.50 2 – loop7 
OHB /0 O7 Arg576 NH1 3.52 3 
OHB /0 O7 Asn302 CB 3.46 2 – loop7 
OHB /0 O7 Asn302 CG 3.40 2 – loop7 
OHB /0 O7 Asn302 ND2 2.82 2 – loop7 
OHB /0 O7 Lys563 NZ 3.63 3 – β16 
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Table 4.4: Interactions between AcsD and N-citryl-EDA 
 
N-citryl-EDA atom citrate 
atom 
AcsD residue 
and atom 
Distance Å Domain 
CAM C1 His170 NE2 3.67 2 – loop4 
CAM C1 Tyr504 OH 3.40 3 – α13 
CAM C1 H2O 410 3.68  
CAJ C2 His170 CD2 3.50 2 – loop4 
CAJ C2 His170 NE2 2.53 2 – loop4 
CAP C3    
CAK C4    
CAN C5 ATP O5’ 3.58  
CAO C6 Arg305 NH1 3.52 2 – loop7 
CAO C6 Thr301 OG1 3.27 2 – loop7 
OAE O1 Lys563 CD 3.68 3 – β16 
OAE O1 Lys563 CE 3.44 3 – β16 
OAE O1 Lys563 NZ 3.05 3 – β16 
OAE O1 Tyr504 CE2 3.67 3 – α13 
OAE O1 H2O 410 2.48  
OAB O2 Asn565 ND2 3.62 3 
OAB O2 His170 CD2 3.69 2 – loop4 
OAB O2 His170 NE2 2.87 2 – loop4 
OAB O2 Tyr504 OH 2.46 3 – α13 
OAB O2 Tyr504 CZ 3.40 3 – α13 
OAB O2 Tyr504 CE2 3.50 3 – α13 
OAB O2 Asn509 ND2 3.20 3 – α13 
NAL O3 (N1) Glu442 OE2 3.07 3 –  loop9 
OAC O4 Arg305 CZ 3.20 2 – loop7 
OAC O4 Arg305 NH1 2.68 2 – loop7 
OAC O4 Arg305 NH2 2.88 2 – loop7 
OAC O4 ATP O5’ 3.39  
OAC O4 ATP O1A 3.67  
OAD O5 Arg305 CZ 3.33 2 – loop7 
OAD O5 Thr301 OG1 3.16 2 – loop7 
OAD O5 Thr301 CB 3.42 2 – loop7 
OAD O5 Asn302 N 2.93 2 – loop7 
OAD O5 Asn302 CA 3.50 2 – loop7 
OAD O5 Asn302 CB 2.99 2 – loop7 
OAD O5 Asn302 CG 3.25 2 – loop7 
OAD O5 Asn302 ND2 3.59 2 – loop7 
OAF O6 Arg305 NH1 3.45 2 – loop7 
OAF O6 ATP O2’ 3.56  
OAF O6 ATP C2’ 3.22  
OAF O6 Thr301 CB 3.35 2 – loop7 
OAF O6 Thr301 OG1 2.65 2 – loop7 
OAG O7 Asn302 ND2 3.52 2 – loop7 
OAG O7 Lys563 NZ 2.74 3 – β16 
OAG O7 Lys563 CE 3.42 3 – β16 
CAI  ATP O1A 3.26  
CAH  Glu442 OE2 3.63 3 –  loop9 
CAH  Glu442 OE1 3.64 3 –  loop9 
NAA  Glu442 OE1 3.10 3 –  loop9 
NAA  H2O 352 3.38  
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B. Circular dichroism spectra of AcsD mutants 
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Figure 4.7: Circular dichroism spectra for AcsD mutants. Scans were carried out with 0.25-0.3 mg/ml protein 
dialysed in 25 mM phosphate buffer pH 7.5 using a JASCO J-810 CD spectropolarimeter across a 0.2 mm 
cuvette. All spectra have a characteristic shape for a folded protein as seen for type II dehydroquinase from S. 
coelicolor (see inset, taken from Kelly and Price 1997). 
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C. Sequence identity of AlcC and other NIS family members 
Table 4.5: Sequence identity and similarities of NIS synthetases in relation to AlcC 
 
Family GI number Protein Identity Similarity                 Organism
A 16118732 AcsD 24.0 39.0 Pectobacterium chrysanthemi
A 42523081 aerobactin siderophore biosynthesis protein iucA 20.0 37.0 Bdellovibrio bacteriovorus HD100
A 38453831 aerobactin synthetase 23.0 40.0 Vibrio mimicus
A 17227890 hypothetical protein all0394 22.0 40.0 Nostoc sp. PCC 7120
A 15615185 hypothetical protein BH2622 21.0 38.0 hypothetical protein [Bacillus halodurans C-125
A 38639599 hypothetical protein LV112 22.0 36.0 Klebsiella pneumoniae
A 21224145 hypothetical protein SCO5800 20.0 34.0 Streptomyces coelicolor A3(2)
A 21224549 hypothetical protein SCO6227 24.0 39.0 Streptomyces coelicolor A3(2)
A 29833864 iron transport protein 26.0 43.0 Streptomyces avermitilis MA-4680
A 29828545 iron transport protein 24.0 35.0 Streptomyces avermitilis MA-4680
A 29829008 iron transport protein 22.0 35.0 Streptomyces avermitilis MA-4680
A 21243906 iron transporter 21.0 36.0 Xanthomonas axonopodis pv. citri str. 306
A 21232484 iron transporter 21.0 35.0 Xanthomonas campestris pv. campestris str. ATCC 33913
A 22034304 IucA 23.0 39.0 Escherichia fergusonii
A 14626624 IucA 21.0 36.0 Shigella boydii
A 26109870 IucA protein 21.0 36.0 Escherichia coli CFT073
A 47569839 MW0093, putative 21.0 38.0 Bacillus cereus G9241
A 38637787 putative iron transport protein 25.0 41.0 Ralstonia eutropha H16
A 49484997 putative siderophore biosynthesis protein 22.0 39.0 Staphylococcus aureus subsp. aureus MSSA476
A 50035243 putative siderophore biosynthesis protein 18.0 39.0 Acinetobacter sp. ADP1
A 16261713 RhbC rhizobactin biosynthesis protein 23.0 38.0 Sinorhizobium meliloti 1021
A 39935459 rhizobactin siderophore biosynthesis protein rhbC 22.0 36.0 Rhodopseudomonas palustris CGA009
A 17548642 siderophore biosynthesis protein 23.0 41.0 Ralstonia solanacearum GMI1000
A 49481200 siderophore biosynthesis protein 22.0 39.0 Bacillus thuringiensis serovar konkukian str. 97-27
A 30020117 siderophore biosynthesis protein 22.0 39.0 Bacillus cereus ATCC 14579
A 24114944 siderophore biosynthesis protein 21.0 36.0 Shigella flexneri 2a str. 301
A 30262010 siderophore biosynthesis protein, putative 21.0 38.0 Bacillus anthracis str. Ames
A 23307118 vibrioferrin biosynthesis protein PvsD 22.0 40.0 Vibrio parahaemolyticus
B 16118729 AcsA 22.0 39.0 Pectobacterium chrysanthemi
B 50085239 hypothetical protein ACIAD2120 21.0 42.0 Acinetobacter sp. ADP1
B 21224548 hypothetical protein SCO6226 21.0 36.0 Streptomyces coelicolor A3(2)
B 27468688 hypothetical protein SE1770 21.0 42.0 Staphylococcus epidermidis ATCC 12228
B 27468690 hypothetical protein SE1772 20.0 39.0 Staphylococcus epidermidis ATCC 12228
B 23307116 ibrioferrin biosynthesis protein PvsD 22.0 40.0 Vibrio parahaemolyticus
B 50123036 putative siderophore biosynthesis protein 25.0 42.0 Pectobacterium atrosepticum
B 38637789 putative siderophore biosynthesis protein 23.0 39.0 Ralstonia eutropha H16
B 38233195d2 putative siderophore biosynthesis related protein 25.0 40.0 Corynebacterium diphtheriae NCTC 13129
B 38233195d1 putative siderophore biosynthesis related protein 25.0 40.0 Corynebacterium diphtheriae NCTC 13129
B 36958857 Siderophore biosynthesis protein 22.0 40.0 Rhizobium sp. NGR234
B 32441989 siderophore biosynthesis protein SbnC 24.0 41.0 Staphylococcus aureus 
B 19749317 Y4xN 22.0 39.0 Sinorhizobium fredii
B 16520030 Y4xN 22.0 40.0 Rhizobium sp. NGR234
C 33593441 AlcC 100.0 100.0 B. bronchiseptica Tohama I
C 33597963 AlcC 99.0 99.0 B. parapertussis 12822
C 29831812 siderophore biosynthetic enzyme 52.0 70.0 Streptomyces avermitilis MA-4680
C 37528447 hypothetical protein plu4630 52.0 69.0 Photorhabdus luminescens subsp. laumondii TTO1
C 21221236 hypothetical protein SCO2785, DesD 51.0 67.0 Streptomyces coelicolor A3(2)
C 37528438 hypothetical protein plu4621 48.0 67.0 Photorhabdus luminescens subsp. laumondii TTO1
C 24374557 siderophore biosynthesis protein, putative 49.0 65.0 Shewanella oneidensis 
C 17227886 hypothetical protein all0390 36.0 54.0 Nostoc sp. PCC 7120
C 15615181 hypothetical protein BH2618 31.0 50.0 Bacillus halodurans C-125
C 22034306 IucC 28.0 50.0 E.coli
C 16120154 IucC 32.0 48.0 Halobacterium sp. NRC-1
C 38639597 IucC 29.0 48.0 Klebsiella pneumoniae
C 14626626 IucC 28.0 48.0 Shigella boydii
C 24114946 siderophore biosynthesis protein 28.0 48.0 Shigella flexneri 2a str. 301
C 50085240 hypothetical protein ACIAD2121 26.0 48.0 Acinetobacter sp. ADP1
C 16263716 RhbF rhizobactin siderophore biosynthesis protein 29.0 47.0 Sinorhizobium 
C 16118727 AcsC 28.0 46.0 Pectobacterium chrysanthemi
C 42523079 putative siderophore biosynthesis protein IucC 26.0 46.0 Bdellovibrio bacteriovorus HD100
C 32441992 SbnF 26.0 46.0 Staphylococcus aureus
C 17548643 siderophore biosynthesis protein 28.0 44.0 Ralstonia solanacearum GMI1000
C 39935458 rhizobactin siderophore biosynthesis protein RhsF 26.0 44.0 Rhodopseudomonas palustris CGA009
C 30020118 siderophore biosynthesis protein 24.0 44.0 Bacillus cereus ATCC 14579  
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D. Sequence alignment of NIS-family C 
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part 2 
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E. Analysis of dimer formation and macrocyclization 
 
Figure 4.8: Analysis of dimer formation and macrocyclization. (a) O/N reactions of AlcC with Sub204 show 
peaks referring to dimeric Sub204 as well as (Sub204)2 macrocycle.  (b) Removing AlcC enzyme by filtration still 
shows the same result as in (a). (c) Stopped enzymatic reactions where AlcC was removed showed no 
significant change in dimer to macrocycle ratio after further incubation of three (c) or thirteen days (d). This 
indicates that the macrocyclization is enzyme catalyzed and does not occur autocatalytically.  
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F. Work on AcsA 
F.1. Introduction 
AcsA is a type B NIS enzyme involved in achromobactin biosynthesis. It performs the 
final production step of achromobactin by attaching two molecules of α-KG on each 
site of the achromobactin precursor (Figure 1.10). Alike AlcC, AcsA is proposed to be 
a processive enzyme. Here the initial work on expression, purification and obtaining 
AcsA crystals is summarized.  
F.2. Results and discussion 
F.2.1. Protein expression and purification 
AcsA DNA (provided by Prof. Challis, Warwick) was transformed (1 min at 42 °C) into 
BL21(DE3) competent cells for protein expression. Cells were incubated for 1.5 h at 
37 °C in 1 mL LB media and then plated on ampicillin agar plates O/N. 
 
 
Figure F.1: Protein purification of AcsA. (a) IMAC purification of AcsA. S: standard; 1: crude; 2: S/N; 3: flow 
through; 4: wash 1: 5: wash 2: 6: elution 1; 7: elution 2; 8: elution 2. (b) TEV-cleavage with 1:10 TEV protease. TEV 
protease treatment was not successful. 1: AcsA E1; 2: AcsA E1 with TEV protease; 3: AcsA E2; 4: AcsA E2 with TEV 
protease. (c) SDS-PAGE of GF fractions.  S: standard; 1:  A9; 2: B4; 3: B3; 4: B3: 5: B2: 6: B1; 7: C3; 8: C5; 9: C7; 10: 
C8; 11: C9. Fraction B4-C5 were combined and used in crystallization trails. (d) AcsA elution profile of GF.  
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Protein expression was carried out as described for AcsD (see chapter2). Cells were 
lysed by sonication (10 times for 30 s with 1 min breaks on ice). His6-AcsA was 
purified via Ni-IMAC and eluted protein desalted (Figure F.1a). TEV cleavage with TEV 
protease at RT O/N was unsuccessful (Figure F.1b). DNA sequencing showed that the 
AcsA plasmid codes for a TEV site. His6-AcsA protein was further purified by gel 
filtration as described for AcsD (Figure F.1c,d). Fractions B4-C5 were combined, 
concentrated to 6 mg/mL and used for crystallization trails.  
F.2.2. Screening for AcsA crystallization conditions 
Initial screening was performed with 6 mg/mL and 3 mg/ml AcsA protein, with and 
without 5-20 mM ATP, using commercial screens (Wizard, Index, Cryo, Crystal 
Screen I+II). Prior to droplet setup, the protein was incubated for 5 min with ATP and 
the precipitant was removed by centrifugation (5 min, 20’000 g, 4 °C). Additionally, a 
custom made stochastic screen (see Table F.1) was used for screening. Several 
conditions resulted in likely micro crystals or crystal spheroids:  
 
1. Index screen (micro crystals) 
well 15 (0.1 M HEPES pH 7.5m 0.5 M Mg formate dihydrate)   
well 32 (1 M (NH4)SO4 0.1 M BIS-TRIS pH 5.5, 1 % (w/v) polyethylene glycol 3350);  
2. Wizard I+II with 5 mM ATP (micro crystals) 
well 7 (10 %  (w/v) PEG 8k, 0.1 M MES pH 6.0, 0.2 M Zn(OAc)2) 
well 55 (30 % (w/v) PEG 3k, 0.1 M TRIS pH 7.0, 0.2 M NaCl) 
3. Stochastic screen (spheroids) 
well C4 (0.053 M MgCl2, 19.47 % (w/v) PEG MME 2k, 0.1 M NaCac pH 6.9) 
4. Stochastic screen with 5 mM ATP (spheroids) 
well A7 (0.091 mM MnCl2, 11.9 % (w/v) PEG MME 5k, 0.1 M MOPS pH 7.2) 
well B5  (0.082 mM MnCl2, 24.8 % (w/v) PEG 8k, 0.1 M HEPES pH 7.5) 
 
For optimization two new custom stochastic screens (Opt1 and Opt2) were prepared 
(Table F.2a, b). Crystal trails were set up with and without substrate (5 mM ATP, 
5 mM α-KG or 5 mM ATP + 5 mM α-KG) with a final droplet size of 2 µL (1 µL AlcC 
protein + 1 µL precipitant). Protein concentrations were chosen as described above. 
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For condition 55 of the Wizard screen (30 % (w/v) PEG 3k, 0.1 M TRIS pH 7.0, 0.2 M 
NaCl) additional grid screens with TRIS and HEPES buffer, and different protein 
concentrations were prepared (Table F.3). Condition C1 (17 mM KCl, 28 % (w/v) 
PEG 3k, 0.1 M MES pH 6.0) of the Opt1 stochastic screen resulted in small crystals, 
which were further optimized in a new grid screen (Table F.4). 
F.2.3. Identification of  protein crystals  
 
Likely crystals were obtained in following conditions:  
1. 6 mg/mL AcsA with 20 mM ATP 
7.9 % (v/v) MPD, 192 mM CaCl2, 25.8 % (w/v) PEG 8K, 0.1 M HEPES pH7.5 
- Not single and no good shape 
2. 2.9 mg/mL AcsA with 5 mM ATP  
189 mM CaCl2, 13.8 % (w/v) PEG MME 2K, 0.1 M NaCac pH6.9, 18 mM ATP 
- Two nice, small crystals 
3. 2.9 mg/mL AcsA and no ATP 
14.7 % (w/v) PEG 8K, 0.1 M HEPES pH7.8, 49 mM ATP 
- Cluster of crystals 
4. 2.9 mg/mL AcsA and 5 mM ATP 
15.8 % (w/v) PEG MME 2K, 0.1 M NaCac pH6.7, 29 mM ATP 
- Cluster of crystals 
 
Most of the crystals were small or clustered and not suitable for data collection, but 
were tested to check their quality. Crystals were cryo-protected with 20 % PEG 400 
or 20-25 % (v/v) glycerol and flash frozen in liquid nitrogen. Crystals did not diffract 
or showed no typical protein diffraction pattern as the example of condition 3 shows 
(Figure F.2). Unfortunately, the nice crystals found in condition 2 (2.9 mg/mL AcsA 
with 5 mM ATP) were identified as salt crystals. No further crystallization screens or 
optimizations have been carried out. 
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Table F1: Stochastic Screen used for inital screening of AcsA crystallization condition
 A01  A02  A03  A04  A05  A06  A07  A08  A09  A10  A11  A12
CaCl2 : 0.131 M LiCl2 : 0.058 M LiCl2 : 0.14 M MgCl2 : 0.053 M LiCl2 : 0.126 M   MNCl2 2: 0.091 M  LiCl2 : 0.091 M MgCl2 : 0.103 M LiCl2 : 0.076 M LiCl2 : 0.052 M
PEG MME 2k : 15.422 % PEG 8k : 26.79 % PEG 2k : 21.527 % PEG MME 5k : 13.369 % PEG 8k : 17.264 % PEG MME 5k : 22.211 % PEG MME 5k : 11.895 % PEG MME 5k : 25.895 % PEG MME 5k : 17.211 % PEG MME 5k : 13.106 % PEG 2k : 13.053 % PEG 8k : 10.632 %
MOPS : pH 7.2 0.1 M HEPES : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M MOPS : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M HEPES : pH 7.2 0.1 M HEPES : pH 7.8 0.1 M NaCac : pH 6.7 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M
Glycerol : 5.369 % ATP : 0.026 M Glycerol : 9.948 %       MPD : 1.601 %  
 B01  B02  B03  B04  B05  B06  B07  B08  B09  B10  B11  B12
 MNCl2 2: 0.107 M  MNCl2 2: 0.162 M CaCl2 : 0.149 M   MNCl2 2: 0.082 M CaCl2 : 0.181 M LiCl2 : 0.154 M MgCl2 : 0.069 M ATP : 0.042 M LiCl2 : 0.14 M CaCl2 : 0.076 M CaCl2 : 0.173 M
PEG MME 5k : 13.579 % PEG MME 2k : 24.211 % PEG MME 2k : 15.264 % PEG 8k : 21.158 % PEG 8k : 24.79 % PEG 8k : 24.685 % PEG 2k : 21.843 % PEG MME 5k : 10.106 % PEG MME 5k : 12.264 % PEG 8k : 27.264 % PEG 8k : 29.264 % PEG MME 5k : 13.369 %
HEPES : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M MOPS : pH 6.5 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M MOPS : pH 6.5 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M MOPS : pH 6.5 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.5 0.1 M
  MPD : 3.032 % ATP : 0.03 M  Glycerol : 10.422 % Glycerol : 11.053 %  ATP : 0.012 M    
 C01  C02  C03  C04  C05  C06  C07  C08  C09  C10  C11  C12
CaCl2 : 0.171 M CaCl2 : 0.122 M MgCl2 : 0.181 M MgCl2 : 0.053 M MgCl2 : 0.164 M  MNCl2 2: 0.122 M      ATP : 0.042 M
PEG MME 5k : 25.106 % PEG MME 5k : 10.737 % PEG MME 2k : 24.106 % PEG MME 2k : 19.474 % PEG MME 5k : 21.843 % PEG MME 5k : 14.895 % PEG MME 5k : 14.422 % PEG MME 2k : 15.79 % PEG MME 2k : 14.264 % PEG MME 5k : 14.053 % PEG MME 5k : 13.264 % PEG 8k : 20.264 %
MOPS : pH 7.2 0.1 M TRIS : pH 7.7 0.1 M MOPS : pH 6.5 0.1 M NaCac : pH 6.9 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.5 0.1 M TRIS : pH 7.7 0.1 M NaCac : pH 6.7 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M MOPS : pH 6.5 0.1 M
  Glycerol : 5.132 %   MPD : 3.453 %  ATP : 0.029 M  ATP : 0.038 M ATP : 0.029 M Glycerol : 5.527 %
 D01  D02  D03  D04  D05  D06  D07  D08  D09  D10  D11  D12
ATP : 0.044 M  MNCl2 2: 0.08 M CaCl2 : 0.147 M CaCl2 : 0.107 M  MNCl2 2: 0.086 M MgCl2 : 0.145 M LiCl2 : 0.12 M ATP : 0.034 M  LiCl2 : 0.115 M LiCl2 : 0.122 M  
PEG MME 5k : 22.474 % PEG MME 5k : 19.264 % PEG MME 2k : 21.316 % PEG MME 2k : 18.737 % PEG MME 2k : 23.158 % PEG MME 5k : 23.843 % PEG MME 5k : 28.527 % PEG 400 : 33.769 % PEG 2k : 24.316 % PEG 2k : 13.843 % PEG MME 5k : 19.474 % PEG 8k : 18.0 %
HEPES : pH 7.8 0.1 M HEPES : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.5 0.1 M TRIS : pH 7.7 0.1 M MOPS : pH 7.2 0.1 M NaCac : pH 6.9 0.1 M NaCac : pH 6.9 0.1 M
Glycerol : 10.185 % Glycerol : 6.474 % ATP : 0.013 M ATP : 0.025 M MPD : 2.443 % Glycerol : 6.237 % MPD : 1.685 % Glycerol : 6.158 % ATP : 0.017 M MPD : 7.411 % ATP : 0.047 M ATP : 0.035 M
 E01  E02  E03  E04  E05  E06  E07  E08  E09  E10  E11  E12
MgCl2 : 0.112 M CaCl2 : 0.194 M ATP : 0.046 M LiCl2 : 0.184 M CaCl2 : 0.074 M   MgCl2 : 0.128 M CaCl2 : 0.189 M   MNCl2 2: 0.154 M  
PEG MME 5k : 16.737 % PEG 8k : 19.053 % PEG 400 : 25.601 % PEG MME 5k : 11.053 % PEG 400 : 23.495 % PEG 2k : 12.948 % PEG MME 2k : 22.211 % PEG 8k : 28.106 % PEG MME 2k : 13.79 % PEG 2k : 22.579 % PEG MME 2k : 22.474 % PEG 8k : 24.211 %
NaCac : pH 6.7 0.1 M MOPS : pH 7.2 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M TRIS : pH 7.7 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.5 0.1 M MOPS : pH 7.2 0.1 M
 Glycerol : 10.737 % MPD : 7.158 %   MPD : 10.19 %  MPD : 3.706 % ATP : 0.018 M ATP : 0.035 M  Glycerol : 7.264 %
 F01  F02  F03  F04  F05  F06  F07  F08  F09  F10  F11  F12
LiCl2 : 0.193 M MgCl2 : 0.145 M CaCl2 : 0.192 M  MNCl2 2: 0.074 M ATP : 0.048 M LiCl2 : 0.18 M LiCl2 : 0.101 M LiCl2 : 0.168 M LiCl2 : 0.067 M MgCl2 : 0.084 M  MNCl2 2: 0.189 M  MNCl2 2: 0.194 M
PEG MME 5k : 17.0 % PEG 8k : 15.158 % PEG 8k : 25.843 % PEG 8k : 13.053 % PEG 2k : 12.422 % PEG MME 5k : 29.053 % PEG MME 2k : 20.106 % PEG 400 : 27.369 % PEG MME 2k : 24.316 % PEG 2k : 11.843 % PEG 8k : 27.474 % PEG MME 2k : 18.158 %
HEPES : pH 7.5 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.2 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M NaCac : pH 6.7 0.1 M TRIS : pH 7.7 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.5 0.1 M
ATP : 0.035 M Glycerol : 9.474 % MPD : 7.916 % ATP : 0.014 M Glycerol : 7.737 % Glycerol : 7.737 % None : 0.0 M Glycerol : 7.737 % None : 0.0 M None : 0.0 M
 G01  G02  G03  G04  G05  G06  G07  G08  G09  G10  G11  G12
ATP : 0.023 M None : 0.0 M MgCl2 : 0.192 M None : 0.0 M MgCl2 : 0.16 M None : 0.0 M  MNCl2 2: 0.128 M LiCl2 : 0.193 M  MNCl2 2: 0.152 M  MNCl2 2: 0.173 M CaCl2 : 0.12 M MgCl2 : 0.181 M
PEG 8k : 15.422 % PEG MME 5k : 13.843 % PEG 2k : 15.79 % PEG 8k : 14.527 % PEG 8k : 13.211 % PEG 8k : 14.685 % PEG 8k : 22.579 % PEG 8k : 18.0 % PEG 8k : 28.106 % PEG MME 5k : 12.0 % PEG 400 : 24.927 % PEG MME 5k : 29.632 %
HEPES : pH 7.5 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M MOPS : pH 6.5 0.1 M MOPS : pH 6.5 0.1 M HEPES : pH 7.5 0.1 M HEPES : pH 7.8 0.1 M MOPS : pH 6.5 0.1 M MOPS : pH 7.2 0.1 M
MPD : 5.306 % Glycerol : 6.316 % Glycerol : 11.448 % ATP : 0.049 M None : 0.0 M ATP : 0.04 M MPD : 3.622 %
 H01  H02  H03  H04  H05  H06  H07  H08  H09  H10  H11  H12
 MNCl2 2: 0.177 M  MNCl2 2: 0.185 M LiCl2 : 0.154 M LiCl2 : 0.155 M LiCl2 : 0.129 M LiCl2 : 0.109 M CaCl2 : 0.12 M None : 0.0 M LiCl2 : 0.1 M None : 0.0 M MgCl2 : 0.154 M MgCl2 : 0.152 M
PEG 400 : 35.874 % PEG MME 5k : 25.685 % PEG 2k : 19.474 % PEG 8k : 21.843 % PEG MME 5k : 12.106 % PEG MME 5k : 26.895 % PEG 400 : 24.085 % PEG 8k : 26.106 % PEG MME 5k : 20.369 % PEG 8k : 11.79 % PEG MME 5k : 13.843 % PEG 8k : 13.737 %
NaCac : pH 6.9 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.8 0.1 M TRIS : pH 7.7 0.1 M HEPES : pH 7.8 0.1 M MOPS : pH 6.5 0.1 M MOPS : pH 7.2 0.1 M MOPS : pH 7.2 0.1 M HEPES : pH 7.8 0.1 M NaCac : pH 6.9 0.1 M TRIS : pH 7.7 0.1 M
Glycerol : 10.658 % ATP : 0.032 M ATP : 0.038 M Glycerol : 5.211 % MPD : 3.369 % Glycerol : 9.237 %
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Table F.2: Stochastic optimization screen Opt1 and Opt2. Conditions highlighted in red led to salt precipitate. 
a 
 A1  A2  A3  A4  A5  A6
MgCl2 : 0.098 M ZnAcet : 0.078 M ZnAcet : 0.025 M MgCl2 : 0.055 M   
PEG MME 2k : 26.101 % PEG 3350 : 27.101 % PEG MME 2k : 28.6 % PEG 4000 : 33.551 % PEG MME 2k : 17.2 % PEG 3350 : 32.05 %
HEPES : pH 7.2 0.1 M TRIS : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M MES : pH 6.5 0.1 M HEPES : pH 7.8 0.1 M NaCac : pH 6.5 0.1 M
a-KG pH7.4 : 0.013 M  a-KG pH7.4 : 0.011 M   a-KG pH7.4 : 0.015 M
 B1  B2  B3  B4  B5  B6
 MgCl2 : 0.022 M  MgCl2 : 0.045 M LiCl2 : 0.047 M ZnAcet : 0.04 M
PEG 3000 : 21.7 % PEG 3000 : 31.95 % PEG 3000 : 41.9 % PEG MME 2k : 20.95 % PEG MME 5k : 31.961 % PEG MME 2k : 28.4 %
TRIS : pH 8.0 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.8 0.1 M TRIS : pH 8.0 0.1 M MOPS : pH 7.2 0.1 M MES : pH 6.0 0.1 M
  ATP pH7.4 : 0.015 M  ATP pH7.4 : 0.013 M a-KG pH7.4 : 0.015 M
 C1  C2  C3  C4  C5  C6
KCl : 0.017 M   LiCl2 : 0.088 M MgCl2 : 0.063 M MgCl2 : 0.036 M
PEG 3000 : 28.3 % PEG 4000 : 33.101 % PEG 8k : 16.321 % PEG 8k : 22.401 % PEG 3350 : 31.301 % PEG 3350 : 23.8 %
MES : pH 6.0 0.1 M MES : pH 6.0 0.1 M NaCac : pH 6.5 0.1 M TRIS : pH 8.5 0.1 M MES : pH 6.0 0.1 M MOPS : pH 6.7 0.1 M
    a-KG pH7.4 : 0.011 M Glycerol : 10.501 %
 D1  D2  D3  D4  D5  D6
   KCl : 0.115 M LiCl2 : 0.088 M ZnAcet : 0.056 M
PEG MME 2k : 17.0 % PEG MME 2k : 16.901 % PEG 8k : 26.241 % PEG MME 2k : 23.401 % PEG 4000 : 21.15 % PEG 8k : 17.601 %
HEPES : pH 7.8 0.1 M HEPES : pH 7.2 0.1 M HEPES : pH 7.8 0.1 M HEPES : pH 7.2 0.1 M HEPES : pH 7.5 0.1 M TRIS : pH 7.5 0.1 M
Glycerol : 9.225 % a-KG pH7.4 : 0.013 M  ATP pH7.4 : 0.013 M ATP pH7.4 : 0.013 M   
 
b 
 A1  A2  A3  A4  A5  A6
LiCl2 : 0.068 M KCl : 0.031 M ZnAcet : 0.05 M ZnAcet : 0.042 M  MgCl : 0.036 M
PEG 3350 : 33.051 % PEG MME 5k : 30.601 % PEG 8k : 22.52 % PEG 8k : 29.801 % PEG MME 2k : 25.0 % PEG 8k : 10.161 %
TRIS : pH 7.5 0.1 M NaCac : pH 6.9 0.1 M MOPS : pH 6.7 0.1 M Tris : pH 7.5 0.1 M TRIS : pH 8.0 0.1 M MOPS : pH 7.0 0.1 M
ATP pH7.4 : 0.015 M a-KG pH7.4 : 0.013 M a-KG pH7.4 : 0.013 M   ATP pH7.4 : 0.013 M
 B1  B2  B3  B4  B5  B6
KCl : 0.03 M  ZnAcet : 0.038 M  KCl : 0.048 M LiCl2 : 0.028 M
PEG 8k : 15.761 % PEG MME 2k : 29.8 % PEG 8k : 11.201 % PEG 3350 : 21.25 % PEG 3000 : 26.5 % PEG MME 5k : 28.2 %
NaCac : pH 6.9 0.1 M TRIS : pH 8.0 0.1 M MES : pH 6.0 0.1 M NaCac : pH 6.9 0.1 M HEPES : pH 7.5 0.1 M MOPS : pH 6.7 0.1 M
   Glycerol : 12.751 %  Glycerol : 11.175 %
 C1  C2  C3  C4  C5  C6
MgCl : 0.045 M LiCl2 : 0.059 M MgCl : 0.082 M  KCl : 0.07 M LiCl2 : 0.049 M
PEG 3000 : 22.101 % PEG 4000 : 12.951 % PEG 3000 : 30.301 % PEG 4000 : 21.15 % PEG 4000 : 30.15 % PEG MME 5k : 32.08 %
MES : pH 6.0 0.1 M HEPES : pH 7.2 0.1 M TRIS : pH 7.5 0.1 M NaCac : pH 6.5 0.1 M HEPES : pH 7.5 0.1 M TRIS : pH 8.5 0.1 M
ATP pH7.4 : 0.013 M     ATP pH7.4 : 0.015 M
 D1  D2
 D3  D4  D5  D6
ZnAcet : 0.076 M ZnAcet : 0.09 M MgCl : 0.014 M LiCl2 : 0.047 M MnCl2 : 0.016 M  
PEG MME 5k : 26.36 % PEG MME 2k : 22.651 % PEG 8k : 29.24 % PEG MME 5k : 31.0 % PEG 3350 : 22.0 % PEG MME 5k : 27.361 %
NaCac : pH 6.5 0.1 M NaCac : pH 6.5 0.1 M NaCac : pH 6.9 0.1 M TRIS : pH 7.5 0.1 M MOPS : pH 7.0 0.1 M MES : pH 6.5 0.1 M
ATP pH7.4 : 0.013 M ATP pH7.4 : 0.013 M a-KG pH7.4 : 0.015 M Glycerol : 5.776 % a-KG pH7.4 : 0.015 M   
Table F.3: Grid screen for condition 55 of Wizard I with TRIS and HEPES buffer. 
 
Site I:  AcsA no ATP (6 + 3 mg/mL (small well)) 
Site II: AcsA (6 + 3 mg/mL (small well)) + 5 mM ATP  
Site II: AcsA (6 + 3 mg/mL (small well)) + 5 mM ATP/ 5 mM α-KG 
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Table F.4: Grid screen II for condition C5 of the Opt1 screen 
 
MES buffer: column 1-3 pH 6.0; column 4-6 pH 6.5 
Site I:  AcsA (6 .4 mg/mL) 
Site II: AcsA (6 .0 mg/mL) 
Site II: AcsA (3 mg/mL) 
drop size 1.5+1.5µL 
 
 
 
Figure F.2: Diffraction pattern of crystal 3 grown in 14.7 % (w/v) PEG 8k, 0.1 M HEPES pH 7.8, 49 mM ATP with 
2.9 mg/mL AcsA in a 0.3 µL drop (150 + 150 nL). 
 
 
F.3. Conclusion and future work 
It was not possible to obtain good initial crystals. All crystals tested were not protein 
crystals or did not diffract when tested. Some of the crystals were identified as salt 
crystals. This His6-tag may be one reason for lack of a good initial hit. This flexible 
series of amino acids may have interfered with crystallization. The His6-tag could not 
be removed by TEV digestion, although DNA sequencing showed that a TEV-cleaving 
site is present. Hence a new vector with a longer spacer between TEV recognition 
site and the N-terminus may help. Construction of a C-terminal His6-tag fusion 
(whether cleavable or not) should also be considered. Since the protein could be 
handled without problems (no degradation or precipitation) it might still be behave 
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well in different buffers and at lower salt concentration. This might decrease its 
solubility and may help in obtaining initial crystal condition. Another possibility 
would be in-situ proteolysis with chymotrypsin, by adding it in trace amounts to the 
crystal trails (Dong et al. 2007). Chymotrypsin cleaves at Y and F and is likely to cut 
off the His6-tag which has the following sequence: MSYYHHHHHHDYDIPTTENLY|FQG. 
This would be a cheap and quick method, since the remaining His6-tagged protein 
can be used, and may lead to an initial condition.   
G. Work on DesD 
G.1. Introduction 
DesD is the last enzyme in the desferrioxamine pathway of Streptomyces coelicolor. 
It catalyzes the trimerization and macrocyclization of N-hydroxy-N-succinyl-
cadaverine, generating desferrioxamine E (Figure 3.30). As mentioned in Chapter 3 
desferrioxamine is a metal complexing agent used in medical applications and a 
structure of DesD is of great interest. Here the initial work on DesD expression, 
purification and initial crystallization attempts is reported. 
G.2. Results and discussion 
G.2.1. Expression and purification of DesD 
 
Expression problems 
Expression trails in BL21(DE3) cells resulted in poor yield of full length as well as 
degraded His6-DesD. Expression trails at different temperatures showed that less 
degradation occurs when His6-DesD was expressed at temperatures lower than 
20 °C. Western blot analysis with an anti-His6 monoclonal antibody confirmed that 
these fragments result from DesD and are not E. coli proteins (Figure G.1). Whether 
these fragments result from protein degradation or are caused by incomplete 
biosynthesis within the cell is not yet clear. However, expression of His6-DesD at 
15 °C O/N did not increase the protein yield. 
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Figure G.1: Expression of DesD in BL21(DE3) competent cells at different temperatures. A Western blot with anti-
His6 monoclonal antibodies showed that expression at higher temperatures (>30 °C) results in more fragments of 
His6-DesD and proves that these bands result from DesD (still His6-tagged) and are not E. coli proteins. 
 
Expression in Rosetta (DE3) competent cells 
The DesD construct was transformed in Rosetta (DE3) competent cells. 1 L cultures 
were grown from 10 mL O/N starter cultures containing 30 µg/mL kanamycin and 
40 µg/L chloramphenicol. Protein expression was induced at an OD600 of 0.8 with 
0.5 mM IPTG and incubated for a further 15 h. This resulted in full length protein 
without degradation and yielded 17 mg protein/1 L LB media. Purification steps were 
performed as described for AcsD (chapter 2) (Figure G.2a). However TEV-cleavage 
with TEV protease was not successful. In a final step His6-DesD was purified on a 
S200 Superdex gel filtration column (Figure G.2b). Protein was concentrated to 
21.4 mg/ml, frozen in liquid nitrogen and stored at -80 °C.  
 
Figure G.2: DesD purification of protein expressed form Rosetta (DE3) cells. (a) IMAC purification of DesD. S: 
standard; 1: crude; 2: S/N; 3: pellet; 4: flow through; 5: wash1, 6: wash2; 7: elution 1; 8: elution 2. (b) SDS-PAGE 
of fractions B3 – E9 from His6-DesD gel filtration. 
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G.2.2. DesD has no TEV-recognition site but thrombin cleaving site 
Tests with different amounts of TEV protease revealed that the His6-tag cannot be 
cleaved (Figure G.3a). This was surprising since the construct was thought to have a 
TEV recognition site. However DNA sequence analysis showed that this construct had 
a thrombin cleaving site instead. The N-terminal His6-tag, including the recognition 
site for TEV and spacer was sequenced as MGSSHHHHHHSSGLVPR|GSSH. The His6-
tag could be removed by incubation with 3 units of thrombin per 100 µg DesD 
protein (Figure G.3b). 40 mg of DesD were treated with 350 units of thrombin for 
30 h at RT. His6-tag and non-cleaved protein were separated with a 5 mL pre-packed 
HisTrap column (GE Healthcare) and dialysed in 50 mM HEPES pH 7.5, 500 mM NaCl 
and 10 % (v/v) glycerol. DesD was concentrated and then purified on a S200 
Superdex GF column (Figure G.3c). Purified protein was concentrated to 5.45 mg/mL, 
frozen in liquid nitrogen and stored at -80 °C. Cleaved DesD has four additional 
amino acids (GSSH) at the N-terminus, comprises 599 amino acids and has a total 
weight of 66957 Da. 
a b c 
          
Figure G.3: TEV-protease cleaving and thrombin cleaving. (a) TEV-cleavage with different protease to DesD ratios. 
More protease does not cleave the tag. (1) 10 µg DesD; (2) 1:50 (TEV:DesD ratio); (3) 1:25; (4) 1:10; (6) 1:5; (7) 
1:2; (8) 1:1.  (b) Thrombin cleavage with 1 U/100 µg DesD led to partly cleaved protein after 18 h. Adding another 
2 units thrombin/100 µg DesD and incubation for another 12 h (total 30 h) resulted in fully cleaved DesD protein. 
(1) DesD without thrombin, (2) DesD with thrombin incubated. (c) Gel filtration of DesD after His6-tag was 
removed by thrombin cleavage and a second Ni-column. 
G.2.3. DesD initial screening for crystallization condition 
Neither with His6-DesD nor with DesD an initial crystal condition could be obtained, 
despite the use of several commercial screens (JMAC, Classics, JCSG+, PEGs, Wizard, 
Crystal Screen or Cryo I+II). Screening with 10 mM ATP (added to the protein prior to 
droplet set up) and/or different protein concentrations were also not successful. 
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However, some condition resulted in spheroids as shown in Figure G.4, though their 
optimization failed.  
     
Figure G.4: DesD spheroids timeline. Spheroids started growing after several days (highlighted with red circles) 
and kept growing until their final size was reached after ~7 weeks. Crystal condition: Well 88 (H11) of the JMAc 
crystal screen with 20 mg/mL His6-DesD and 10 mM ATP. 
 
G.2.4. Methylation of DesD 
DesD protein was methylated using the JBS methylation Kit (Jena Bioscience). 
Methylation efficiency was verified by mass spectrometry and confirmed that 100 % 
of the possible sites had been methylated. Methylated DesD (DesD-Met) protein was 
dialyzed in 50 mM TRIS-HCl pH 7.5, 250 mM NaCl and 10 % (v/v) glycerol to remove 
chemicals of the methylation step. Thereafter protein was concentrated to 5.8 
mg/mL and used for crystallization screens (Wizard I+II, Index, Cryo I+II and Crystal 
screen I+II). Crystal screens were set up with 5.8 mg/mL and 2.9 mg/mL DesD-Met 
(incubated with or without 10 mM ATP). Some initial hits were obtained but the 
optimized conditions proved to be salt or non-diffracting crystals.  
G.2.5. DesD-GFP-His8 fusion construct 
Since no crystallization condition was found, a C-terminal His8-tag fusion protein of 
DesD and GFP (as reporter protein) was constructed using the pWaldo-GFPd vector 
(Drew et al. 2001; Rapp et al. 2004). DesD primers containing a Nde1 (forward 
primer) and a BamH1 (reverse primer) recognition site were synthesized and used in 
PCR reactions to introduce the restriction site (Figure G.5).  
primer name primer 
orientation primer DNA sequence
N GC 
No
AT 
No
Tm 
no
GC 
pp
Tm 
pp
Tm pp
DesDcTGFP_f forward GAAGAACATATGAGCCTCGCCGACGCCG 28 3 6 24 14 5 66
DesDcTGFP_r reverse GATTTCGGATCCCCGGCCTGCCAGG 25 6 6 36 11 2 48     
Figure G.5: Primers for DesD-GFP-His8 construct. 
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PCR was carried out with a temperature annealing gradient from 53.5-70.5 °C. 
Details of PCR reaction and the program schedule are shown in Table G.1a, b. The 
most PCR product was yielded when 400 nM primers were used with an annealing 
temperature of 70.5 °C. Four 50 µL PCR reactions were carried out with these 
optimized settings using the same PCR program as before. The amplified DesD DNA 
was separated on a preparative 0.9 % (w/v) argarose gel. The DesD PCR fragment 
was extracted using the Promega gel extraction kit.  
Table G.1: Protocols for DesD-GFP-His8 vector construct. (a) Reaction scheme for PCR. (b) PCR program with 
different annealing temperatures; T1=70.5 °C, T2=68 °C, T3=64.2 °C, T4=59.5 °C, T5=55.9 °C and T6=53.5 °C. (c) 
Restriction digest with Nde1 and BamH1 of eluted DesD DNA and pWaldo-GFPd vector at 37 °C for 4 h. After the 
first 2 h of incubation additional 2.5 µL BamH1 to each reaction was added, since enzyme is only 75 % active in 
restriction buffer D (Promega). (d) Protocol for ligation of prepared vector and  DesD DNA with T4 ligase. 
a b 
primer conc. (nM) 50 150 250 400
stock final
PFU buffer (x) 10 1.00 35.0 µL 35.0 µL 35.0 µL 35.0 µL
dNTPs (mM) 10 0.25 8.8 µL 8.8 µL 8.8 µL 8.8 µL
DesD WT (ng) 65 32.50 1.0 µL 1.0 µL 1.0 µL 1.0 µL
primer fw (nM) 10000 x 1.8 µL 5.3 µL 8.8 µL 14.0 µL
primer re (nM) 10000 x 1.8 µL 5.3 µL 8.8 µL 14.0 µL
MgSO4 (mM) +2 mM 50 3.00 21.0 µL 21.0 µL 21.0 µL 21.0 µL
DMSO (%) 100 2.00 7.0 µL 7.0 µL 7.0 µL 7.0 µL
water 273.8 µL 266.8 µL 259.8 µL 249.3 µL
Polymerase PFU 0.5 µL 0.5 µL 0.5 µL 0.5 µL
     
step cycle temp. time
1 1x 95 °C 4 min
2 30x 95 °C 45 s
72 °C
52 °C↑ 45 s
72 °C 4 min
3 1x 72 °C 10 min
4 °C ∞ 
 
 
c d 
 
   
DesD PCR GFPd vector
Restriction buffer D (10x) 10.0 µL 10.0 µL
BSA (10 mg/mL) 1.0 µL 1.0 µL
DesD PCR product (1.26 µg) 56.0 µL /
GFPd vector / 5.0 µL
BamH1 (10 U/µL) 2.5 µL 2.5 µL
Nde1 (10 U/µL) 2.5 µL 2.5 µL
Water 28.0 µL 79.0 µL
volume tot. 100.0 µL 100.0 µL
         
DesD control
Vector DNA 150 ng 150 ng
DesD DNA 150 ng /
Ligation buffer (10x) 1x 1x
T4 Ligase 1.5 U 1.5 U
 
Extracted DesD DNA and the pWaldo-GFPd vector were digested with Nde1 and 
BamH1 restriction enzymes for 4h at 37 °C. After the first 2 h of incubation more 
BamH1 (25 U) was added to get full cleavage of DNA and vector (Table G.1c). 
Thereafter one unit of shrimp alkaline phosphatase (SAP) was added to the pWaldo-
GFPd reactions to dephosphorylate the 5’-phosphates of the vector. DNA of digested 
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DesD and the prepared vector were purified with the “MinElute Reaction Cleanup” 
kit (Qiagen). The ligation of vector and DesD was carried out with 1.5 units of T4 
ligase and equal amounts of vector and DNA (150 ng each) at RT over night (Table 
G.1d). DH5α competent cells were transformed with 0.5 – 1 µL of this ligation 
product. DesD plasmid containing clones (grown on 30 µg/L kanamycin LB agar 
plates) were identified by colony PCR and a control digestion with BamH1 and Nde1, 
but finally checked by sequencing. The final DesD-GFP-His8 fusion protein sequence 
comprised 855 amino acids with a His8-tag and is displayed in Figure G.6.  
 
Figure G.6: Protein sequence of the final DesD-GFP-His8 fusion construct.  
 
G.2.6. DesD-GFP-His8 protein expression 
DesD-GFP-His8 fusion vector was transformed into Rosetta (DE3) competent cells for 
protein expression. Cells were grown in 6x 1 L cultures, inoculated with 5 mL O/N 
starter cultures, containing 30 µg/L kanamycin and 40 µg/mL chloramphenicol. 
Protein expression was induced with 0.5 mM IPTG at culture density of OD600 =0.8 
and incubated for a further 15 h. Cell lysis and protein purification were carried out 
as described for AcsD (chapter 2) (Figure G.7). GFP-His8 tag of elution 1 and 3 was 
removed by incubation with TEV protease (1:50) (Figure G.7c).  
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Figure G.7: DesD-GFP-His8 purification. (a) IMAC purification of DesD-GFP-His8. S: standard; 1: crude; 2: S/N; 3: 
flow through; 4: wash 1; 5: wash 2, 6: elution 1; 7: elution 2; 8: elution 3. (b) Elutions 1-3 contain DesD-GFP 
fusion protein. (c) TEV cleavage of DesD-GFP-His8. S: standard; 1: E1 not cleaved; 2: E1 cleaved; 3: E3 not cleaved; 
4: E3 cleaved. (d) Gel filtration of cleave E1 containing DesD. (e) Gel filtration of E2 containing DesD-GFP-His8. 
 
Cleaved GFP-His8 and TEV protease were removed on a second Ni-column (see 
chapter 2). Elution 1 (DesD) and elution 2 (DesD-GFP-His8) were further purified on a 
S200 Superdex GF column, concentrated to 6.5 mg/mL, frozen in liquid nitrogen and 
stored at -80 °C. The final protein has 8 additional C-terminal residues (GSENLYFG) 
and comprises 603 amino acids with a total weight of 67528 Da. The non-cleaved 
GFP fusion protein comprises 855 residues with a total weight of 96032 Da. 
G.2.7. Screening with cleaved and non cleaved DesD-GFP-His8 
DesD-GFP-His8 and cleaved DesD were used for screening with four commercial 
screens (Wizard I+II, Crystal screen I+II, JCSG+ and Cryo I+II) and one custom 
stochastic screen (screen 20 Run2 (10/09/08)). Wizard I condition 22 (0.1 M Tris 
pH 8.5, 10 % (v/v) 2-propanol) resulted in small crystals (needles) with 6.5 mg/mL 
DesD-GFP-His8 protein. Since the crystals were quite small (Figure G.8) optimization 
of crystals will be needed. However, it has not yet been confirmed, whether these 
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crystals are protein crystals or not. But since no salt was used as precipitant or as an 
additive it is likely that these are DesD-GFP fusion crystals. The crystals are too small 
to judge whether they are stained, as GFP usually has a green color (see also Figure 
G.7b). 
    
Figure G.5: Likely DesD-GFP-His8 crystals. Crystals are tiny and have a “needle” morphology. They still have to be 
identified as protein crystals, but need to be improved to test them by x-ray or by staining with Coomassie blue.  
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G.3. Conclusion and future work 
Initial expression and purification problems have been solved and pure N-terminal 
tagged DesD has been expressed and purified. It was shown that the used vector has 
no N-terminal TEV recognition site for cleaving the His6-tag, but a thrombin 
recognition site. The tag-removal with thrombin was successful, but screening for an 
initial crystal condition remained unsuccessful. A C-terminal His8-tagged DesD-GFP 
fusion vector was constructed, the fusion protein expressed, purified and 
successfully cleaved with TEV protease. Crystal trails with cleaved and uncleaved 
DesD-GFP were screened for a potential crystallization condition. One promising 
condition in the Wizard I screen was obtained. However crystals still have to be 
identified as protein crystals, and need further optimization. This could be achieved 
by systematic use of grid screens, which eventually might lead to good quality 
crystals.  
